A non compartmental method for functional quantitative imaging with Positron Emission Tomography and irreversible tracers by Veronese, Mattia
Departiment of Information Engineering
Padova University, Padova, Italy
Ph.D. School on Information Engineering
Section: Bioengineering - Cycle: XXV
A non compartmental method for functional
quantitative imaging with Positron Emission
Tomography and irreversible tracers
Headmaster of the school: Prof. Matteo Bertocco
Supervisor: Prof. Alessandra Bertoldo
PhD candidate: Mattia Veronese
c© 2013 - Mattia Veronese
ALL RIGHTS RESERVED.
TO MYSELF, A SELFISH BUT VERY SATISFYING GIFT.

A non compartmental method for functional
quantitative imaging with Positron Emission
Tomography and irreversible tracers
ABSTRACT
In dynamic Positron Emission Tomography (PET) studies the term spec-
tral analysis indicates a time-invariant single input/single output model,
used for the data quantification [Cunningham and Jones, 1993]. Despite
the name and its common use in the engineering field, SA does not in-
dicate an analysis in the frequency domain but, instead, it represents a
method from which the radioactivity concentration measured with PET
can be related to the underlying physiological processes of the investi-
gated system. SA is so-called, because it provides a spectrum of the ki-
netic components from which it is possible to derive a large variety of
physiological parameters, depending on the characteristics of the ana-
lyzed tracers.
In the last years SA has been widely used with a large number of PET
tracers to study brain and non brain tissues, demonstrating to be a very
flexible method. Differently from the most used PET quantification ap-
proaches, like the compartmental modelling [Godfrey, 1982] or the graph-
ical methods [Patlak, 1983; Logan et al., 1990], SA can be applied to homo-
geneous as well as to heterogeneous kinetic tissues without any specific
compartmental model assumption. This characteristic makes it a high in-
formative investigative tool especially for the analysis of novel PET trac-
ers.
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The most critical aspect of SA is related to its sensitivity to the presence
of noise in the data. This characteristic makes SA not properly indicated
for the application to low signal-to-noise ratio (SNR) data [Turkheimer
et al., 1994]. During the past several years, several solutions have been
introduced to improve the robustness of SA in the presence of noise. The
most famous example is represented by rank-shaping spectral analysis
(RS) [Turkheimer et al., 2003]. However, even if RS has been shown to
be a precise and accurate quantification method, its applicability is lim-
ited to tracers with reversible uptake. This is a severe restriction if we
consider that one of the most used PET tracer for clinical research, 18F-
Fluorodeoxyglucose ([18F]FDG), is irreversible.
In this work we present SAIF, (Spectral Analysis with Iterative Filter),
a SA-based method for the quantification of PET data investigated with
irreversible-uptake tracers. SAIF has been designed in order to maintain
the main advantages of SA but providing a superior robustness to mea-
surement noise. The final aim was to create a reliable and flexible PET
quantification tool, offering a valid alternative to standardmethodologies
for functional quantitative imaging with PET and irreversible tracers.
The organization of this thesis is as follows: Chapter 1 offers a brief in-
troduction to PET technique and its quantification methods. A compari-
son between compartmental modelling approaches and graphical meth-
ods is also presented, in order to provide the operative context in which
SA is located. Chapter 2 contains the mathematical formalization of the
SA model. Standard and filtered SA versions are presented with partic-
ular attention to novelty elements introduced by SAIF. In Chapter 3 and
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Chapter 4, SAIFwill be tested with brain and non brain PET data. Several
datasets obtained by using different PET tracers are considered. As an ex-
ample for brain tissue quantification, SAIF application to L-[1-11C]Leuci-
ne and [11C]SCH442416 data is presented. For non brain tissues, instead,
analysis of three datasets is reported: 1) [18F]FDG PET studies applied to
skeletal leg muscle, 2) [18F]FLT PET studies applied to breast cancer pa-
tients and 3) [18F]FDG PET studies applied to normal control and acute
lung injury patients. For each dataset SAIF results are compared with
those provided by already validated methods and used in the literature
as reference for the quantification. This analysis allows to compare SAIF
performances with those offered by the current state of the art. Chapter
5 investigates the conditioning of the kinetic heterogeneity to PET quan-
tification. The relationship between this problem, the spatial resolution
of the imaging technique and the noise level of the data is also consid-
ered. This aspect is a critical point for PET quantification because when
it is not taken into account it can lead to heavily biased results. Particu-
lar attention is given to how SAIF addresses this issue. In Chapter 6 we
present SAKE, a software application developed in-house which imple-
ments themajor SA algorithms. SAKEmanages the whole process of PET
quantification: from data preprocessing to the result analysis. No other
program or additional tool is required. Chapter 7 discusses the most rel-
evant criticalities of the SA approach and of SAIF method in particular.
Considerable attention is given to the definition of the setting algorithm
as well as to the model assumptions used by SAIF to describe the data.
In Chapter 8 an overall discussion is presented with a conclusive sum-
mary about strengths and weakness of SAIF method. The appendix of
the thesis is dedicated to the some additional works, not directly related
to the main argument of this PhD project, but of interest for the PET field.
This research concerns 1) the development of voxelwise quantification
methods for [11C](R)Rolipram PET data, 2)the use of non linear mixed
effects modelling for plasma metabolite correction, and 3) the evaluation
of the sensitivity of PET receptor occupancy studies to the experimental
design.
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Un metodo non compartimentale per l’imaging
funzionale quantitativo con Tomografia ad Emissione
di Positroni e traccianti irreversibili
SOMMARIO
Negli studi dinamici di Tomografia ad Emissione di Positroni (dall’in-
glese Positron Emission Tomography, PET) il termine analisi spettrale
(SA) indica unmodello tempo-invariante singolo-ingresso/singola-uscita
per la descrizione temporale dei dati acquisti dall’esame [Cunningham
and Jones, 1993]. Nonostante l’accezione con cui viene comunemente
utilizzata all’interno del contesto ingegneristico, SA non fa riferimento
ad un’analisi nel dominio delle frequenze quanto, piuttosto, rappresenta
un metodo attraverso cui la radioattivita` misurata durante l’esame PET
viene messa in relazione con i processi fisiologici del sistema investigato.
Il metodo SA e` cosı` chiamato perche` fornisce lo spettro cinetico dell’attita`
del tracciante nei tessuti, a partire dal quale e` possibile derivare una
grande varieta` di parametri fisiologici relativi al sistema in esame.
Come riportato negli studi di Tadokoro (1993), Fujiwara (1996), Richard-
son (1996), Bertoldo (1998), Hinz (2008), Brooks (2008) e Myers (2012),
negli ultimi anni SA e` stata ampiamente utilizzata per lo studio dei tes-
suti cerebrali e non, dimostrando di essere uno strumento adattabile ad
una grande varieta` di traccianti e processi. Allo stesso tempo SA richiede
minime assunzioni per la sua applicazione: differentemente da molti ap-
procci di quantificazione di immagini PET, come la modellistica compar-
timentale [Godfrey, 1983] o i metodi grafici [Patlak, 1983; Logan et al.,
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1990], SA puo` essere applicata ai tessuti omogenei cosı` come ai tessuti
eterogenei senza la necessita` di ulteriori assunzioni. Questa caratteristica
fa della SA uno strumento investigativo altamente informativo special-
mente per l’analisi di nuovi traccianti PET in cui le conoscenze a priori
risultano limitate.
La maggiore criticita` della tecnica SA e` legata alla sensitivita` della me-
todologia alla presenza di rumore nei dati, caratteristica che ne limita
l’applicabilita` in caso di basso rapporto segnale rumore (SNR) [Turkheimer
et al., 1994]. Durante gli anni svariate alternative sono state introdotte
per migliorare la robustezza della tecnica alla presenza di rumore. La
soluzione di maggior successo e` rappresentata dalla rank-shaping spec-
tral analysis (RS) [Turkheimer et al., 2003]. Tuttavia, sebbene sia stato
dimostrato come RS rappresenti un preciso e accurato metodo di quan-
tificazione, l’applicabilita` della tecnica resta limitata ai soli traccianti con
cinetica reversibile. Tale peculiarita` costituisce una severa restrizione
all’uso della RS se si considera chemolti traccianti non rientrano in questa
categoria. L’esempio piu` importante e` rappresentato dal [18F]FDG (Fluo-
rodeoxyglucose), il tracciante PET piu` impiegato al mondo nella ricerca
clinica e pratica medica.
In questo lavoro viene presentata SAIF (Spectral Analysis with Iter-
ative Filter), un versione filtrata della spectral analysis per la quantifi-
cazioni di dati PET ottenuti a partire da traccianti con cinetica irreversibile.
SAIF e` stata sviluppata per mantenere i principali vantaggi della SA ma
allo stesso tempo si propone di offrire una superiore robustezza all’errore
di misura.
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Il contenuto della presente tesi si articola come segue: il capitolo 1 offre
una breve introduzione alla tecnica PET e ai principali metodi di quantifi-
cazione. Un confronto tra metodi compartimentali e metodi grafici viene
presentato in modo da definire le caratteristiche del contesto in cui la tec-
nica SA si colloca. Il capitolo 2 contiene la formalizzazione matematica
della SA. Il metodo standard e le relative versioni filtrate vengono presen-
tante, prestando particolare attenzione agli elementi di novita` introdotti
dalla tecnica SAIF. Nei capitoli 3 e 4 SAIF viene testata in diversi casi
di studio, rispettivamente per esami PET cerebrali e non. Come esem-
pi per la quantificazione dei tessuti cerebrali si presenteranno i casi di
applicazione della SAIF ai traccianti L-[1-11C]Leucina e [11C]SCH442416.
Relativamente ai tessuti non cerebrali, invece, si prenderanno in conside-
razione tre casi di interesse: 1) quantificazione di immagini PET ottenuti
con tracciante [18F]FDG per lo studio del muscolo scheletrico; 2) quantifi-
cazione di immagini PET ottenuti con tracciante [18F]FLT in pazienti on-
cologici con tumori al seno; 3) quantificazione di immagini PET ottenuti
con tracciante [18F]FDG per lo studio dei tessuti polmonari in soggetti
sani e in pazienti affetti da sindrome polmonare acuta. Per ogni dataset
i risultati ottenuti con il metodo SAIF saranno confrontati con quelli ot-
tenuti da metodi di quantificazione gia` validati e indicati dalla letteratura
come standard di misura. Tali analisi permetteranno di capire le perfor-
mance della SAIF rispetto al corrente stato dell’artemetodologico. Il capi-
tolo 5 approfondisce il condizionamento della eterogeneita` cinetica dei
sistemi biologici sulla quantificazione delle immagini PET, analizzando
la dipendenza del problema rispetto alla risoluzione spaziale delle im-
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magini e al rumore dei dati. Particolare attenzione verra` riservata a come
la metodologia SAIF si approccia al problema. Nel capitolo 6 verra` in-
trodotto SAKE, un’applicazione software sviluppata per implementare i
maggiori algoritmi di spectral analysis. Il capitolo 7 propone un’analisi
delle criticita` degli approcci SA in generale e SAIF in particolare. Verra`
discusso come definire il setting applicativo degli algoritmi cosı` come
gestire le assunzioni cinetiche dei vari approcci modellistici. In fine ver-
ranno presentate le considerazioni complessive dell’intero lavoro, propo-
nendo un riassunto dei punti di forza e debolezza del metodo SAIF.
L’appendice della tesi e` dedicata ad alcuni lavori addizionali non diret-
tamente collegati all’argomento principale di questa tesi di dottorato, ma
di interesse per l’ambito PET. Le ricerche si riferiscono 1) allo sviluppo
di metodi voxel-wise per la quantificazione di dati PET ottenuti con trac-
ciante [11C](R)Rolipram, 2) all’uso del metodo non linear mixed effects
modelling per la correzione deimetaboliti plasmatici, e 3) alla valutazione
della sensitivita` degli studi recettoriali PET al protocollo sperimentale.
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If the facts don‘t fit the theory, change the facts.
Albert Einstein
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Introduction to quantitative PET
POSITRON EMISSION TOMOGRAPHY (PET) is a nuclear medicine imaging
technique that produces in vivo three-dimensional images of functional
dynamic processes in the body. The system detects pairs of gamma rays
emitted indirectly by a positron-emitting radionuclide (tracer), which is
introduced into the body on a biologically active molecule. Thus, de-
pending on the characteristics of the injected compound, it is possible
to derive a large variety of physiological parameters such as blood flow,
glucose metabolism or neuroreceptor binding. In contrast to structural
imaging techniques, like X-ray or MRI, PET can be used to examine dy-
namic changes in selected functional processes showing not only where
these changes takes place but also measuring their magnitude. In order
to relate the radioactivity concentration measured with PET to the un-
derlying physiological or biochemical processes, the application of math-
ematical models to describe tracer kinetics within an area of interest is
1
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necessary. For this purpose, several solutions are available.
In clinical practise PET quantification is routinely performed by using the
Standard Uptake Value (SUV), a semi-quantitative index in use since the
1980s (Kubota, 1985). Its computation is very simple since it requires only
the PET measure at a pre-fixed sample time and the injected dose nor-
malized by some anthropometric characteristics of the subject (generally
the body weight or the body surface area) (Kim et al., 1994; Thie, 2004).
SUV is characterised by general applicability and no additional assump-
tion concerning reversibility/irreversibility of the tracer and the system
under study is necessary. However its use is controversial because SUV
computation is affected bymany technical and physiological factors lead-
ing to biased results (Boellaard et al., 2004; Hamberg et al., 1994; Huang,
2000).
An alternative to SUV is represented by the tissue-to-plasma ratio (RA-
TIO) method (Lehtio et al., 2003; Mitkovski et al., 2005). As indicated by
the name, this index is computed as the ratio between the activity of the
tracers measured in the tissue and the activity of the tracers measured in
the plasma pool within a pre-fixed time window. Fundamental require-
ment for RATIO definition is the presence of kinetic equilibrium in the
system of interest. As with the SUV, the RATIO is a very simple and fast
index to compute and it is generally applicable to most of the PET tracers.
However, both SUV and RATIO do not return any information about the
kinetics of the investigated system and therefore their application in dy-
namic PET studies is poorly informative. For this reason SUV and RATIO
are more commonly applied as diagnostic indexes rather than quantita-
tive PET methods for clinical research.
Themost used approach for quantification of dynamic PET studies is rep-
resented by compartmental modelling (Godfrey, 1982). This method is
based on a first-order differential description of the main physiological
processes in which the tracer is involved. Once the best compartmental
structure describing the behaviour of the tracer in the tissues has been de-
fined, it is possible to estimate the system’s micro and macro parameters.
This can be achieved at the Region of Interest (ROI) level, i.e. generating
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a tissue Time Activity Curve (TAC) of the average activity concentration
within a specific tissue area, or at the voxel level, i.e. deriving the tissue
TAC from one single image unit. The ROI level approach is commonly
used to quantify PET images by using nonlinear estimators since ROI
TACs are characterized by a good signal-to-noise ratio (SNR). However,
the use of ROI TACs causes a loss of spatial resolution since it does not
allow the quantification of the physiological information with the same
spatial detail as the acquired PET data. Voxel level analysis allows one
to avoid the operator-dependency of manually delineated ROIs and pro-
duces parametric maps having the same spatial resolution as the original
PET image. However, TACs derived from single voxels are characterized
by a low SNR. This renders the use of nonlinear estimators difficult and
unwieldy because of their computational cost. Thus, more robust and
faster estimation algorithms are necessary in order to quantify the physi-
ological information at the voxel level within a reasonable computational
time.
To improve robustness and/or computational efficiency of voxel-wise
quantification level via compartmental modelling several solutions have
been proposed in literature. The most used are represented by the gen-
eralized linear least square (GLLS) (Feng et al., 1996), the basis function
methods (BFMs) (Gunn et al., 1997; Hong and Fryer, 2010; Rizzo et al.,
2012a), Global Two Stage (GTS) (Tomasi et al., 2009a, 2011a), and Bayesian
estimation (Alpert and Yuan, 2009; Rizzo et al., 2012b). However, even if
these methodologies have been shown to provide some improvements
compared to the standard compartmental modelling approach, each one
presents its ownweaknesseswhich limit the applicability of thesemethod-
ologies.
A valid alternative to compartmental modelling is represented by Pat-
lak (Patlak and Blasberg, 1985) and Logan (Logan et al., 1990) graphical
methods. Both of them have been widely used for PET quantification,
because of their simplicity and model independence. In fact, they do not
need any a priori definition of the model structure, requiring only the in-
formation on the reversibility or irreversibility of the tracer kinetics. Be-
3
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ing easy to implement, they have been routinely used for the generation
of parametric maps. Nevertheless, they are affected by several limita-
tions. First of all both methods allow the estimation of a uniquemacropa-
rameter (i.e. the tracer net trapping uptake for Patlak and the tracer dis-
tribution volume for Logan) without fully describing the tracer kinetics.
At the same time they do not account for the vascular component. More-
over, due to the noise in the data, they may lead to biased parameter esti-
mates, especially when applied voxel-wise (Slifstein and Laruelle, 2001).
Another approach for PET data analysis is represented by Spectral Analy-
sis (SA) (Cunningham and Jones, 1993). In dynamic PET studies the term
spectral analysis indicates a single-input/single-output model used for the
data quantification. Thus, it is important to note that SA is not an analysis
in the frequency domain but it is so-called because it provides a spectrum
of the kinetic components from which it is possible to derive a selected
set of physiological parameters independently from the specific model
configuration. Even if in PET community SA belongs to the group of
data-driven methods, for its application it requires the fulfilment of some
assumptions about the tracer kinetics. First, the SAmodel is defined only
for single input systems (Schmidt, 1999). Moreover SA is not applica-
ble to cyclic systems, a condition which is very uncommon between PET
tracers (Schmidt, 1999). On the other hand, SA allows to obtain the com-
plete description of tracer kinetics as well as the number and the type of
compartments necessary for the data modelling (Cunningham and Jones,
1993; Turkheimer et al., 1994). This information can be very useful for
the specification of the kinetic model of a novel PET tracer. Compared to
graphical methods and compartmental modelling approaches, these SA
features represent a good trade-off between the information obtainable
by the method and the requirements for its application.
Figure 1.0.1 reports a schematic summary of the major PET quantifica-
tion methods organized by considering for each method the information
returned as function of its application requirements. Within this diagram
it results clearly evident a diagonal distribution of the methodologies.
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Figure 1.0.1: Quantification in Positron Emission Tomography. The figure
shows a schematic representation of the main quantification methods used in PET.
The spatial position of each method in the diagram indicates the information ob-
tainable by the method at the cost of the assumptions necessary for its application.
Orange and purple colours indicate respectively the methods used in clinical practise
and in research. Static and dynamic imaging are separately reported.
This indicates that it is possible to choose a more informative method
only at the cost of additional assumptions about the investigated system.
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Aerodynamically, the bumble bee shouldn’t be
able to fly, but the bumble bee doesn’t know it so
it goes on flying anyway.
Mary Kay Ash
2
A non compartmental method for
quantitative PET imaging: Spectral
Analysis
2.1 THE INPUT/OUTPUT SPECTRAL ANALYSIS MODEL
2.1.1 MATHEMATICAL FORMALIZATION
IN SPECTRAL ANALYSIS, the concentration of radioactivity in the tissue at
time t, Ctiss(t), is modelled as a convolution of the plasma time-activity
curve, Cp(t), with the sum ofM + 1 distinct exponential terms as
Ctiss(t) =
M∑
j=0
Cp(t)⊗ αj · e
−βjt (2.1)
7
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where αj and βj (β1 < β2 < · · · < βM ) are assumed to be real-valued
and nonnegative. This constraint derives from the assumption that SA
is modelling a first order compartmental system with a single arterial in-
put. The upper limit,M + 1, represents the maximum numbers of terms
to be included in the model and this is, in general, set to a large number
to be established, usually 100. The values of βj are predetermined and
fixed in order to cover an appropriate spectral range. For the studies in-
volving short lived positron emitting isotopes this range needs to extend
to the slowest possible event of the tracer in the tissue up to a value ap-
propriate to transient phenomena (e.g. the passage of activity through
the tissue vasculature). The values of αj are estimated from the blood
and tissue time activity curves by a nonnegative least squares (NNLS)
procedure. In practice, only a few components with αj > 0 are detected,
originating what is called the kinetic spectrum of the tracer in the tissues
(Fig. 2.1.1A). The estimated spectral components assume different mean-
ing depending on the position of the beta grid where they are located.
For example, the corresponding term for lim βj → ∞ (i.e., components
with βj very large), become proportional to Cp(t), and can be seen as
“high-frequency” components. In the same way the corresponding term
with βj = 0 or near zero, becomes proportional to
∫
Cp(τ)dτ and can be
viewed as the “low-frequency” component, i.e. accounting for trapping
of the tracer. Components with intermediate values of βj (“equilibrat-
ing components”) reflect tissue compartments that exchange material di-
rectly or indirectly with the plasma with their number corresponding to
the number of identifiable tissue compartments within the region of in-
terest. In light of these particular features, it is very common to define
the SA model equation explicitly showing trapping in the following way
Ctiss(t) = α0 ·
∫ t
0
C(τ)dτ +
M∑
j=1
Cp(t)⊗ αj · e
−βjt (2.2)
where βj > 0, j = 1, 2, . . . ,M .
The spectral analysis model has general applicability. However the func-
8
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tional base Cp(t)⊗
(−βjt) is an overcompleted base of the space of interest1
(Schmidt and Turkheimer, 2002). This r results in two main problems:
first of all the error properties of the estimates as well as the influence of
the error on the estimated components are difficult to estimate and con-
trol (Turkheimer et al., 1998); secondly to identify an unique and sparse
solution the coefficients αj must be constrained to be positive. Unfortu-
nately not all compartmental models satisfy these assumptions (Schmidt,
1999). Reference region models, for example, may result in negative αj
and therefore SA is not applicable (Gunn et al., 2001). On the other hand,
all the models with plasma or blood input functions and noncyclic struc-
tures result in positive αj values (Schmidt, 1999), allowing the applica-
bility of SA. Most of the kinetic models used with many PET tracers met
these conditions and therefore they do not represent any limitation for
spectral analysis utilization (Schmidt, 1999).
2.1.2 ESTIMATION OF THE PARAMETERS OF INTEREST
The main purpose of SA application to dynamic PET data is the quantita-
tive characterization of the tracer kinetics within the target tissues. This is
possible by linking the estimated spectral components, i.e. the estimated
αj and βj , with a selection of parameters of interest that do not depend
on a specific model representation. As demonstrated by Gunn and col-
leagues (2001) when a particular system meets the conditions to be mod-
elled with spectral analysis2 the unique idenfiability of some macropa-
rameters of interest is guaranteed. These parameters coincide with the
influx rate constant (K1, ml/cm
3/min), the net uptake of the tracer in the
1In functional analysis, an orthogonal basis is any generalization of an Hilbert basis
obtained from the multiplication between a orthonormal basis using multiplication by
nonzero scalars. An orthonormal basis for a Hilbert space H is an orthonormal set of
vectors with the property that every vector in H can be written as an infinite linear
combination of the vectors in the basis.
2The SA applicability is limited to those systems in which the state transition ma-
trix is negative semidefinite (Schmidt, 1999). This condition is met by all single-
input/single-output noncyclic systems (Schmidt, 1999). The subset of cyclic systems
in which the product of the rate constants is the same regardless of directions for every
cycle respects the constraints to be modelled with SA (Godfrey, 1982).
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tissues (Ki, ml/cm
3/min) and the volume of distribution (VT , ml/cm
3)3.
The last two elements cannot be estimated simultaneously, because they
respectively depend on the irreversibility or reversibility of the tracer ki-
netic.
The relationship between the parameter values and estimated spectrum
is as follows. The transport of tracer from plasma to tissue, K1, coincides
with the sum of components’ amplitudes, i.e.
K1 =
M∑
j=0
αj (2.3)
In case of irreversible tracers, Ki can be derived by the limit of the SA
model impulsive response function (IRF (t)) for t → ∞, which is also
equal to the amplitude of the estimated component corresponding to
βj = 0:
Ki = lim
t→∞
IRF (t) = lim
t→∞
M∑
j=0
{αj · e
−βjt} = α0 (2.4)
In case of reversible tracers, instead, VT can be computed from the inte-
gral of IRF (t) as:
VT =
∫ ∞
0
IRF (τ)dτ =
M∑
j=1
αj
βj
(2.5)
In addition to these parameters, if the measurement equation for the total
radioactivity measured by the PET scanner takes into account the tracer
contribution in both blood and tissues, it is also possible to derive the
blood volume (Vb, unitless). Generally this corresponds to the case in
which
Cmeasured(t) = (1− Vb) · Ctiss(t) + Vb · Cb(t) (2.6)
where Cmeasured(t) represents the total activity measured by the scanner
within a specified volume of observation, Ctiss(t) represents the tissue
3The measurement units here reported for Ki, K1 and VT follow the guidelines of
PET modeller consensus (Innis et al., 2007).
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kinetic activity and Cb(t) the blood tracer activity. The use of this mea-
surement equation (Eq. 2.6) in combination with the SA model (Eq. 2.1)
allows SA to fully characterized the whole time-course of tracer kinetics
starting from the activity measured by the scanner as
Cmeasured(t) = (1− Vb) · {
M∑
j=0
Cp(t)⊗ αj · e
−βjt}+ Vb · Cb(t) (2.7)
From SA application it is also possible to characterize how the SA mo-
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Figure 2.1.1: Spectral Analysis output. Panel A shows an example of a possible SA
spectrum. Panel B shows the relative SA model fit (dashed line) to the measured data
(black dots). Panel C reports the corresponding IRF time-activity (solid line) and the
single component time-courses (dashed lines). IRF is computed from the SA model
(Eq. 2.1) by assuming unit impulsive. Thus it results that IRF (t) =
∑M
j=0 αj ·e
−βjt.
del-prediction fits to the measured data (Fig. 2.1.1B). This visual analysis
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provides a first qualitative evaluation about the reliability of the SA data
description. In addition, for each estimated component, it is also possible
to compute the correspondent time-course (Fig. 2.1.1C), breaking down
in single kinetic elements the total tracer activity.
From the analysis of the SA estimated spectrum, however, it is not pos-
sible to compute the micro-parameters of the system, unless a fully char-
acterization of the compartmental model describing the system is known
in advance. In fact, from the indistinguibility theorem (Gunn et al., 2001)
any two plasma input models with a total number of N tissue compart-
ments are not distinguishable. The lack of a unique bidirectional relation-
ship between SA spectra and compartmental models, prevents the identi-
fication of a unique compartmental model given a specific spectrum and
thus a unique set of system micro-parameters.
On the contrary, given a compartmental model which fulfills the SA re-
quirements (i.e. noncyclic and with single arterial input), there is a fully-
described relationship between the spectral components and the model
configuration.
As example we can considered a two tissue compartmental model with
trapping (Fig. 2.1.2A). This represents a very interesting case as it is ap-
plied for describing several tracer brain kinetics like [18F]FDG (Phelps et al.,
1979; Sokoloff et al., 1977) and L-[1-11C]Leucine (Schmidt et al., 2005). With
some renumbering the equations of the model are


C1(t)
dt
= K1Cp(t)− (k2 + k3)C1(t)
C2(t)
dt
= k3C1(t)
y(t) = C1(t) + C2(t)
(2.8)
corresponding to the explicit solution
y(t) =
K1k3
k2 + k3
∫ t
0
Cp(τ)dτ +
K1k2
k2 + k3
∫ t
0
Cp(τ) · e
−(k2+k3)(t−τ)dτ (2.9)
In this case the spectrum provided by the SA consists of two components,
a trapping component and an equilibrating component (Fig. 2.1.2B). The
12
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Figure 2.1.2: Two-tissue compartmental model with trapping (Panel A) and its
relative spectrum (Panel B). Two-tissue compartmental model (Panel C) and its
relative spectrum (Panel D).
associated SA equation is
y(t) = α0
∫ t
0
Cp(τ)dτ + α1
∫ t
0
Cp(τ) · e
−β1(t−τ)dτ (2.10)
where 

K1k3
k2+k3
= α0
K1k2
k2+k3
= α1
k2 + k3 = β1
(2.11)
If in the model we include a rate constant for the transfer of the tracer
from C2 to C1, k4, the spectrum changes its configuration and what was
the trapping component becomes a new equilibrating component (Fig.
13
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2.1.2D). This behaviour is consistent with the change of the model con-
figuration shown in Figure 2.1.2C. Obviously the relationship between
the αs and βs of the new spectrum with the rate constants is different
from the one expressed in Eq. 2.11. The new equivalence can be defined
from the solution of the new model.
2.1.3 SA AND TISSUE KINETIC HETEROGENEITY
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Figure 2.1.3: An example of heterogeneous system. The figure shows the
general kinetic model for a heterogeneous system composed by n kinetically homoge-
neous subregions. Each subregion is then composed by N compartments connected
with each other; the configuration can change between subregions. The variables
wa, wb, · · · , wn indicate the weight of each subregion within the observed volume of
interest, by assuming that wa + wb + · · ·+ wn = 1.
Because SA does not require the number of compartments to be fixed
a priori, the SA technique applies to heterogeneous as well as the homo-
geneous tissues without any additional assumptions. This characteristic
is particularly useful for tracer kinetics studies where the limited spatial
14
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resolution of the PET scanner produces a heterogeneous mixture of ki-
netically dissimilar tissues within the field of view. In PET brain studies,
for example, it not uncommon to have a combined signal from gray and
white matter, especially in cortical regions. However, due to the addi-
tivity of the spectral components in Eq. 2.1, this effect can be taken into
account. In fact, whenever a homogeneous tissue model can be appropri-
ately analyzed with SA, its heterogeneous counterpart can be modelled
as well (Schmidt and Turkheimer, 2002).
In the case of heterogeneity, however, the parameters of interest K1, Ki
and VT resulting from the estimated spectrum assume a different mean-
ing. Considering the general case of a system with n kinetically homoge-
neous subregions, the activity of the tissue as a whole can be expressed as
a convex combination of activity in its subregions (a, b, . . . , n) (Fig. 2.1.3).
It follows that the total activity in the observed volume is given by
Cmeasured(t) = (1−Vb) · {waCT,a+wbCT,b+ · · ·+wnCT,n}+Vb ·Cb(t) (2.12)
where CT,i represents the tracer activity in the i-th subregion.
From Eq. 2.12 it can be easily derived that the kinetic spectrum of the
heterogeneous system corresponds to the sum of the kinetic spectra of
its subregions. In this case, independently from the number of compart-
ments and the reversibility/irreversibility of each subregion, the sum of
estimated components (
∑M
j=0 αj) as well as the trapping one (α0) repre-
sent the weighted averaged influx rate constant and weighted average
trapping of the heterogeneous system. A different treatment has to be
reserved for the distribution volume. In fact, only in the case that each
subregion presents reversible kinetics, the result of Eq. 2.5 indicates the
weighted average distribution volume. On the contrary, in presence of
at least one irreversible subregion, no more can be said without the com-
plete modelling of the system. This last condition is however very un-
common among the PET tracers, since the reversible/irreversible kinetic
behaviour of a specific tracer tends to be maintained between different
biological tissues.
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A great advantage of applying SA to inhomogeneous systems is the pos-
sibility of detecting the degree of heterogeneity. From SA analysis it is
possible to compute the heterogeneity fraction (HF ), defined as the num-
ber of homogeneous distinguishable subregions within the investigated
system. As consequence of the indistinguibility theorem, however, it is
important to note that the computation of HF can be performed only
when the system is completely characterized and the corresponding com-
partmental model fully-described.
Since the problem of heterogeneity involves not only the modelling ap-
proach used to quantify the data but also the structural limits of imaging
instruments as well as the measurement noise, it will be more exhaus-
tively discussed in Chapter 5.
2.1.4 SA AND MODEL DEVELOPMENT
Alternative to tissue kinetic quantification, SA has been used as tool for
the compartmental model development of several PET tracers. Exam-
ples of this can be found in (Bertoldo et al., 1998, 2001, 2005; Myers et al.,
2012). This approach is particularly useful when new PET tracers are an-
alyzed for the first time. In this context, SA offers the possibility of deter-
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Figure 2.1.4: Two compartmental models with equivalent kinetic spectrum.
Although they have different configurations both methods are compatible with the
same spectrum defined by a trapping and an equilibrating component.
mining the number of compartments present in a system as well as their
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types, distinguishing between equilibrating components and trapping.
However, as discussed in the previous paragraph, it cannot say any-
thing about their interconnections, and without any information about
the system-of-interest physiology it is impossible to determine an un-
equivocal correspondence between the spectrum and its equivalentmodel.
Thus, for a particular estimated spectrum it is only possible to associate
a class of equivalent compartmental representations which have in com-
mon the same number of compartments (Fig. 2.1.4). Then, using the
physiological knowledge of the system, it is possible to choose from among
the class alternatives the optimal compartmental configuration for the de-
scription of the kinetics of the tracer under study. This procedure is the-
oretically always applicable but may not be advisable for real practice. It
can happen very often that the presence of noise in the data (especially
for high level of error) produces a biased number of SA estimated compo-
nents (generally higher than the true value) leading toward an erroneous
class of model configurations.
For this reason when the purpose of SA is to find the number of exponen-
tial components of the system impulse response without having to define
a structure beforehand, defining a grid of eigenvalues βj and estimating
only the relative amplitudes αj is not necessary. The right approach to
follow is simply to estimateM the number of exponentials necessary for
the SA model (Eq. 2.1) to give a good fit to the data by using models of
increasing order. For instance, one can start first with a one-exponential
model
CT (t) = α1 · Cp(t)⊗ e
−β1t (2.13)
and estimate by Non Linear Least Squares (NLLS) the parameters. Then
trying a two-exponential order, with one trapping component
CT (t) = α1 ·
∫
Cp(t) + α2 · Cp(t)⊗ e
−β2t (2.14)
and then with two equilibrating components
CT (t) = α1 · Cp(t)⊗ e
−β1t + α2 · Cp(t)⊗ e
−β2t (2.15)
17
Spectral Analysis for quantitative PET imaging
and so on. The standard model parsimony criteria techniques (Hirotugu,
1971) can be used to choose the best model. This approach firstly pre-
sented by Bertoldo and colleagues (Bertoldo et al., 1998) is also called
nonlinear spectral analysis (NLSA). Compared to standard SA it offers
several advantages. First of all not only the standard deviation error of
the αs estimates, but also the precision of the βs are provided. In fact, if βs
are selected from a predetermined grid, as in the standard SA approach,
it is impossible to obtain a measure of their precision. This information
can be combined with the parsimonia criteria for the selection of the best
model. Secondly, estimation of the βj within a pre-fixed compartmental
structure avoids the problem of the extra components as in the standard
SA. For all these reasons NLSA represent the most appropriate SA ap-
proach for model identification.
2.2 LINEAR AND FILTERED SOLUTIONS
2.2.1 EXPONENTIAL SPECTRAL ANALYSIS (ESA)
The first applications of the SA model (Cunningham and Jones, 1993),
were done with brain PET datasets, specifically for the evaluation of cere-
bral blood flow, cerebral glucose utilization and for opiate receptor ligand
binding. H2
15O, [18F]FDG , and [11C]DPN PET data were considered for
this purpose. The definition of the βs grid was simply based on a loga-
rithmical distribution, while the estimation was solved with the simplex
method (Cunningham and Jones, 1993).
After these attempts, the SA model has been widely used in a large vari-
ety of testing conditions, although with different solutions for the β grid
and for the implementation of the nonnegative estimator. Despite these
dissimilarities, it is very common to refer to this class of methods in the
same way, as Exponential Spectral Analysis (ESA). ESA has been applied
to preclinical (rats and rabbits) (Bentourkia, 2003; Marshall et al., 2004) as
well as clinical data. Most of its applications are related to the investiga-
tion of brain tissues (Edison et al., 2009; Grunder et al., 2001; Hammers et al.,
18
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2005, 2007;Miederer et al., 2009;Myers et al., 2012; Ramlackhansingh et al.,
2011; Richardson et al., 1996; Turkheimer et al., 1994, 1998, 2007;Weeks et al.,
1997;Wester et al., 2000;Willoch et al., 2004) even if ESA has been applied
to PET studies involving heart (Bertoldo et al., 1998), skeletal leg mus-
cle (Bertoldo et al., 2001; Pencek et al., 2006), breast cancer (Kenny et al.,
2005; Tomasi et al., 2011b, 2012) and gastrointestinal cancer (Wells et al.,
2003). Most of these applications aimed to provide reliable and robust
alternatives to the standard quantification methodologies.
2.2.2 NUMERICAL FILTERING
The ESA method is well known to be sensitive to noise in the data, with
the bias being highly dependent on the level of noise present (Cunningham et al.,
1998; Gunn et al., 2002; Turkheimer et al., 1994, 1998). Over the years sev-
eral strategies to lessen the impact of noise in the data on estimated spec-
tra and on the parameters of interest have been proposed in literature.
The first attempt to solve the problem was done by including penalty
functions on the NNLS algorithm (Cunningham et al., 1993). However,
the definition of an adequate penalty function to use in practice has proved
to be difficult. This concept was further developed by Gunn and col-
leagues in 2002 and it originated what are now called basis pursuit meth-
ods (Gunn et al., 2002; Peng et al., 2008).
In 1994, Turkheimer and colleagues proposed an high-pass filter for equi-
librating components, with the aim of improving estimates of α0 and
thus determining amore accurate and precise regional cerebral metabolic
rate for glucose in [18F]FDG PET studies (Turkheimer et al., 1994). The
filter assumes that equilibrating components detected with 0 < βj <
βcutoff result from noise in the data, shifting trapping components from
their true position at βj = 0. The filter was effected by subtracting from
the measured ROI TAC all components with βj ≥ βcutoff ; the remain-
der, which was assumed to equal the integrated component α0
∫
Cp(τ)dτ ,
was used to re-estimate α0. Even though the use of this filter have been
shown to produce better estimates of α0 than the standard ESA, it rep-
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resents an incomplete solution. In particular this method does not ac-
count for the phantom components at intermediate and high frequency
(Veronese et al., 2010), which, aswell the low-frequency components, con-
tribute to the description of tissue tracer kinetics. This may lead to biased
estimate forK1 and Vb (Veronese et al., 2010), indicating that a correct SA-
based quantification requires a correct estimation of the whole spectrum.
In 1993 and 1997, Takodoro andWeeks (Takodoro et al., 1993;Weeks et al.,
1997) proposed to use the SA impulsive response function, IRF (t), as an
alternative to the SA spectrum to compare studies. In particular they
suggested to use the IRF (t) value at early times of the PET study for
the analysis of tracer delivery and at the late times for tracer retention.
However, even if IRF (t) parametric imaging proved to be more robust
to the noise, a quantitative formalization about the relationship between
this approach and the underlying kinetic processes is missing.
In 1998 two different alternatives were proposed. First of all a bootstrap
approach based on residual resampling was implemented to simulate
the effect of the noise on the SA spectrum and to correct for possible
bias (Turkheimer et al., 1998). The bias-corrected bootstrap spectrumwas
shown to be a good estimator of the average spectrum that would have
been obtained if repeated samples of the measured data were available.
In addition the technique was shown to require minimal assumptions
about noise in the measurements and thus to have general applicabil-
ity. However, because the procedure was computationally intensive, its
applicability is limited in the case of very large datasets such as in voxel-
wise PET analysis. In the same year, a new procedure for the suppres-
sion of noise artefacts on the estimated SA spectrum was proposed by
Cunningham and colleagues (Cunningham et al., 1998): standard statis-
tical tests and information criteria were applied to subselect the true esti-
mated components from a given SA spectrum, removing those related to
the noise in the data. In the same work, some important considerations
about the spacing of the basis functions to be used in SA were presented
(Cunningham et al., 1998).
Parallel to the developing of new SA improved versions, some efforts
20
2.2 Linear and filtered solutions
were done to denoise the PET images, exploiting the idea that quantifi-
cation can be improved by increasing the SNR of the analyzed data. This
preprocessing step to smooth the data then allows subsequent analysis
by methods such as SA to be substantially improved in terms of their
mean squared error. Several solutions have been proposed in literature,
but specifically to SA methodology, the most significant attempts were
represented by the use of wavelets (Turkheimer et al., 1999, 2000) and by
the functional smoothing approach (Jiang et al., 2009). Despite of their great
potential, both of these approaches have not significantly impacted the
PET modelling community.
At the present time, the most successful filtered version of the SAmethod
is represented by Rank-shaping spectral analysis (RS) (Turkheimer et al.,
2003). RS is a Bayesian development of standard SA, optimized for re-
versible tracers, which works on the same principles as SA but without
requiring the non-negativity constraint in the estimator. In fact, to over-
come the high sensitivity of the standard SA to the noise in the data, RS
implements a Kalman filter of the estimated kinetic spectrum providing
reliable estimates of VT (for the derivation of this method, the interested
reader is referred to the original reference by Turkheimer and colleagues
(Turkheimer et al., 2003)). Unlike other SA-based methods, RS can be ap-
plied with an arterial input function as well as with a reference region.
RS has been shown to be a precise and accurate quantification method
(Hammers et al., 2007; Turkheimer et al., 2003, 2007, 2012), demonstrat-
ing to be a reliable tool for parametric imaging, even in high-noise con-
ditions (Turkheimer et al., 2003). On the other hand, RS applicability is
limited to the reversible tracers only. This is an important restriction for
PET quantification because there are several PET tracers with irreversible
trapping. The most relevant example is represented by [18F]FDG , one of
the most used PET tracers in research and clinical practices4. It is mainly
for this reason that a complementary version of RS for irreversible tracers
4There are more than 15-thousand works registered in Pubmed
(http://www.ncbi.nlm.nih.gov/pubmed) database involving [18F]FDG PET tracer.
Among these works almost 3-thousand refer to 2012.
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needs to be developed.
In the next section we will introduce SAIF (Spectral Analysis with Iterative
Filter) (Veronese et al., 2010), a filtered SA-based algorithm for the quan-
tification of PET tracers with irreversible uptake.
2.3 A NOVEL SA METHOD FOR IRREVERSIBLE TRACER: SAIF
2.3.1 THE ALGORITHM
In irreversible tracers, the quantification of the trapping and the tracer
transport (from plasma to tissue) requires good estimates of both α0 and∑M
j=0 αj . From these parameters it is then possible to derive tracer-
specific parameters of interest like the regional glucose utilization, in
case of [18F]FDG PET studies (Turkheimer et al., 1994), or the rate of cere-
bral protein synthesis, as in case of L-[1-11C]Leucine brain PET studies
(Veronese et al., 2010). To do this, it is necessary to separate low fre-
quency equilibrating components from trapping as well as to separate
high frequency equilibrating components from blood. If the latter is not
done successfully, K1 will be substantially overestimated.
The starting point for definition of a new filter was the high-pass filter
of Turkheimer (1994) (Turkheimer et al., 1994). Instead of considering the
components with 0 < βj < βcutoff as resulting from trapping components
and noise in the data, the new filter allows that these components may
also be due, at least in part, to slowly equilibrating components present
in the system. Therefore, the effect on remaining equilibrating compo-
nents of removing components with 0 < βj < βcutoff must be considered.
The second aspect of the new filter was setting an upper cut-off frequency
above which equilibrating components are assumed to be indistinguish-
able from blood in brain. Removal of these components from the spec-
trum affects estimates of remaining equilibrating components as well as
blood volume. The filtering includes two steps that are repeated until
stabilization of Weighted Residual Sum of Squares (WRSS) is reached.
Because of the iterative cycle, this new SA algorithm is called Spectral
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Analysis with Iterative Filter” (SAIF). The procedure is as follows:
1. Define the grid for βj , j = 1, 2, ...,M and perform spectral analysis with-
out filtering.
2. Set up Bandpass filter: Define an equilibrating component passband
[βL,βU ] such that all components with β ∈[βL,βU ] are considered to be
real equilibrating components of the system.
3. New estimates of trapping and blood volume: Assume all compo-
nents with 0 < βj < βL result from noise having shifted some or all of
the trapping components from their true position in the spectrum, and all
components with βj > βU are shifted blood components. Subtract compo-
nents inside the passband from measured activity (Cmeasured(t)) and esti-
mate new values of the coefficient of the trapping compartment (α0) and
the blood volume fraction (Vb).
4. New estimates of equilibrating components: Recognizing that com-
ponents outside the passband may have at least partially resulted from real
equilibrating components that were shifted due to noise, re-estimate equi-
librating components as follows. Using the new values of α0 and Vb from
Step 3, subtract the contribution of the trapping and blood components
from the measured data, and re-estimate the set of equilibrating compo-
nents using NNLS with the grid restricted to β ∈[βL,βU ].
5. Stop Criterion: Calculate the difference between WRSS before after Step
3 and after Step 4; if it is less than ε = 0.0001 stop . Otherwise restart at
Step 3.
Using change in WRSS as the stop criterion allows the data to auto-de-
termine the number of iterations. When all equilibrating components
initially identified with spectral analysis (before filtering) are inside the
passband, only one iteration is required. A schematic summary of the
SAIF procedure is reported in Figure 2.3.1.
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Figure 2.3.1: SAIF filtering procedure. (A) The spectrum provided by ESA;
(B) The choice of the cut-off interval on the evaluated spectrum; (C) 1st filtering:
The contributions of components inside the cut-off interval are subtracted from the
data and new values of the trapping and Vb are estimated; (D) 2
nd filtering: The
contributions of the trapping and blood volume are subtracted from the data and new
values for the components inside the cut-off interval are estimated. The iteration cycle
is the repetition of the last two points. The WRSS variation provides the stopping
criterion.
2.3.2 SAIF IMPLEMENTATION
As all the SA methods, implementation of SAIF requires 1) the definition
the βs grid, 2) the selection of weighting factors for nonnegative least
squares estimation, 3) the correction for the artefacts that arise from the
discrete, non-continuous nature of the grid, and 4) the computation of the
standard errors in the parameter estimates. In addition to these elements,
SAIF needs for the passband filter interval, i.e. [βL,βU ].
Since the implementation choices can impact the performance of themethod,
we decided to follow the literature suggestions for its realization. The
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logarithmic distribution of βj , j = 1 : M was chosen according to (DiStefano,
1981; Turkheimer et al., 1994). The lower limit of the distribution was de-
fined as β1 = 1/(3Tend) where Tend is the end time of PET study, and the
upper limit was provided by βM = 3/Tin where Tin is the duration of the
first PET scan of the study (Turkheimer et al., 1994). One hundred points
were included (M = 100). Therefore:
βj =
1
τj
(2.16)
and
τj = τj−1 ·
(
Tend
Tin
) 1
1−M
(2.17)
with j = 2 : · · · : M . TheM + 1 unknown values αj were estimated with
the nonnegative linear least squares algorithm implemented in Matlab R©
(TheMathWorks, Inc, Natik, MA, USA) by the lsqnonneg.m function. Wei-
ghts were assumed proportional to the variance of the decay-corrected
measured activity in the region, which was differently defined depend-
ing on the characteristics of the tracer. In all the cases a relative weight-
ing scheme was applied, with a scale variance factor (σ2) estimated a
posteriori from the WRSS (Carson et al., 1983). A lower bound on the
standard deviation of the estimated αj was determined from the inverse
of the Fisher Information matrix, following the Cramer-Rao Theorem
(Cramer and Herald, 1946).
Due to the discrete nature of the grid of βs, the algorithm cannot always
place a component in the exact position that would yield the best fit of the
data; it is instead constrained to use only βs included in the grid. When
an adequate approximation of the optimal β is not on the grid, the algo-
rithm chooses instead two consecutive values of βs that bracket the opti-
mal value. Under the assumption that consecutive components resulted
from this phenomenon rather than from two nearly equal components in
the data, we replaced consecutive components pairs Compj (βj ;αj) and
Comp(j+1) (β(j+1);α(j+1)) with a new, single component Compj∗(βj∗;αj∗)
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calculated from the amplitude-weighted average as follows:
αj∗ = αj + αj+1 (2.18)
βj∗ =
βj · αj + βj+1 · αj+1
αj + αj+1
(2.19)
2.3.3 APPLICABILITY POTENTIAL
For the characteristics of the SA model and the way in which it has been
implemented, SAIF presents general applicability to all the PET tracers
with irreversible uptake. Coherently with all the SA-based methods, also
SAIF is adequate only for the description of single-input/single-output
noncyclic biological systems. In terms of parameters of interest, SAIF
returns the information Ki and K1 rate constants (as expressed by Eq.
2.3 and 2.4), as well as the blood volume (Vb). In addition, it provides
the whole spectrum of the kinetic components indicating the number of
compartments necessary to describe the data.
To show the potential offered by the method, the next chapters present
some representative examples of SAIF application to several human PET
studies performed using different tracers. The analyzed datasets were
specifically chosen with the aim of testing SAIF under different condi-
tions. For a clearer presentation, the results related to brain and non brain
studies will be separately reported.
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Never trust anything that can think for itself
if you can’t see where it keeps its brain.
J. K. Rowling
3
Applications to brain studies
THIS CHAPTER PRESENTS some applications of SAIF in simulated and
measured brain PET data. For the characteristic of irreversibility required
by the method, SAIF was tested in L-[1-11C]Leucine and [11C]SCH442416
PET datasets its performance compared with those offered by the current
state of the art presented in literature.
3.1 BRAIN SIMULATED DATASETS
3.1.1 DEFINITION OF SIMULATED DATA
Previous to measured data analysis, SAIF was tested on a representative
set of simulated datasets representing both regional and voxel-wise noise
level. The following subsection summarize themain details of simulation
procedure. Firstly, noise-free tissue kinetic TACs (Ctissue(t)) were gener-
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ated by the convolution between a pre-defined measured arterial input
function (Cp) with a selection of simulated kinetic spectra as in Eq. 2.1.
Cpwas computed as the population average of 50manually-measured ar-
terial input functions derived from 50 L-[1-11C]Leucine PET studies. For
the selection of kinetic spectra, instead, we chose a variety of results ob-
tained from the analysis of several brain PET studies performed with ir-
reversible tracers (Bertoldo et al., 1998; Bishu et al., 2008). A total number
of 75 spectra were generated. The correspondent parameters of interest
(K1, Ki and Vb) derived from the simulated spectra are reported in Table
3.1.1. Noise-free simulated TACs Csim(t) were generated according PET
Table 3.1.1: Simulated parameter values
Ki K1 Vb
Index (ml/cm3/min) (ml/cm3/min) (unitless)
Mean 0.026 0.078 0.071
SD 0.031 0.060 0.015
min 0.006 0.025 0.040
max 0.100 0.200 0.104
measurement equation (Chapter 2, Eq. 2.7), here recall
Csim = (1− Vb) · Ctissue(t) + Vb · Cb(t) (3.1)
where Cb(t) represents the concentration of the tracer in the whole blood
including radiometabolites. For consistency with arterial data,Cb(t) curve
was derived through the same procedure used for the definition of Cp(t).
A total number of 75 noisy-free simulated TACs, one per simulated ki-
netic spectrum, were computed (Fig. 3.1.1A). Noisy-TACs data were then
generated by the sum of noise-free data and simulated white noise (zero-
mean and Gaussian distribution). Data were sampled according to the
PET acquisition protocol defined in (Bishu et al., 2008), i.e. 42 frames of
data (16x15, 4x30, 4x60, 4x150, 14x300 seconds). The simulated noise vari-
ance was defined as it is most frequently done in PET, i.e. according to
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the formula proposed by Mazoyer and colleagues (Mazoyer et al., 1986):
V ar(t) = σ2 ·
(Csim(t))
∆t
(3.2)
where σ2 represents the scale factor for the error variance, Csim(t) rep-
resents the simulated noise-free TAC and ∆t represents the lengths of
scan intervals. In order to test the performance of SA methods at both
region and voxel levels, high and low SNR scenarios were generated by
modulating the simulated noise for different values of σ2. More than 2
orders of magnitude were used to simulate voxel SNR level respect to
the regional one. For each simulated kinetic, 100 noisy realizations were
generated for both high and low SNR scenarios, for a total of 15, 000 sim-
ulated noisy TACs. A representative set of the signals obtained for each
scenarios is reported in Figure 3.1.1 (B and C).
3.1.2 METHOD IMPLEMENTATION AND PERFORMANCE INDEXES
For comparative purposes, simulated data analysis was performed with
both ESA and SAIF algorithms. The same grid of βs and the sameweight-
ing procedure, as defined in Section 2.3.2 were applied for consistency.
SAIF passband interval bounds were respectively defined as the mini-
mum and the maximum of the simulated equilibrating β components
([βL,βU ]=[0.02 min
−1, 0.3 min−1]). The same passband was maintained
for the analysis of both low and high SNR data. Trapping rate constant
(Ki), average influx rate constant (K1) and blood volume (Vb) were con-
sidered as parameters of interest. For each noise level and each parameter
of interest p, the mean percentage bias (%bias(p)) was computed as:
%bias(p) =
75∑
s=1
[
1
75
100∑
k=1
1
100
(
pk,s − ˆpk,s
ˆpk,s
)]
(3.3)
where pk,s represents the k-th estimated values of the s-th simulated ki-
netic spectrum and ˆpk,s represents the k-th simulated reference values of
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Figure 3.1.1: Simulated dynamic PET TACs. Panel A shows noise-free Ctissue
TACs. Panel B and C show some representative noisy realizations of dynamic PET
data at high and low SNR level.
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the s-th simulated kinetic spectrum. To note that k ranges from 1 to 100
(number of simulated noisy TACs per spectrum) and s ranges from 1 to
75 (total number of simulated spectra). To complete the method perfor-
mance analysis, ESA and SAIF accuracies were evaluated through the
calculation of %bias SD and min-max range.
In addition to%bias characterization, for each tested method, the success-
ful rate (SR) was computed as the fraction of the successfully estimates
over the total number of simulations1.
3.1.3 RESULTS
Table 3.1.2: Simulated parameter values
ESA SAIF
Parameters BiasKi BiasK1 Bias Vb WRSS SR BiasKi BiasK1 Bias Vb WRSS SR
(%) (%) (%) (unitless) (%) (%) (%) (%) (unitless) (%)
Region Level
Mean -4 -4 -4 1.6 100 1 1 1 2.2 100
SD 1.9 1.9 1.9 2.7 0 2.5 2.5 2.5 4 0
Min -6.3 -6.3 -6.3 0.3 100 -0.6 -0.6 -0.6 0.3 100
Max -0.2 -0.2 -0.2 8.7 100 9.1 9.1 9.1 13.8 100
Voxel Level
Mean -13 -13 -13 236 86 0 0 0 239 94
SD 6 6 6 197 7 6 6 6 199 6
Min -22 -22 -22 88 73 -7 -7 -7 89 84
Max -2 -2 -2 723 95 17 17 17 736 100
Table 3.1.2 summarizes the main results obtained by ESA and SAIF in
the simulations. In particular it can be observed that:
• the increase of noise level produced a worsening of precision an
accuracy in both methods for all the parameters of interest. This
behaviour was quite expected, and it is consistent with one of most
common engineering principles for which the higher the noise, the
more difficult the measure. Also the number of outliers results in-
fluenced by noise level as indicated by the decrease of SR from ROI
to voxel analysis;
1We considered successfully estimates all the cases in which the algorithm converged
to a physiologically-acceptable solution.
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• compared to ESA, SAIF provided higher precision and accuracy for
most of the parameters of interest. In addition SAIF mean SR was
found always equal or lower than the ESA one, indicating a supe-
rior robustness of the method to the testing conditions;
• compared to SAIF, ESA provided lower WRSS. This is consequence
of the filtering procedure implemented in SAIF.
Since the results in Table 3.1.2 might be mitigate by the average effect,
we considered also the whole distribution of %bias, i.e. the distribution
of %bias obtained comparing each simulated and estimated TACs. Fig-
ure 3.1.2 reports the%bias(Ki) distributions obtained with ESA and SAIF
(selecting the 90% of confidence interval). Both low and high noise sce-
narios are visualized. ESA results were comparable with those already
presented (Turkheimer et al., 2003; Veronese et al., 2010), which had high-
lighted the high sensitivity of the ESA method to the noise in the data: at
high SNR level%bias(Ki)was limited in both term of mean and variabil-
ity (%bias(Ki) mean±SD: -1.4%±4.9%) while at low SNR level it is evi-
dent aworsening of its performances (%bias(Ki)mean±SD: -4.3%±20.0%).
On the other hand, SAIF demonstrated limited mean%bias(Ki) (for high
SNR 0.35%; for low SNR 1.5%) and variability consistent with the level of
noise of the analyzed data (SD%bias(Ki) for high SNR 1.9%; SD%bias(Ki)
for low SNR 9.6%). Similar results were obtained also for the other pa-
rameters of interest.
A visual but very intuitive comparison of ESA and SAIF performances at
high noise level can be done by analyzing the results reported in Figure
3.1.3. The 75 simulated spectra were associated to 75 different regions of
a MNI brain atlas, derived from (Hammers et al., 2003). The correspon-
dence between spectra and regions was done only for graphical purpose,
without any precise relationship between simulated kinetic and the phys-
iology of the anatomical region. In this way, however, it was possible to
identify each ROI with a different vector of simulated parameters (Ki,K1
and Vb) (Fig. 3.1.3A). Then, like a MonteCarlo simulation, all the vox-
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Figure 3.1.2: %bias(Ki) distribution obtained with ESA and SAIF in simula-
tion. The figure shows the single-estimate Ki bias distribution at high and low SNR
levels (top and bottom of the panel respectively).
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els within a given ROI were associated with different noise realizations
of the same simulated kinetic activity correspondent to specific region.
The results obtained by applying ESA and SAIF to this dataset are re-
ported in Figure 3.1.3B,C. It is clearly evident how ESA Ki results are
completely out of the range of the simulated values. On the contrary,
SAIF presents Ki estimates in agreement with the reference values. The
fraction of SAIF failures and outliers was <1% respect the total number
of simulated TACs. The presence of salt and pepper disturb on the SAIF
Ki maps (Fig. 3.1.3C), consequence of the effect that the simulated noise
had on SAIF quantification, represents a good indication of unbiased be-
haviour of SAIF.
Figure 3.1.4 shows the SAIF %bias(Ki) as function of simulated kinetics
(randomly chosen from the previous simulated spectra, Table 3.1.2) and
a set of arterial input curves (AIF) (Fig. 3.1.4A). For this purpose, 50 AIFs
were extracted from several multicentre PET studies, referring to manual
and automatically sampling. This choice was made to be as much gen-
eral and tracer independent as possible. Analysis of SAIF performance in
relationship to AIF was performed at both high and low SNR levels.
In agreement with previous results, it can be noticed how the increase of
noise is coupled with a decrease of estimate precision and accuracy (Fig.
3.1.4B,C). The same figure shows also how the SAIF performances are
quite independent from the characteristics of AIF used, while they can
be correlated with the choice of spectral kinetic: it appears evident from
the matrix analysis (Fig. 3.1.4B,C) that some rows result more biased than
others, indicating a higher sensitivity of the method to the particular sim-
ulated spectrum. Since a unique SAIF passband was set, it might result
that this choice was not adequate for all the simulated kinetic spectra.
3.1.4 CONSIDERATIONS
The ESA simulation results were found in agreement with those pre-
sented already in literature, which had highlighted the necessity of fil-
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Figure 3.1.3: Parametric maps of %bias(Ki) obtained with ESA and SAIF
in simulation. Panel A-C report respectively simulated, ESA-estimated and SAIF-
estimated Ki parametric maps, obtained from high-noise simulated PET data.
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Panel A shows the time-activity course of the AIFs used for the simulation. Panel
B and C report the %bias(Ki) obtained for different simulated kinetic spectra and
different AIFs. Both regional and voxel noise level were simulated.
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tered version of SA to improve the robustness of the method to the pres-
ence of noise (Section 2.2.2). On the contrary, SAIF proved to be a robust
and reliable quantification method, providing precise and accurate esti-
mates with limited number of outliers even at high noise conditions. Al-
though a methodological validation cannot be limited to simulated data
analysis, these results represent a good starting point for SAIF develop-
ment and its application in real measured PET data.
To note that SAIF performances are heavily dependent from the choice of
the passband filter. In this simulation it was possible to define the SAIF
filter bounds accordingly with the characteristics of the simulated kinetic
spectra. However, when SAIF has to be applied to measured data, this
information is not available and other strategies need to be found for the
passband filter definition.
3.2 L-[1-11C]LEUCINE PET STUDIES IN HEALTHY SUBJECTS
In this section themain results related to SAIF application to L-[1-11C]Leu-
cine PET images are presented. Historical, SAIFwas developed for region-
wise quantification of this data (Veronese et al., 2010). the, since it showed
to be robust to the presence of noise in the data, its use was extended for
the voxe-lwise analysis (Veronese et al., 2012b).
3.2.1 INTRODUCTION
The L-[1-11C]Leucine PET method was developed and validated in or-
der to make possible fully quantitative measurement of regional rates
of cerebral protein synthesis (rCPS) in human subjects (Schmidt et al.,
2005; Smith et al., 2005). Biosynthesis of proteins is a fundamental pro-
cess necessary for physiological maintenance and functioning of all or-
ganisms and its alteration is related to a large set of clinical disorders
(Collins et al., 1980; Qin et al., 2005; Smith and Kang, 2000;Widmann et al.,
1991, 1992). rCPS also changes during brain development (Sun et al.,
1995) and normal aging (Ingvar et al., 1985).
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In the first fully quantitative L-[1-11C]Leucine PET studies in human sub-
jects (Bishu et al., 2008, 2009; Sundaram et al., 2006) rCPS was determin-
ed at the region-of-interest (ROI) level. Because the analysis was based on
a homogeneous tissue kinetic model for leucine, heterogeneity within a
region was not taken into account. Tomasi and colleagues (Tomasi et al.,
2009b) recently developed a method to estimate kinetic model parame-
ters and rCPS on a voxel-by-voxel basis. By averaging the estimated pa-
rameters and rCPS over all voxels within a ROI, this method produces
estimates for the region as a whole that take into account differences in
kinetics among the regions voxels. In simulation studies, estimates de-
rived from the voxel-wise approach were shown to bemore accurate than
those derived by fitting ROI data to a homogeneous tissue kinetic model
(Tomasi et al., 2009b). This effect wasmainly caused by the presence vari-
able fraction of kinetic heterogeneity in the data (Bishu et al., 2008, 2009),
characteristic that prevented also the application of a fixed compartmen-
tal model configuration for ROI level quantification.
For its characteristics of robustness to the noise in the data and appli-
cability to both homogeneous and heterogeneous tissues without any a
priori, SAIF might be a valid solution for both regional and voxel-wise
quantification of rCPS with L-[1-11C]Leucine PET images.
3.2.2 DATASET AND METHODS OF ANALYSIS
Data from 12 healthy awake male subjects (age 20-24) from previous
study (Bishu et al., 2008) were used. The criteria for subject inclusion and
the procedure for L-[1-11C]Leucine PET studies are described in detail in
(Bishu et al., 2008). All studies were performed on the ECAT High Reso-
lution Research Tomograph (HRRT) (CPS Innovations, Knoxville, TN),
which has spatial resolution of ∼2.6 mm full width at half maximum
(Wienhard, 2002). The 90-min emission scan was initiated coincident
with a 2-min intravenous infusion of 20-30 mCi of L-[1-11C]Leucine (one
subject received a 1-min infusion). Estimated leucine specific activity was
3 mCi/nmol. Images were reconstructed using motion-compensated 3D
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ordinary Poisson ordered subset expectation maximization (Carson et al.,
2003) as 42 frames (16x15, 4x30, 4x60, 4x150, 14x300 sec); voxel size was
1.21x1.21x1.23 mm. Arterial blood sampling was performed; concentra-
tions of unlabeled and labeled leucine in plasma and total 11C and 11CO2
activities in whole blood were measured according to methods detailed
in (Bishu et al., 2008). All subjects underwent a T1-weighted MRI of the
brain for ROI placement. A total of 18 regions and whole brain were eval-
uated in all subjects except one in which the hypothalamus could not be
drawn.
SAIF analysis was performed both at region level (9 subjects) and at
voxel level (6 subjects). As parameter of interest, particular attention
was given to K1 (Chapter 2, Eq. 2.3), the fraction of unlabeled leucine
in the precursor pool for protein synthesis derived from arterial plasma,
λ, (λ = (K1 −Ki)/K1) and rCPS defined as:
rCPS =
Ki
λ
· Cˆp (3.4)
where Cˆp represents the measured concentration of unlabeled leucine
in arterial plasma. SAIF results were compared with those estimated
voxel-wise with the Basis Function Method (BFM) developed by Tomasi
and colleagues (Tomasi et al., 2009b), representing the current standard
method for quantification of L-[1-11C]Leucine PET.
3.2.3 PASSBAND FILTER DEFINITION
As with the high-pass filter of Turkheimer et al (1994) (Turkheimer et al.,
1994), the choice of upper and lower cutoff frequencies βL and βU for
SAIF represents incorporation of prior information about the data into
the algorithm. The particular choice of interval influences the final esti-
mated spectrum, and therefore also estimates of the parameters of inter-
est. Since the distributions of the kinetic components in L-[1-11C]Leucine
PET data was a priori unknown it was impossible to directly define the
correspondent passband interval for SAIF application. Thus we set up
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a simulation approach based on the information available in literature
(Bishu et al., 2008; Tomasi et al., 2009b). The procedure consisted of sim-
ulating noisy TACs that were subsequently analyzed by SAIF with dif-
ferent passband intervals. The optimal passband was chosen as the one
that provided the best trade-off between precision and accuracy of the
estimates of rCPS and other parameters of interest.
Noise-free voxel TACs were simulated according to a heterogeneous ki-
netic model, with two equilibrating components and one trapping com-
ponent. Model parameters were generated by the random sampling of
normal distributions as follow: Vb=0.064±0.009 (unitless), α0=0.012±0.002
(ml/cm3/min), α1=0.0096±0.0004 (ml/cm
3/min), α2=0.0197±0.0015 (ml-
/cm3/min), β0=0 (min
−1), β1=0.032±0.004 and β2=0.15±0.03 (min
−1). The-
se values were extracted from (Bishu et al., 2008, 2009) considering tis-
sues with fast and slow kinetics. One thousand noisy TACs were sim-
ulated by adding to the noise-free simulated TACs Gaussian noise with
zero-mean and variance consistent with the level of noise in ROI and
in voxel data. For each noise level, different passband intervals (βL =
0.005:0.06 min−1; βU = 0.1:0.6 min
−1) were tested. To select the best in-
terval, performance indices percent bias (%bias) and percent root mean
square error (%RMSE) were computed. Any noise realization that re-
sulted in a negative entry in the simulated TAC was discarded and re-
placed with a new realization. Passband filter analysis was performed
separately for region and voxel noise level.
At the ROI level, the interval [0.03 min−1; 0.3 min−1] was selected as a
good compromise compromised between precision and accuracy, with
particular attention to the rCPS parameter. Based on the same criteria,
for voxel-wise SAIF quantification we chose 0.02 min−1 and 0.2 min−1
for βL and βU respectively. Due to the large discrepancy in signal-to-
noise ration it was expected that the optimal voxel-SAIF passband filter
differed somewhat from that used for ROI-SAIF. In particular, high fre-
quency noise present in voxel data but attenuated in the ROI data reduces
the accuracy with which high-frequency components can be estimated.
Thus, to reduce the impact of high frequency noise, the upper-bound for
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the voxel-SAIF passband filter has to be more selective compared to the
filter for ROI-SAIF (0.2 min−1 instead of 0.3 min−1). At the other end of
the spectrum, the less restrictive lower bound of the voxel-SAIF passband
(0.02 min−1 for voxel-SAIF; 0.03 min−1 for ROI-SAIF) has the effect of al-
lowing greater kinetic variability in low-frequency components among
individual brain voxels.
3.2.4 METHOD IMPLEMENTATION
Once the choice of passband was made, SAIF was applied to the mea-
sured datasets. The distribution of the βs grid as well as the weighting
procedure were applied as described in Section 2.3.2. The error variance
was modelled assuming Poisson statistics as
var (CT (ti)) = σ
2 e
γti · CT (ti)
∆ti
(3.5)
(Wu and Carson, 2002) where γ is the decay constant for 11C,∆ti is length
of Frame i, and σ2 is a proportionality coefficient reflecting the noise level
in the data.
The difference between tracer arrival time in brain and arterial sampling
site was estimated by shifting blood curves 0 − 20 sec, fitting the whole
brain TAC, and selecting the delay that produced the smallest WRSS.
Tracer appearance times in various parts of the brain differ from themean
of the brain as a whole by ±2 sec (Iida et al., 1988); therefore, in each
study, for all ROIs and all voxels, whole brain tracer arrival delay was
used.
For consistency the same setting was extended to BFM also. This decision
was taken, in order to avoid differences between the methods related to
discrepancy in the algorithm setting. Since the similarity of the methods
(Tomasi et al., 2009b; Veronese et al., 2010), the utilization of the a com-
mon setting did not represent a critical point for BFM application.
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3.2.5 RESULTS
REGION-WISE QUANTIFICATION For what concerns the regional
analysis, SAIF produced good fits of ROI TACs (Fig. 3.2.1). In all ROIs
one trapping component, one blood component, and at least two equili-
brating components were detected. Components detected in frontal cor-
tex, thalamus, and corona radiata in one subject are illustrated in Figure
3.2.1A-C. Of the 170 ROIs analyzed (19 in 8 subjects and 18 in one sub-
ject), in 24 ROIs (14%) three equilibrating components were necessary to
describe total activity in the region. It was not consistent among subjects,
however, which ROIs required the larger number of components. Fig-
ure 3.2.1D-F compares the best-fit of measured total activity determined
with SAIF to that obtained with voxel-wise BFM analysis in one subject.
In general, total activity estimated with SAIF fits measured data as well
as or slightly better than the mean of voxel-wise-estimated activities. The
twomethods also provided comparable trends for predicted time courses
of labeled free leucine and protein in tissue. After the first approximately
15-20 min, labeled free leucine tended to be slightly lower, and labeled
protein slightly higher, when estimated with SAIF compared with voxel-
wise analysis. In the initial portion of the curves, particularly in corona
radiata, these trends were reversed. Overall, similarities between estima-
tion methods in predicted time courses of labeled free leucine and protein
are reflected in similarities in estimated rCPS in this subject: the percent
differences between SAIF and voxel-wise estimates were 1.5%, 1.9%, and
3.1% for frontal cortex, thalamus and corona radiata, respectively.
Figure 3.2.2 illustrates the comparison of region-SAIF estimates with re-
gional mean values of voxel-BFM estimates of K1, λ, and rCPS in in-
dividual subjects. The percent difference between SAIF and voxel-wise
estimates for each parameter was computed for each subject. Graphs
represent inter-subject means and SDs of the percent differences between
analysis methods. In general, differences between methods were small,
but inter-subject variability tended to be greater in smaller, and therefore
noisier, regions. Across all regions and subjects, the percent difference
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in K1 ranged from a minimum of -12% (in the precentral gyrus of one
subject) to a maximum of 6% (hipppocampus); inter-subject mean values
ranged from -5% to 1%). The percent difference in , across all regions and
subjects, ranged from -14% (hippocampus) to 6% (hypothalamus); inter-
subject mean value range: -5% to 4%. The range of percent differences
in rCPS, across all regions and subjects, was -18% (occipital cortex of one
subject) to 23% (hippocampus); inter-subject mean values ranged from
9% to 7%.
Table 3.2.1 summarizes values of K1, λ, and rCPS estimated by ROI--
SAIF and those estimated voxel-wise with BFM. Means and SD for 9 sub-
jects are reported for 18 ROIs and whole brain. There is good agreement
between the mean values of the two methods in most regions, but inter-
subject variability was somewhat higher in λ and rCPS estimated with
SAIF than with the BFM method. In most regions, there was also good
agreement between themethods in estimates of Vb. SAIF andmean voxel-
wise estimates of Vb in whole brain were 0.062±0.009 and 0.062±0.008,
respectively. In all regions examined, the inter-subject mean of the SAIF
estimates of Vb was 95% to 102% the corresponding mean of the voxel-
wise estimates.
VOXEL-WISE QUANTIFICATION When SAIF was applied at voxel
level, a superior agreement was found with BFM method in the descrip-
tion of all the parameters of interest. Respect to regional-SAIF, this be-
havior was awaited, since the two methodologies were compared at the
same resolution level.
Table 3.2.2 summarizes the relative difference of mean voxel estimates
within ROIs of K1, λ, and rCPS. Results refer to those obtained with
SAIF and BFM across subjects. The relative rCPS difference across ROIs
and subjects was 6%±5% (mean±SD). The best agreement was found in
Thalamus and Putamen (1.5% and -1.9% respectively), while the worst
was detected inHippocampus andAmigdala (17% and 15%, respectively).
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Figure 3.2.1: Time courses of total activity and activity in tissue components
estimated with SAIF. Total activity was measured in frontal cortex (A), thalamus
(B) and corona radiata (C) in one subject. Open squares and solid lines represent the
measured and fitted total activity in the ROIs. Open circles represent activity of blood
in the brain. Solid diamonds, solid squares and solid triangles represent trapping,
slow, and fast components, respectively, detected by SAIF. Concentration of 11CO2
in brain is not shown. (D-F) SAIF and voxel-wise fits. The graphs show the time
courses of total activity, labeled protein and labeled free leucine in frontal cortex (D),
thalamus (E) and corona radiata (F) of one subject. Open squares indicate measured
total activity in the ROI, and solid lines represent activity estimated by fitting the
ROI TAC using SAIF. The average time course of the activities determined in each
voxel from the parameter estimates for that voxel is shown by the dashed lines. Free
leucine and protein time courses estimated by the two methods are similar in the very
early portion of the curve; they gradually separate with increasing time. In the last
15-30 min, one sees slightly lower total activity and free leucine estimated by SAIF,
and slightly higher concentrations of labeled protein.
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Figure 3.2.2: Percent difference between SAIF and voxel-wise estimates of K1
(A), λ (B) and rCPS (C). For each of the nine subjects, for each ROI, and for each
parameter, the percent difference was computed as 100 ∗ (pSAIF − pBFM )/pBFM ,
where pSAIF is the SAIF estimate and pBFM is the mean of the voxel-wise estimates
of the parameter. For each ROI indicated, the bar represents the inter-subject mean
of the percent difference in the parameter estimates. The inter-subject standard
deviation is indicated by the error bar.
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Table 3.2.1: Regional Estimates of K1, λ and rCPS
ROI TAC-based Estimation with SAIF Voxelwise Estimation with BFM
Region K1 λ rCPS K1 λ rCPS
(mL/g/min) (unitless) (mL/g/min) (mL/g/min) (unitless) (mL/g/min)
Whole Brain (1,397±133 cm3) 0.047 ± 0.004 0.77 ± 0.03 1.57 ± 0.13 0.049 ± 0.004 0.77 ± 0.02 1.61 ± 0.08
Cerebellum (115±15 cm3) 0.067 ± 0.007 0.80 ± 0.02 1.85 ± 0.14 0.07 ± 0.007 0.78 ± 0.02 1.96 ± 0.10
Vermis (6±1 cm3) 0.064 ± 0.007 0.79 ± 0.04 1.85 ± 0.16 0.066 ± 0.008 0.77 ± 0.03 1.96 ± 0.09
CORTICAL
Frontal cortex (135±61 cm3) 0.051 ± 0.005 0.75 ± 0.03 1.83 ± 0.11 0.052 ± 0.005 0.75 ± 0.02 1.89 ± 0.09
Temporal cortex (58±12 cm3) 0.044 ± 0.004 0.73 ± 0.03 1.74 ± 0.15 0.046 ± 0.004 0.75 ± 0.02 1.73 ± 0.10
Occipical cortex (29±12 cm3) 0.064 ± 0.006 0.78 ± 0.03 1.93 ± 0.21 0.063 ± 0.006 0.76 ± 0.03 2.09 ± 0.17
Parietal cortex (17±5 cm3) 0.053 ± 0.004 0.76 ± 0.04 1.78 ± 0.28 0.054 ± 0.004 0.76 ± 0.02 1.86 ± 0.2
Supraorbital gyrus (4±1 cm3) 0.047 ± 0.006 0.74 ± 0.03 1.76 ± 0.14 0.048 ± 0.005 0.75 ± 0.03 1.77 ± 0.10
Precentral gyrus (3±0 cm3) 0.057 ± 0.005 0.78 ± 0.04 1.75 ± 0.29 0.056 ± 0.006 0.76 ± 0.02 1.88 ± 0.22
Postcentral gyrus (2±0 cm3) 0.059 ± 0.006 0.79 ± 0.03 1.71 ± 0.16 0.059 ± 0.006 0.77 ± 0.02 1.87 ± 0.18
SUBCORTICAL
Thalamus (15±6 cm3) 0.05 ± 0.004 0.79 ± 0.02 1.47 ± 0.07 0.051 ± 0.003 0.78 ± 0.02 1.54 ± 0.10
Caudate (8±1 cm3) 0.033 ± 0.004 0.77 ± 0.02 1.04 ± 0.10 0.034 ± 0.005 0.79 ± 0.02 1.01 ± 0.07
Putamen (9±1 cm3) 0.048 ± 0.005 0.80 ± 0.03 1.3 ± 0.13 0.051 ± 0.006 0.80 ± 0.02 1.33 ± 0.08
Hippocampus (4±1 cm3) 0.035 ± 0.004 0.71 ± 0.04 1.58 ± 0.2 0.037 ± 0.004 0.74 ± 0.02 1.47 ± 0.15
Amygdala (5±1 cm3) 0.031 ± 0.003 0.71 ± 0.05 1.42 ± 0.18 0.033 ± 0.003 0.74 ± 0.03 1.35 ± 0.11
Hypothalamus (0.6±0.2 cm3) 0.035 ± 0.015 0.69 ± 0.26 1.11 ± 0.53 0.041 ± 0.005 0.79 ± 0.03 1.24 ± 0.24
WHITE MATTER
Corona radiata (46±5 cm3) 0.026 ± 0.004 0.76 ± 0.02 0.87 ± 0.08 0.027 ± 0.004 0.79 ± 0.02 0.83 ± 0.06
Centrum semiovale (35±11 cm3) 0.028 ± 0.003 0.76 ± 0.03 0.97 ± 0.12 0.03 ± 0.004 0.78 ± 0.02 0.91 ± 0.08
Cerebellar peduncles (14±2 cm3) 0.043 ± 0.004 0.81 ± 0.03 1.07 ± 0.13 0.044 ± 0.004 0.80 ± 0.02 1.16 ± 0.08
4
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Similarly to rCPS, limited discrepancy was found also forK1 (mean±SD
relative difference = -4%±4%) and λ (mean±SD relative difference = -
3%±2%.
The same good agreement between SAIF and BFM can be noticed in Fig-
ure 3.2.3. The scatter analysis of the mean of voxel estimates within re-
gions showed Perason’s correlation coefficient (R2) ranged from 0.89 (for
λ) (Fig. 3.2.3A) up to 0.99 (for rCPS) (Fig. 3.2.3B). No statistical differ-
ence (p <0.05) was found by the comparison of mean of voxel estimates
between SAIF and BFM (Fig. 3.2.3C).
Figure 3.2.4 allows a visual comparison of rCPS and λ parametric maps,
obtained with BFM and SAIF respectively. Coherently with previous re-
sults, the spatial distribution of the voxel estimates appears very similar
between different methods.
In term of fit of the data (Fig. 3.2.5) SAIF and BFM provided similar de-
scription. Altough WRSS was generally lower with SAIF, the difference
with BFM was < 1% (mean across all the subjects). The total rate
Table 3.2.2: Percent relative differences of voxel-wise SAIF and BFM for K1, λ,
and rCPS
Region K1 λ rCPS
WholeBrain -4.90% ± 1.90% -3.10% ± 1.40% 5.10% ± 3.60%
Cerebellum -11.00% ± 2.10% -4.30% ± 0.80% 6.50% ± 3.90%
CORTICAL
Frontal cortex -3.00% ± 2.90% -2.90% ± 1.90% 4.40% ± 3.80%
Temporal cortex -1.80% ± 1.80% -2.80% ± 0.90% 4.70% ± 4.10%
Occipital cortex -6.20% ± 2.00% -2.30% ± 1.30% 2.30% ± 2.80%
Parietal cortex -6.10% ± 3.20% -3.50% ± 2.30% 4.60% ± 3.80%
SUBCORTICAL
Thalamus -5.80% ± 2.70% -1.80% ± 0.90% 1.50% ± 4.20%
Putamen -0.30% ± 2.40% 0.00% ± 0.90% -1.90% ± 5.00%
Caudate 0.40% ± 3.00% -2.00% ± 2.00% 4.20% ± 8.30%
Hippocampus -1.10% ± 3.30% -6.60% ± 2.60% 16.60% ± 6.60%
Amygdala -2.10% ± 3.00% -6.60% ± 2.10% 14.70% ± 5.00%
WHITE MATTER
Corona Radiata 0.70% ± 4.10% -2.40% ± 2.40% 7.10% ± 8.30%
Cerebellar peduncles -8.00% ± 3.00% -2.90% ± 1.20% 4.90% ± 5.20%
Mean -3.80% -3.20% 5.80%
SD 3.50% 1.80% 5.00%
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Figure 3.2.3: BFM and SAIF comparison.
of failures and outliers was low with both BFM (0.4%±0.3%) and SAIF
(1.7%±1.0%). The fraction of voxels with zero rCPSwas almost negligible
(<1%) for all the methods and all the tested scenarios. In term of number
and type of components return with voxel-SAIF, one trapping and one
blood component were found in 100% of successfully estimated voxels,
but, differently ffrom regional analysis, only 45% of them included two
or more equilibrating components. The finding of more than one equi-
librating component suggests kinetic heterogeneity of the tissue in these
voxels. In the remaining voxels only one equilibrating component was
detected, indicating the homogeneous tissue model was appropriate to
describe 55% of brain voxel TACs.
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A) T1 weighted MRI
C) rCPS parametric maps
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(nmol g-1 min-1)
0.00
3.50
1.25
(unitless)
0.0
1.0
0.5
B) Dynamic PET
BFM SAIF
BFM SAIF
Figure 3.2.4: Parametric Maps.
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Figure 3.2.5: BFM and SAIF model fit of the data.
3.2.6 CONSIDERATIONS
Use of the iterative filter implemented in SAIF improved the robustness
of the method to noise; SAIF provided good estimates of leucine kinetic
parameters and rCPS, for both low and high noise level. ROI-based- and
mean voxel-based rCPS estimates were highly correlated with BFM, the
current state of the art method for leucine kinetic quantification.
Very interesting considerations can be done when means of voxel-SAIF
estimates within a region are compared to ROI-SAIF estimates. In gen-
eral, even though two different levels of resolution (ROI and voxel) were
compared each other, it can be found good agreement between analysis
methods. Unlike fixed compartmental model analyses, spectral analy-
sis allows the tissue ROI to be represented as a linear combination of
any number of tissue compartments. Because the tissue ROI could be
represented as a linear combination of the compartments of each voxel
comprising the ROI, we could expect good agreement between the ROI-
SAIF estimates and mean voxel-SAIF estimates of linear parameters of
the model. Indeed, the linear parameter Vb and the parameter K1, which
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is the sum of the linear coefficients αi, exhibit the best agreement (1%±4%
and 1%±4%, mean±SD of the difference between ROI-SAIF and mean
voxel-SAIF estimates of Vb and K1, respectively) and highest correlation
between methods (R2 = 0.97 for both Vb and K1). In practice, of course,
the number of components identified in ROI data is far smaller than the
sum of the unique components found in the voxels of the ROI, principally
due to the small number of observations in a single ROI TAC, which lim-
its the number of components that can be identified. In contrast to linear
parameters, λ and rCPS are non-linear combinations of parameters, and
therefore less agreement between ROI-SAIF and mean voxel-SAIF esti-
mates is to be expected. Estimates of λ were 2%±2% higher with ROI-
SAIF and correlation between estimates provided by the two methods
was 0.67. Correlation between rCPS estimated with the two methods
was very high (R2=0.92), but estimates were 8%±6% lower with ROI-
SAIF. Determination of λ from the SAIF-estimated coefficients αi is based
on the assumption that all λ in the subregions of a heterogeneous tissue
are equal; this constraint is likely to have a greater impact when data are
analyzed at the ROI level, where a uniform value of λ for the entire re-
gion is assumed, than when data are analyzed at the voxel level and λ
can vary among voxels within the region. The constraint contributes to
differences between ROI-SAIF and voxel-SAIF estimates of λ and, esti-
mates of rCPS. For this reason, voxel-SAIF method should be preferred
from the ROI one.
Essential to performance of SAIF is selection of appropriate upper and
lower bounds of the passband. The passband interval can be thought of
as prior information on the data; it is defined as the interval in which true
equilibrating components in the system are expected to be found. We
chose passband limits based on results of a simulation study, but if the
true kinetics of leucine in the tissue differ appreciably from those used
in the simulation, the optimal passband may differ from the one we se-
lected. Other approaches to selection of passband endpoints may lead to
further improvements in SAIF performance and should be explored.
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3.3 [11C]SCH442416 PET STUDIES IN HEALTHY SUBJECTS
3.3.1 INTRODUCTION
A2A receptor represents one of the four types of adenosine receptors.
A2A plays roles in the heart, regulating myocardial oxygen consumption
and coronary blood flow, and it also has broader anti-inflammatory ef-
fects throughout the body (Hasko and Pacher, 2008). In the brain A2A
are involved in the regulation of the neurotransmitter release such as
dopamine and glutamate, making it a potential therapeutic target for
the treatment of conditions such as insomnia, pain, depression, drug
addiction and Parkinson’s disease (Cunha et al., 2008; Fuxe et al., 2007;
Mihara et al., 2008; Schiffmann et al., 2007).
[11C]SCH442416 is a nonxanthine radioligandwhich binds selectively and
reversibly to striatal A2A receptors, abundant in basal ganglia, vascula-
ture and platelets (Moresco et al., 2005). A2A receptor interacts struc-
turally and functionally with the dopamine D2 receptor and this interac-
tion is of particular interest as it is thought to be central to basal ganglia
dysfunction in Parkinson’s disease (Schiffmann et al., 2007). Preclinical
studies on rats and nonhuman primates suggest that [11C]SCH442416 is
suitable for the in vivo imaging of adenosine A2A receptors with PET
because of its high affinity and selectivity, good signal-to-noise ratio, and
low levels of radioactive metabolites in the brains (Moresco et al., 2005;
Todde et al., 2000).
Quantitative assessment of A2A receptor expression from [11C]SCH442416
PET images in human brain have been made by using spectral analy-
sis (Hinz et al., 2003) revealing the presence of both reversible and irre-
versible components. From SA application it has been possible to define
[11C]SCH442416 compartmental model (Rizzo, 2012) (Fig. 3.3.1), com-
posed of one reversible tissue compartment and one additional irreversible
compartment. The latter is required to describe the vascular kinetics of
the tracer.
These conditionsmight appear not adequate for SAIF applicability, which
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has been defined for tracers with irreversible tissue kinetics. However,
the flexibility of the SA model could theoretically allow to extend the use
of SAIF even in presence of vascular trapping. The aim of this section is
to verified this possibility.
C1
Tissue
k2
K1
C2
Kb
Blood
Plasma
Figure 3.3.1: [11C]SCH442416 compartmental model. Two tissue-three rate
constants in parallel (3K-parallel) compartmental model. K1 (ml/cm
3/min) and
k2 (min
−1) represent first order rate constants for transport of ligand from plasma
to tissue (C1) and vice versa. Kb (ml/cm
3/min) represents the trapping vascular
component (C2).
3.3.2 ADAPTABILITY OF SAIF TO TRACER WITH BLOOD TRAPPING
As indicated by Rizzo (2012), the correct model for describing the [11C]SCH442416
kinetics consists in:

C1(t)
dt
= K1Cp(t)− k2C1(t) C1(0) = 0
C2(t)
dt
= KbCp(t) C2(0) = 0
Cmeasured(t) = (1− Vb)C1(t) + Vb [C2(t) + Cb(t)]
(3.6)
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where K1 (ml/cm
3/min) and k2 (min
−1) are the first order rate constants
for transport of ligand from plasma to tissue and vice versa. Kb (ml/-
cm3/min) represents the rate constant from plasma to the trapping vas-
cular component C2.
From Eq. 3.6, the explicit solution can be derived as
Cmeasured(t) = (1− Vb)
[
K1Cp(t)⊗ e
−k2(t)
]
+ Vb
[
Kb
∫ t
0
Cp(τ)dτ + Cb(t)
]
(3.7)
From the comparison between Eq. 3.7 and SA model equation (Eq. 2.7),
a close relationship can be find. The only difference is represented by the
trapping component that in standard SA is related to the tissues (and for
this reason multiply by the term (1 − Vb)) while in [
11C]SCH442416 is re-
lated to the blood (and for this reason multiply by the term Vb).
Thus, it is not difficult to modify the SA equation for both ESA and SAIF
in order to extend themethod applicability to [11C]SCH442416 data. Once
the kinetic spectra are estimated, it is sufficient to rescale the trapping
coefficient for the blood volume fraction instead of the tissue fraction.
Moreover, since the Kb indicated the trapping in the vascular compart-
ment, all the equilibrating components found with SA model can be as-
sumed as belonging to the kinetic of the tracer in tissues and therefore
used to compute the distribution volume. Thus, the same formula of Eq.
2.5 here recall
VT =
M∑
j=1
αj
βj
(3.8)
3.3.3 DATASET AND METHODS OF ANALYSIS
Data of [11C]SCH442416 of 5 healthy subjects from previous study were
used (Hinz et al., 2003). Each subject underwent a 90-min dynamic PET
scanning in a Siemens ECAT EXACT HRD scanner after a bolus injec-
tion of an average of 612 MBq of [11C]SCH442416 over 10 seconds, 30
seconds after the start of the scan. All PET data were acquired in 3-
dimensional mode, corrected for attenuation, detector efficiency, random
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events, and scatter, and reconstructed into tomographic images using fil-
tered back-projection[9]. Acquisition was performed in list-mode (event
by event) and scans were rebinned into 34 time frames (6x10, 3x20, 3x30,
4x60, 6x120, 8x300, 3x600 seconds). The reconstructed voxel sizes were
2.096 mm x 2.096 mm x 2.43 mm. After injection of [11C]SCH442416 the
radioactivity concentration in blood was measured continuously for the
first 15 minutes with discrete blood samples taken at baseline, 5, 10, 15,
20, 30, 40, 50, 60, 75, and 90 minutes. Eight of these samples were also
used for quantification of the fraction of radioactivity attributable to un-
metabolized parent radiotracer, generating the metabolite-corrected arte-
rial plasma input function for all subjects. The tissue, blood and plasma
data were corrected for decay of 11C.
Each subject had a T1-weighted MRI used only for region of interest
placement through the coregistration with a maximum probability brain
atlas (Hammers et al., 2003). Among all the 73 regions present in the at-
las, Hippocampus , Amygdala, Cerebellum, Caudate, Putamen, Thala-
mus, Temporal Cortex, Pallidum and Frontal Cortex were selected for
the analysis. Right and left hemispheres were considered combined.
As current state of the art for [11C]SCH442416 quantification we selected:
• Weighted Non Linear Least Squares (WNLLS) applied to literature
reference [11C]SCH442416 compartmental model (Fig. 3.3.1);
• Standard and not filtered SA (ESA);
All the methods were applied voxel-wise and results were compared
with those provided by SAIF applied at the same resolution level. For
each subject, SAIF passband was derived by WNLLS results, by setting
the filter bounds equal to the minimum and maximum of k2 parame-
ter estimated with the non linear method. This criterion was defined by
considering the relationship between [11C]SCH442416 (Eq. 3.7) and SA
model.
Distribution volume of the tracer in tissue, VT (ml/cm
3) was considered
as parameter of interest. With WNLLS, VT was calculated as the ratio of
tissue kinetic rate constant (VT = K1/k2). Mean of voxel estimates within
55
Applications to brain studies
regions and outliers were used for the computation of the performance
indexes.
3.3.4 RESULTS
Figure 3.3.2 reports a comparison of mean of voxel VT estimates within
ROIs, by considering all the tested methods. The same subset of voxels in
which all the methods successfully converged to physiological solutions
were considered. While WNLLS and ESA correlation was clearly weak
(R2=0.55), SAIF and WNLLS estimates resulted well correlated (R2=0.91)
(Fig. 3.3.2A). Also the inter-subject variability of VT estimates were com-
parable between WNLLS and SAIF, while with ESA the variability be-
tween subjects resulted higher (Fig. 3.3.2B). The same relationship be-
tween themethods can be noticed by considering the VT parametric maps
(Fig. 3.3.3). The spatial distribution of VT values computed with ESA is
clearly not coherent with those reported by SAIF andWNLLS. Even if we
do not know the true distribution of these values, due to the physiologi-
cal organization of the brain tissues and their spatial smoothness, we can
hypothesize that the results provided with ESA are unreliable respect to
those provided by SAIF and ESA.
Despite this difference, all the methods provided almost the same de-
scription of the data (Fig. 3.3.4): WRSS and RSS derived from WNLLS
application were found approximately 10% higher respected to those re-
turned by ESA and SAIF.
3.3.5 CONSIDERATIONS
[11C]SCH442416 kinetics showed an important vascular component whose
effect was to complicate the anatomical atlas co-registration to the PET
images as well as to mislead the estimation of the model parameters.
This characteristic combined with the high sensitivity of the noise can be
the justification for which ESA method did not provide reliable results.
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Figure 3.3.3: Comparison of VT parametric maps.
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Figure 3.3.4: Data fit performance. Solid lines refer to WNLLS, dotted line refer
to ESA and dashed line refer to SAIF.
By considering the results presented in literature (Galazzo et al., 2010;
Rizzo, 2012) we can suggest to limit ESA application to [11C]SCH442416
data only for regional analysis. On the contrary, SAIF performed simi-
larly to WNLLS method. The good agreement was verified in term of
parametric maps and description of the data. Respect to the non linear
method, the advantage of SAIF can be represented by its computational
time (reduced by 50%). However, if we considered the outliers, both SAIF
and WNLLS were penalized by a high fraction of not physiological esti-
mates (in some subjects >30% of the whole field of view). This suggests
that SAIF as well as WNLLS might not represent the best approaches
for quantification of [11C]SCH442416 PET data and that different alterna-
tives, like the HMAP or HBFMdeveloped by Rizzo (Rizzo et al., 2012a,b),
should be considered.
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If we don’t succeed, we run the risk of failure.
Dan Quayle
4
Applications to non brain studies
THIS CHAPTER PRESENTS some representative applications of SAIF in
non brain PET studies, with the aim to demonstrate the adaptability of
the technique to physiological systems different from brain, the anatom-
ical context for which SAIF was originally developed. SAIF performance
will be compared with those provided by the standard and already vali-
dated methods of analysis, in order to stress advantages and drawbacks
of the presented quantification tool respect to what is currently used in
literature.
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4.1 [18F]FDG PET STUDIES IN SKELETAL LEG MUSCLE
4.1.1 INTRODUCTION
The evaluation of SAIF performance cannot be complete without an ap-
plication with [18F]FDG , the most used PET irreversible tracer in clinical
practice. In PET imaging [18F]FDG has been widely applied for the as-
sessment of glucose metabolism in the heart (Miyauchi and Wahl, 1996),
lungs (Service, 2005) and the brain (Bartenstein et al., 2002). After [18F]FDG
injection, the tracer is taken up by cells where it is phosphorylated by
hexokinase and hence trapped. This results into two important conse-
quences:
• the phosphorylation prevents the glucose from being released again
from the cell, once it has been absorbed. Thus no metabolites prod-
uct are cycling in the system;
• the spatial distribution of [18F]FDG tracer uptake directly reflects
the metabolic activities of the tissues.
This last characteristic is the main reason for why [18F]FDG -PET has been
so largely utilized for tumor imaging in oncology (Mihailovic et al., 2012)
where it is used for diagnosis, staging, and monitoring treatment of can-
cers.
In this sectionwe considered [18F]FDG for the investigation ofmetabolism
of skeletal muscle and its relationship with insulin-glucose system. The
analysis requires to consider the entire interactions between delivery, trans-
port and phosphorylation of glucose in governing the uptake into human
skeletal leg muscle (Bertoldo et al., 2006).
Generally the main methods for quantitative [18F]FDG imaging are SUV
and Patlak. Both of them, however, return only the information about
the tracer uptake, which is not sufficient when the purpose is to fully-
characterized the kinetic of the tracer. An alternative for [18F]FDG quan-
tification is represented by WNLLS applied to [18F]FDG skeletal muscle
compartmental model (Bertoldo et al., 2001). WNLLS demonstrated to
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be extremely precise and accurate when it is applied to high SNR level
(Bertoldo et al., 2001), but at high noise level like in voxel-wise analy-
sis, its applicability results limited. On the contrary, SAIF might repre-
sent a valid alternative for the parametric imaging of [18F]FDG in skeletal
muscle, by combining robustness to the noise with high informative out-
comes.
Cp Ci Ce Cm
K1
k2
k3
k4
k5
Figure 4.1.1: [18F]FDG compartmental model. K1 and k2 refer to reversible
exchange between plasma and the interstitial space (Ci); k3 and k4 refer to reversible
exchange attributed to bidirectional glucose transport (Ce); k5 describes the kinetic
of glucose phosphorylation.
4.1.2 DATASET AND METHODS OF ANALYSIS
[18F]FDG data of 5 healthy subjects from previous study (Bertoldo et al.,
2006) were used. Each subject underwent a 90-min dynamic PET scan-
ning after a bolus injection of an average of 222 MBq (6 mCi) of [18F]FDG
over 20 seconds. A Siemens/CTI ECAT HR+ PET scanner in 3-D imag-
ing mode (63 parallel planes, axial field-of-view 15.2 cm, slice width 2.4
mm) was used. The final reconstructed PET image resolution was about
6 mm. Participants were positioned in the PET scanner with the mid-calf
area in the center of the field, and to minimize movement during PET
imaging, the legs were supported with pliable block molding. MRI was
also performed for the ROI placement. For further details the interested
reader is referred to (Bertoldo et al., 2006).
As reference methods for [18F]FDG quantification we considered:
• WNLLS applied to [18F]FDG skeletal muscle model. This coincides
with a 3-tissue model, composed by two equilibrating compart-
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ments (interstitial space and cellular compartments) and one trap-
ping (Fig. 4.1.1) (Bertoldo et al., 2001);
• Patlak graphical analysis;
All the methods were applied voxel-wise and their results were com-
pared with those provided by ESA and SAIF applied at the same reso-
lution level. SAIF passband interval was derived according to previous
[18F]FDG study in human skeletal muscle (Bertoldo et al., 2001) and fixed
to 0.05 min-1 and 0.7 min-1 for lower and upper bound respectively. Ki
was considered as the main parameters of interest for the evaluation of
the method performances. Mean of voxel estimates within regions and
outliers were also computed performance indexes.
4.1.3 RESULTS
The comparison of Ki parametric maps obtained for the mid-calf area
in one representative subject (Fig. 4.1.2), provides a direct information
about the method performances: SAIF parametric maps resulted in the
best anatomical description of the investigated tissues. In particular it can
be seen how well delineated are the soleos and tibialismuscles (Panel A),
respect to the other methods. In fact, moving from top to the bottom and
from left to right (Fig. 4.1.2B-D), there is an evident decrease of method
performances coupled with a voxel outlier increase, especially for WN-
LLS and ESA methods. This is consequence of the different method sen-
sitivity to the noise in the data.
However, when the same subsets of voxels in which all the methods suc-
cessfully converged into physiological estimates were selected, high cor-
relation (R2>0.97) and consistency was found for Ki parameter, for all
subjects and all regions (Fig. 4.1.3 A). The main difference was related
to the number of voxel outliers: SAIF proved to be robust with a voxel
failure rate <1%, whereas more than 40% of ESA estimates had to be
eliminated because out of the physiological range(Fig. 4.1.3B).
Figure 4.1.4 shows some an additional outcomes of SAIF. In panel A two
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representative voxel-TACs (one for muscle and one for low-uptake tis-
sue) are reported. This information is not available with SUV and Patlak
methods and, due to the high fraction of failures, it is only partially ob-
tainable withWNLLS. In these reported voxels (Fig. 4.1.4A), for example,
WNLLS did not converge to physiological solutions. Panel B and C, in-
stead, show the SAIF parametric maps for K1 and Vb. As for the model
description of the data, this information was not available with SUV and
Patlak.
PatlakSAIF
WNLLS SA
0.00 0.250.200.150.100.05
K
i
(ml/cm3/min)
A)
C)
B)
D)
Figure 4.1.2: Ki Parametric maps. Panel A-D show the Ki parametric maps
obtained respectively with SAIF, Patlak, WNLLS and ESA. Results refer to the mid-
calf area in one representative subject, reported in both axial and coronal views.
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obtained with voxel-wise SAIF in one representative subject.
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4.1.4 CONSIDERATIONS
SAIF demonstrated to be the best method among those tested for [18F]FDG
PET quantification in skeletal muscle: it provided the best Ki parametric
maps with minimum failures and high anatomical resolution; respect to
SUV or Patlak plot, it returned complete information about tracer kinet-
ics, by providing for >99% of the voxels the model description of the
data; as WNLLS, SAIF returned K1 and Vb parametric maps but with a
significantly lower number of outliers.
Consistently with the results obtained, it can be concluded that SAIF
represents a valid and complete tool for the voxel-wise quantification of
[18F]FDG PET data in skeletal muscle.
4.2 [18F]FLT PET STUDIES IN BREAST CANCER PATIENTS
4.2.1 INTRODUCTION
Breast cancer is the most common cancer in women worldwide and one
of the principle cause of death from cancer among women globally. De-
spite the high incidence rates, in Western countries, 89% of women diag-
nosed with breast cancer are still alive 5 years after their diagnosis, which
is due to detection and treatment (Parkin et al., 2008). Nevertheless ap-
proximately 30% of patients develop metastases (SEER Cancer Statistics
Review, 1975-2005, http://www.seer.cancer.gov) and despite the ad-
vances in treatment, a too large portion of these patients will be incur-
able.
One important aspect to ameliorate the efficacy of the breast cancer treat-
ment is related to the capacity of an early and object measurement of
the therapy response. This possibility would allow a better calibration
of the therapy to the individual, minimizing patient exposure to inef-
fective and potentially toxic treatment regimens. At the present time,
response to chemotherapy is routinely measured with RECIST criteria
(Therasse et al., 2000), which relies on changes of dimensions of target
lesions. This method, however, takes time to be developed and does
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not provide any indication about the kinetic changes within the tumour
region. Different alternatives are already used in clinics, like histolog-
ical examinations (Dowsett et al., 1999) or molecular imaging methods
(Wahl et al., 1993). The PET tracer [18F]FLT (fluorothymidine), for exam-
ple, is a cell proliferation marker which have been successfully applied
in breast cancer (Kenny et al., 2005), showing good correlation between
its tissue uptake and tumour biopsies (Kenny et al., 2005). In literature,
standard approaches for voxel-wise quantification of [18F]FLT images are
represented by the SUV and Patlak analysis, justified by the irreversibil-
ity of the [18F]FLT tracer (Gray et al., 2010; Kenny et al., 2007, 2005). Both
methods, however, return incomplete information about the investigated
system: SUV represents a semi-quantitative approach and its results are
strongly dependent from the factors used to normalized the injected dose
(Kenny et al., 2005); Patlak plot, instead, provides a partial description of
tracer kinetic limited to the trapping in tissues, without accounting for
other important elements like tracer delivery or blood volume fraction.
The latter might be a very penalizing factor, since the blood fraction in
tumour regions could be much higher than 5% typically measured in the
brain. It follows that blood contribute to the measured PET signal has to
be taken into account in the quantification of this type of data. Some at-
tempts have done with kinetic modelling (Gray et al., 2010; Kenny et al.,
2005) but, due to the high noise of data, it was applied only at region
level. Thus, a robust, reliable and informative quantification method for
[18F]FLT PET images is still missing.
Due to its characteristics SAIF might represent a valid solution for voxel-
wise quantification of [18F]FLT PET data, even though this problem is
very challenging. In fact, respect to the brain, the kinetic variability of
anatomical regions like breast, lung, liver, heart, results amplified, orig-
inating dynamic data with high heterogeneity. As consequence a very
flexible quantification methods is needed. Moreover, in order to use the
kinetic estimates to predict the response to the treatment, the quantifica-
tion methods have to be first characterized by high reproducibility.
To evaluate the applicability of SAIF to [18F]FLT PET in breast cancer data
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we tried to consider all these issues. Thus, 1) we tested the reliability and
the robustness of SAIF approach by comparing its results with those pro-
vided by the standard procedures; 2) we evaluated the reproducibility
of SAIF in test/retest studies; 3) we verified the capacity of SAIF for the
prediction of therapy response.
4.2.2 DATASET AND METHODS OF ANALYSIS
Our dataset was composed by 10 subjects with stage II-IV breast cancer.
Briefly, all the subjects were scanned twice prior to and at 1 week after
treatment, using [18F]FLT tracer with an injected dose from 153 to 380
MBq. Automatic arterial blood sampling was also performed for each
PET study and plasma metabolites were removed from arterial concen-
trations. Full details about subject inclusion criteria and the acquisition
protocol are reported in (Kenny et al., 2005). As reference methods for
FLT quantification we considered:
• Weighted non linear least squares (WNLLS) applied to literature
reference [18F]FLT compartmental model. This coincides with a 2-
tissue model, composed by one equilibrating compartment and one
trapping (Fig. 4.2.1) (Kenny et al., 2005). The contribute of [18F]FLT
metabolites during the delivery phase was neglected, as indicated
by Kenny and colleagues (2005) (Kenny et al., 2005);
• Patlak graphical analysis;
• SUV defined as the measured radioactivity at 90 min, normalized
by injected dose and body surface area (Kenny et al., 2005).
All the methods were applied voxel-wise and results were compared
with those provided by SAIF applied at the same resolution level. Ki,
K1 and Vb were considered as parameters of interest. Mean of voxel esti-
mates within regions and outliers were used for the computation of per-
formance indexes. For each patient primary tumour, healthy breast and
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vertebra were used as regions of interested. Liver and heart were ex-
cluded from the analysis since the different physiology of the systems
might require a different description of the FLT kinetic.
Vascular 
compartment 
(Cp)
Free space
K1
k2
k3
Metabolic 
compartment
Figure 4.2.1: [18F]FLT compartmental model. K1 and k2 refer to blood to
tissue FLT transport while k3 describes irreversible tracer uptake. The open solution
of the tissue kinetic is given by Ctissue(t) =
K1k3
k2+k3
∫ t
0 Cp(τ)dτ +
K1k2
k2+k3
∫ t
0 Cp(τ) ·
e−(k2+k3)(t−τ)dτ , which corresponds to the SA model composed by 1 trapping and 1
equilibrating compartment Ctissue(t) = α0
∫ t
0 Cp(τ)dτ + α1
∫ t
0 Cp(τ) · e
−β1(t−τ)dτ .
4.2.3 SAIF PASSBAND FILTER DEFINITION
As seen from previous chapters, the most critical variable for SAIF uti-
lization is related to the choice of the filter passband. In this applicative
context the simulation-based approach previously used for passband def-
inition was not applicable for two reasons in particular: 1) a priori infor-
mation about the tracer kinetics in the investigated system was not avail-
able; 2) the variability of the kinetics within the analyzed field of view
was too high to allow the use of a unique passband for all the analyzed
ROIs. Thus a criterion to select an appropriate passband depending on
the characteristics FLT uptake in the tissues was required.
Analysis of L-[1-11C]Leucine SAIF passband (Section 3.2) had provided
precious suggestions to address the problem, in particular for what con-
cerns the relationship between SAIF passbands used for the region-wise
and voxel-wise L-[1-11C]Leucine quantification. In fact, even if the ROI
and voxel analysis had shown to require different passband filters, the
two entities were quite close to each other. Thus we decided to use a
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hierarchical approach through which we extended the SAIF applicative
setting used for the region-wise analysis to the voxel one. Since ROI anal-
ysis presents low noise and high SNR, SAIF passband is much easier to
characterize, representing a good starting point for the definition of voxel
SAIF setting. The criteria we implemented was as follows:
1. For each patient, we organized the dynamic PET data in homogeneous
clusters, following an anatomical segmentation. Then, for each cluster we
extracted the correspondent ROI-TAC and we applied WNLLS to com-
partmental [18F]FLT model at region level;
2. For each ROI, using the equivalence between [18F]FLT compartmental
model and spectral analysis, we computed the values of spectral compo-
nents (β∗) and derived their uncertainty (SD) from the values and the
precision of WNLLS regional estimates;
3. For each ROI we fixed the voxel-wise SAIF passband as [β∗-4SD; β∗+4SD].
The choice of using 4 times the estimated SD was justified by the idea
to be as much conservative as possible, in order to avoid the selection
of a too narrow filter interval. Notably, this criterion not only provides
different passbands for different ROIs but, in the case that a subject is
scanned more than one time, it allows to adapt the filter passband for
each PET scan.
4.2.4 RESULTS
When the methods were compared in the same subsets of voxels in which
all provided reliable and physiological estimates, there was a good agree-
ment between the results (Fig. 4.2.2A). This findings was verified for all
the analyzed ROIs and all the subjects. Similarly, mean of voxel estimates
within ROIs resulted well correlated each other (R2>0.95).
The main differences between method performances were related to the
voxel failures rates (V FR) (Fig. 4.2.2B): WNLLS proved to be most sen-
sitive to noise in the data (V FR >50% in healthy breast and >20% in
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tumour); Patlak and SUV, instead corresponded to the most robust meth-
ods, especially in tumours and vertebra with an average V FR of 10%.
SAIF performances improved with the increasing of [18F]FLT uptake: in
healthy breast, where the cellular proliferation is normally low and FLT
uptake limited, SAIF V FR was equal to 20%±22% (mean±SD); in tu-
mour and vertebra, where the FLT uptake is 10 folds higher than in nor-
mal tissues, SAIF V FRs corresponded respectively to 9%±13% and 14%±14%.
Visual comparison ofKi and SUV parametric maps (Fig. 4.2.3) confirmed
the good agreement between the methods, providing similar information
about FLT uptake in tissues. The only exception was represent by WN-
LLS, in which the high amount of outliers prevented the possibility to
compute adequate parametric maps.
Reproducibility analysis, performed by comparing test/retest scans, demon-
strated the repeatability of SUV (R2=0.93) and Patlak Ki (R
2=0.97) pa-
rameters (Fig. 4.2.4A,B). Similarly, also SAIF and WLNNS methods re-
ported a good repeatability of Ki test/retest estimates (R
2∼0.90). K1 and
Vb estimates, instead, demonstrated weak reproducibility (K1 R
2<0.65; Vb
R2<0.16) and higher test/retest variability respect to Ki (Figure 4.2.4C-
E). These results were in agreement with previous analysis performed in
literature (Kenny et al., 2007, 2005).
Since theKi was the most reproducible parameter, it was also considered
for assessment of therapy response. The main aim of this analysis was to
evaluate the possibility of predicting the patient response to treatment,
by comparing the variation ofKi in tumour region between pre and post
treatment scans. For therapy responding subjects results showed a sig-
nificant Ki decrease in tumour regions (p <0.05), while it was not found
for non-responding subjects. Results were comparable for both WNLLS
and SAIF (Fig. 4.2.5).
In the same way, the analysis of the distributions for voxel-wise Ki esti-
mates showed a relevant shift toward lower values for responding sub-
jects, while for non-responders pre-post treatment distributions remained
almost comparable (Fig. 4.2.6). Analysis of Ki distributions confirmed
also that the evaluation of only the mean Ki values could be misleading
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for response to treatment discrimination. In fact, as indicated from Figure
4.2.5, there is a non-responding subject (*) which presents a substantial
decreasing of mean Ki in the tumour region, typical of responding sub-
jects. However, analyzing the distribution of Ki estimates (Fig. 4.2.6B) it
is evident that the reduction of the mean did not coincide with a general
reduction of the tracer uptake.
4.2.5 CONSIDERATIONS
Application of SAIF to [18F]FLT PET data proved to be a complete and re-
liable tool for the voxel-wise quantification of this tracer. SAIF provided
reliable Ki estimates, with high reproducibility and limited outliers. Re-
spect to Patak, SAIF allows the computation of additional parameters of
interest like Vb and K1. However, these parameters were characterized
by low reproducibility and did not show any relationship with therapy
response. The results obtained with SAIF were in agreement with previ-
ous analysis presented in literature (Kenny et al., 2007, 2005) which had
demonstrated that Ki was the most significant parameter for the char-
acterization of the FLT kinetic in tumour regions, with good correspon-
dence with histological samples (Kenny et al., 2007, 2005).
The strategy implemented for the selection of SAIF passband demon-
strated to be appropriate for this dataset: by comparing the distribu-
tion of beta components derived by voxel-SAIF with the regional spectral
components derived by WNLLS, we found very good correspondence
between the two entities (Fig. 4.2.7). At the same time, there was also
a high concentration of spectral components (∼ 80% of analyzed voxels)
at the border of passband intervals, suggesting that the choice could be
probably too narrow. However, when we tried larger passbands (2 times
wider than the original ones) the problem remained. Therefore, it is more
reasonable to attribute these components to noise artefacts rather than
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Figure 4.2.2: Method Performance. Panel A shows the mean of voxel estimates
within ROIs for all the methods. Bars represents the mean+SD calculated among the
subjects. Methods show good agreement for all the analyzed ROIs. Panel B shows
the fraction of voxel failures over the total number of voxels in each ROI. Values
are the mean+SD calculated among the subjects. WNLLS was found as the most
sensitive to the noise in the data, while SUV was found to be the most robust. The
limited proliferation in healthy breast tissues caused a very low signal-to-noise ratio
and consequently high failure rates for all the methods.
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Figure 4.2.3: Parametric maps. Panel A shows the dynamic PET image summed
over time. Panel B shows SUV parametric map. Panel C and D show the Ki maps
obtained with Patlak and SAIF respectively. Results refer to a representative slice
for the same subject. Due to high voxel failure rate (>50%), WNLLS result is not
shown.
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Figure 4.2.4: Reproducibility. The figure show test/retest variability of some
parameters of interest. Panel A and B show respectively Patlak Ki and SUV scatter
plots. Panels C, D and E show the mean relative differences between test and
retest parameter estimates, obtained with WNLLS (+) and SAIF (o). Analysis was
performed for Ki, K1 and Vb considering all the subjects and all the ROIs.
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Figure 4.2.5: Response to treatment. The figure shows the change of mean
voxel Ki estimates in tumour pre and post treatment for all the subjects. Dashed
line=responders; Solid line=non-responders. WNLLS and SAIF results are in agree-
ment for all the subjects. All the responders show a decrease in Ki values, while the
non-responders present a general increase. The only exception is represented by *,
who report a decreasing of Ki values even if non-responder.
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Figure 4.2.6: Response to treatment. The figure shows the change of mean voxel
Ki estimates in tumour pre (black bars) and post (white bars) treatment for two
representative subjects (responder and non-responder respectively). In general for
the non-responder subjects the pre-post Ki distributions are overlapped, while for
responders post treatment Ki distributions are shifted towards lower values. With
this analysis, the subject marked with * in Fig. 4.2.5, was correctly classified as
non-responder (Panel B).
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real components of the system.
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Figure 4.2.7: Distribution of beta components. The four panels of the figure
show the distribution voxel-wise SAIF beta components (top of panels) with those
estimated at region level with WNLLS (bottom of the panels). Four representative
subjects are reported, each one considering the tumour region. For each panel, test
(dashed lines) and retest (solid lines) results are visualized.
4.3 [18F]FDG PET STUDIES IN ACUTE LUNG INJURY PA-
TIENTS
4.3.1 INTRODUCTION
Acute lung injury (ALI) is a severe lung pathology that usually occurs as
consequence of ordinary injuries (e.g. trauma, burns, aspiration) or an
acute illness (e.g. pneumonia, acute pancreatitis) (Bernard, 2005). ALI
has no specific therapy but it is common practice to treat it with me-
chanical ventilation in supportive care in order to reduce airway pres-
sure while maintaining adequate oxygenation. Despite this, ALI is char-
acterized by considerable morbidity and high mortality (Bernard, 2005;
Matthay, 2008).
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The main problem of ALI is that the physiological processes that are be-
hind this evolution are not completely clear. The most shared hypothesis
is that they are correlated to polymorphonuclear neutrophils (PMNs) ac-
tivation, that is the mainstay of inflammation. However the uncertainty
about the dynamic of the system justifies an onward interest in studying
lung inflammation.
Since neutrophils activation is associated to an increase in cellular meta-
bolism of 20-30 times respect to normal, [18F]FDG -PET studies have been
successfully applied for the description of the dynamic of lung inflamma-
tion (Bellani et al., 2009, 2011). With [18F]FDG PET method, in particular,
clinical investigation of the inflammation distribution as well as its state
of activation has been possible (Bellani et al., 2009, 2011).
In disagreement with this theory, Prost and colleagues (de Prost et al.,
2010) found in a sheep-model of alveolar lavage that an increase in lung
water can generate an additional volume of distribution of [18F]FDG .
This volume is not a precursor for phosphorylation and can artifactually
increase lung [18F]FDG uptake independently of lung inflammation.
The source of contradiction is mainly related to lack of an exhaustive ki-
netic model able to fully describe the [18F]FDG processes in both healthy
and injured lung tissues. In these context SAIF might be a valuable in-
vestigative tool to explore the kinetics of the tracer in the tissues.
4.3.2 DATASET AND METHODS OF ANALYSIS
A dataset of [18F]FDG PET images composed by 16 subjects was consid-
ered, with the aim of quantifying the dynamic of the glucose metabolism
in healthy and injured lung tissues. Eleven subjects were patients affected
by a severe form of ALI undergoing mechanical ventilation. Five sub-
jects were healthy volunteer, whose studies were used as control. Nor-
mal aerated tissues (NA) and hyper-dense tissues (CO) were automati-
cally segmented on PET images based on CT values. NA and CO were
then used as regions of interest. For each subject, imaged-derived input
functions were obtained from the descending aorta directly from PET im-
79
Applications to non brain studies
ages. Complete details about acquisition protocol, subject inclusion cri-
teria and data pre-processing are reported in (Bellani et al., 2009).
SAIF quantificationwas applied voxel-wise and its results comparedwith
Patlak graphical analysis, tissue-to-plasma ratio and SUV, defined as the
measured radioactivity at 90 min, normalized by injected dose and body
weight (Grecchi, 2011).
SAIF passband was chosen based on the distribution of spectral compo-
nents obtained with ESA at region level. This resulted in a unique pass-
band interval, for both NA and CO ROIs and all the subjects equal to
[0.05,1] min−1.
Comparison of Ki parametric maps as well as the mean of voxel Ki esti-
mates with ROIs was performed to test the reliability of the SAIF meth-
ods respect to the standard procedures used in literature for [18F]FDG
quantification in lung, i.e. Patlak graphical analysis, SUV and tissue-to-
plasma ratio (RATIO). The pseudo distribution volume VT , defined as the
distribution volume calculated on SAIF reversible components, was also
computed.
Once the correctness of SAIF was assessed, the analysis of the number
and the types of spectral components returned with SAIF at both ROI
and voxel level was performed. The final aim was to characterize the
[18F]FDG kinetic model in healthy and injured lung tissues and to evalu-
ate the presence of eventual differences between the two conditions.
4.3.3 RESULTS
ASSESSMENT OF SAIF QUANTIFICATION The comparison of paramet-
ric maps (Fig.4.3.1) showed that the estimates of Ki obtained with SAIF,
RATIO and Patlak are overall consistent while some activated areas are
lost with the SUV (in particular in the lower portion of the lung). This
lack of performance is even clearer looking at Figure 4.3.2. While the
SAIF exhibits the same Ki of Patlak (R
2=0.98, Fig. 4.3.2A) and similar
behaviour with the RATIO method (R2RATIO=0.97, Fig. 4.3.2B), the cor-
relation of SUV results with the SAIF ones was found not satisfactory
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(R2SUV =0.67, Fig. 4.3.2C). This suggests that the more the dynamic con-
tribution is taken into consideration, the more useful and reliable the in-
formation about the system will be. For this reason the application of the
SUV could be questionable or not completely representative.
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Figure 4.3.1: Quantification of [18F]FDG PET lung images. Comparison of
quantification methods.
ANALYSIS OF SPECTRAL COMPONENTS Region- and voxel-wise SAIF
analysis allowed to separate 3 kinetic components: the first associated
with the trapping of FDG-6-P in the tissue, the second one with an inter-
mediate reversible process, and the last one with a fast reversible plasma-
tissue exchange process. In comparison with the controls, the spectra
of the patients were, generally, shifted towards the right side indicating
the presence of faster kinetics (Fig. 4.3.3). In particular, the degree of
the shift of the faster component allowed distinguishing normal-dense,
hyper-dense or edematous tissue. We found a 25-foldmean increase ofKi
between controls vs. patients (0.0006 ml/cm3/min vs. 0.015 ml/3/min)
and a 3-fold mean increase in VT (0.15 ml/
3 vs. 0.50 ml/3). The higher VT
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Figure 4.3.2: Method Correlations. The figure reports the scatter plots that show
the correlation among the considered quantification methods. Panel A-C indicate the
correlation between SAIF and Patlak, RATIO and SUV analysis respectively. Black
circles indicate the mean voxel estimates within a specific region of interest (ROI).
NA and CO tissues were reported for all the subjects analysed. Pearson’s coefficient
(R2), slope and intercept of regression line (solid line) are also shown.
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indicates an increased availability of [18F]FDG in the extravascular space
which is related to the pathological status of the tissue within the voxel.
Figure 4.2.4 shows the kinetic characterization provided by SAIF in one
ALI patient. Respect to SUV and RATIO which only return the infor-
mation about the tracer trapping, SAIF allows a more complete descrip-
tion of the tracer kinetic in the tissues. It can be noticed how Vb and K1
parametric maps offer a different insight of the lung area (Fig. 4.2.4B,D)
respect to Ki map, indicating that the blood volume and the tracer de-
liver play different roles in the inflammation process. In the same way
V1 and V2, respectively the distribution volume of the fastest and slowest
spectral reversible component, resulted different between each other and
different respect to tracer uptake.
The analysis of these parameters for the entire dataset (Fig. 4.2.5) allowed
amore precise classification for both control and patient groups. Notably,
healthy and injured patients do not differ only in the tracer uptake but
also in the [18F]FDG transportation from plasma to tissue as well as in the
kinetic within tissues.
4.3.4 CONSIDERATIONS
SAIF results were found well correlated with those provided by the stan-
dard quantification methods for the description [18F]FDG uptake in lung,
corroborating trustworthiness of subsequent SAIF estimations. This cor-
relation was strengthened by the voxel-by-voxel analysis so that we can
reasonably consider SAIF method as valid alternative for [18F]FDG quan-
tification in lung tissues.
In fact, despite the noisiness of PET data, especially at voxel level, SAIF
revealed to be highly informative about tracer kinetic. The analysis of
SAIF spectra showed differences between controls and patients but also
between different types of pathological tissues. Looking at the results
obtained at both ROI and voxel analysis we could conjecture that FDG
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Figure 4.3.3: Spectral components of [18F]FDG lung kinetics. The figure reports
the spectra obtained with SAIF of two representative subjects: (A) control subject,
(B) normal-dense tissue of a patient affected with acute lung injury, (C) hyper-dense
or edematous tissue of the same patient affected with acute lung injury. Each line
represents a component that characterizes the tracer kinetic (the x axis indicates
the velocity of the kinetic component, while the y axis its amplitude). In particular
the amplitude of the one in zero coincides with the uptake of the tracer in tissue.
Note that the patient maintains similar Ki (i.e. amplitude of the lower component)
for both normal- and hyper-dense tissues, while the latter demonstrates a significant
shift of the faster components and an increase of their amplitudes (panels B and C).
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Figure 4.3.4: SAIF kinetic characterization: parametric maps. (A)Summed
dynamic PET over time; (B) tracer uptake; (C) distribution volume for the fastest
reversible component; (D) blood volume; (E) plasma to tissue transport; (F) distri-
bution volume for the slowest reversible component. All the maps refer to the same
ALI patient.
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Figure 4.3.5: SAIF kinetic characterization: bar graphs. Panels A-D shoe
respectively the tracer uptake, the tracer delivery and the distribution volumes for
the fastest and slowest reversible component in all the analysed subjects. Black bars
refer to NA region. Gray bars refer to CO region. Each bar represents the mean+SD
of the voxel estimates within the ROI.
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kinetic in lung tissue is described by a three compartmental model. Even
though we did not have enough data to formulate the connection be-
tween compartments, the good agreement between ROI and voxel anal-
ysis suggested that this effect was improbably due to related to the tis-
sue kinetic heterogeneity. Further analysis, using model-fixed structures
needs to be done, but preliminary results would suggest to start the in-
vestigation by using a homogeneous compartmental model with two equi-
librating components and one trapping. This hypothesis is in agreement
with the model formulated by Schroeder and colleagues (Dittrich et al.,
2012; Schroeder et al., 2008) about [18F]FDG kinetic in sheep lung, even if
SAIF did not provide any support to the model configuration presented
by the authors.
87
Applications to non brain studies
88
I am not discouraged,
because every wrong attempt discarded
is another step forward.
Thomas A. Edison
5
The tissue kinetic heterogeneity
problem
5.1 TISSUE KINETIC HETEROGENEITY IN PET DOMAIN
5.1.1 INTRODUCTION IN BIOMEDICAL IMAGING CONTEXT
When a specific physiological process is investigated in vivo in a biolog-
ical organism, it is reasonable to expect a variability of response. This
variability is not a priori predictable as it is result of a combination of dif-
ferent factors, which basically depends on:
• The intrinsic biological variability of the system of interest
• The variability of the process under study within the investigated
system
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These two elements combined together (variability of system + variabil-
ity of process) are origin of what is called as tissue kinetic heterogeneity
phenomenon. Even it is not possible to quantify in advance its amount,
there are some general qualitative rules with which manage it. First of all,
the tissue kinetic heterogeneity has always to be contextualized respect
to the particular process and system under study. Secondly, it is proved
that, the higher the complexity of a system of interest, the higher the
variability observed. This concept is based on the idea that heteroge-
neous systems are characterized by higher variability respect to corre-
spondent homogeneous ones. In addition, the variability of a specific
process within a biological system is not randomly distributed but it
follows the anatomical and physiological organization of the elements
which composed it. This criteria is based on the common sense that sim-
ilar elements have similar behaviour.
Theoretically, it is possible to assume that the kinetic heterogeneity be-
comes negligible only when the system can be break up in homogeneous
subsets of elements. This condition is very difficult to be reached because
it requires to recognize and manage all the single constitutive elements
of the system of interest (Fig. 5.1.1).
When an investigative tool like biomedical imaging is applied to explore
biological tissues, the presence of kinetic heterogeneity becomes a prob-
lem especially for in vivo applications. Since the spatial resolution of the
imaging instruments is generally several order of magnitude inferior to
the cell dimensions which composed the tissues 1, it is not possible to
decompose the observation into its constitutive sources. Thus it is nec-
essary to introduce the assumption that within the minimum volume of
observation provided by the instrument, the voxel, the particular inves-
tigated process can be approximate by its mean value (Fig. 5.1.2). This
assumption is less restrictive that what it appears, because, following the
principle that heterogeneity degree is function of the tissue spatial organi-
1The spatial resolution for in vivo biomedical imaging tools is measurable in millime-
tres, while cell dimensions are of micrometer order.
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C)
B)
A)
Figure 5.1.1: The Sunday Afternoon on the Island of La Grande Jatte (1886).
This painting from George Seurat is one of the most famous example of pointillism,
but it can be also use as a schematic representation of kinetic heterogeneity concept.
From a visual analysis, it appears clear that the whole picture is the result of several
graphics elements which all contribute to the final effect of the painting (Panel A). If
we zoom in a particular area of the painting (panel B), the general overview is replaced
by the combination of new different elements which compose the new image. If we
zoom further (Panel C), we can now visualize the single constitutive elements of
colour. It is following this hierarchical organization, based on the heterogeneous
combination of small points of colour, that the famous painting is obtained.
In the same way, the overall response of a biological system to a specific process can
be seen as the heterogeneous combination of single cell responses, that through their
organization in tissues, organs and apparatus form the entire organism.
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C)
B)
A)
Figure 5.1.2: Heterogeneity and imaging spatial resolution. Panel A shows a
T1 weighted magnetic resonance. By zooming in a particular area, like the cerebral
cortex (Panel B), the whole complexity of the brain is replaced by the combination
of white and gray matter. However, due to the limit of MR scanner resolution, it is
not possible to zoom in until the constitutive elements of the tissues, the cells, are
individually reported. The best analysis is limited at the voxel level, where each voxel
represents the mean activity measured in the tissues within its volume (Panel C).
This assumption can be acceptable only when the tissues within the voxel volume are
homogeneous and therefore indentifiable through the mean operator. On the contrary,
when the voxel contains a mixture of different tissues, like when it is located at the
border between gray and white matter, the heterogeneity of the tissues must be taken
into account for a correct quantification.
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zation, the higher the spatial resolution is, the lower the error introduced
by the average simplification. On the other hand, the presence of partial
volume (PV) 2 introduced by the imaging technique becomes an addi-
tional source of error.
From these observations it follows that the impact of kinetic heterogene-
ity is not the same for different imaging techniques, and not only because
the resolutions are different, but also because the image contents can
more or less conditioned by the problem. In structural imaging, where
the main goal is to characterize the anatomy of the system and not to
evaluate its physiology, the presence of kinetic variability of the tissues
does not represent a problem. On the other hand, in functional imaging,
the presence of heterogeneity not only has to be taken into account for
a correct quantification of the process, but its measures might represent
an information of the system status underling the eventual presence of
pathologies. Thus, case by case the presence of heterogeneity becomes
an issue with different importance which has to be characterized in the
particular context of interest.
5.1.2 KINETIC HETEROGENEITY AND PET
One of the great strengths of PET is that it can be used to provide quan-
titative measurements of physiological and biochemical processes. The
ability to determine absolute rates of a specific, well-defined biological
process is essential when different individuals or groups are to be com-
pared. In this respect, quantitative PET functional imaging methods con-
trast with methods in which only relative rates of a process are mea-
sured, or methods whose measures reflect an indeterminate combination
of many biological processes.
2The partial volume effect can be defined as the loss of apparent activity in small
objects or regions because of the limited resolution of the imaging system. It occurs
in medical imaging and more generally in biological imaging such as PET and single-
photon emission computed tomography (SPECT). If the object or region to be imaged
is less than twice the full width at half maximum (FWHM) resolution in x-, y- and z-
dimension of the imaging system, the resultant activity in the object or region is under-
estimated (Hoffman et al., 1979).
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Functional quantification with PET is generally based on kinetic mod-
elling approaches that relate a particular biological process of interest
to measurements of activity in blood and tissue following administra-
tion of a radiolobelled tracer. Kinetic models used in PET are necessarily
simplified representations of tissue processes, and one of the simplifying
assumptions frequently made is that tissue regions are kinetically homo-
geneous, i.e., rates of blood flow, delivery and efflux of tracer to/from
tissue, metabolism, and incorporation into labelled products do not vary
in the tissue region. In brain, for example, these assumptions are difficult
tomeet. As succinctly stated by Sokoloff et al (1977) (Sokoloff et al., 1977):
The mammalian brain is a complex heterogeneous organ comprising many
structural and functional components with different and independently regu-
lated levels of functional activity and energy metabolism.
At spatial resolutions approximately an order of magnitude higher than
PET, such as achieved in autoradiographic studies, one clearly sees het-
erogeneity of rates of blood flow, glucose metabolism, and protein syn-
thesis across the brain (Schmidt et al., 2005). Not only are rates of these
processes different in gray andwhitematter, butwithin graymatter struc-
tures themselves, and to a somewhat lesser extent in white matter, rates
of these processes can vary considerably. At the relatively lower spatial
resolution of PET scanning, therefore, activities measured in brain can be
expected to originate from kinetically heterogeneous mixtures of tissue.
Application of kinetic models designed for homogeneous tissues to het-
erogeneous tissues has been shown to lead to errors in estimated rates of
cerebral blood flow and glucose metabolism, as well as to errors in esti-
mates of receptor binding parameters (Schmidt and Turkheimer, 2002).
The same reasoning can be extended when PET is applied for the analy-
sis of non brain tissues. As for the brain, also other apparatus are char-
acterized by highly complex structural and physiological organizations,
which required to be taken into account for a correct quantification. The
problem is complicated by the fact that the degree of tissue heterogeneity,
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within a given volume of observation, is not a priori known but it has to
be determined from the data. Thus, to address the issue of kinetic het-
erogeneity in PET, the quantification method has not only to account for
its eventual presence but, at the same time, it has also to be adaptable to
different heterogeneity levels.
5.1.3 SA: A FLEXIBLE TOOL FOR KINETIC HETEROGENEITY IN PET
In Chapter 2, it has been demonstrated that SAmodel has the potential to
be applied to homogeneous as well as heterogeneous tissues without any
a priori assumptions. Moreover by evaluating the number kinetic spec-
tra estimated, it can be defined the number of sub regions composing
the system of interest and thus it is possible to identify the heterogene-
ity degree of the particular volume of interest. These two features of SA
combined together offered the potential to exhaustively face the problem
of heterogeneity in PET.
Unfortunately standard SA has shown to be sensitive to the noise in
the data, characteristic that not only prevents its application at low SNR
level, but which also conditions the capability of the method to correctly
manage and measure the kinetic heterogeneity of the tissues. Since SAIF
has demonstrated a superior robustness to the noise, especially when ap-
plied voxel-wise, it might represent a better tool for tissue kinetic het-
erogeneity measurement in PET. In the next sections we will test it, by
evaluating SAIF performance in simulation as well as on L-[1-11C]Leuci-
ne measured PET data.
5.2 MEASUREMENT OF KINETIC HETEROGENEITY IN SIMU-
LATION
5.2.1 DATASET
In order to test the SAIF capability to correctly manage the tissue kinetic
heterogeneity of the data, the same simulation procedure described in
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Chapter 3 was considered.
Briefly, 75 simulated irreversible tracer kinetics were used to define noise-
free tissue TACs. Both homogeneous and heterogeneous spectra were
considered. For each simulated TAC, two Montecarlo simulations were
performed, respectively by using region-wise and voxel-wise simulated
SNR levels (for further details about the simulation procedure, please re-
fer to section 3.1.1).
SAIFwas then applied to the simulated data and, in order to test the SAIF
correctness on measuring the heterogeneity degree of the data, the num-
ber of equilibrating components estimated from the data was compared
with the simulation reference values. The analysis did not include dou-
bling components, which were removed from the estimated spectrum
through correction previously described in Sect. 2.3.2. The means of Ki,
K1 and Vb bias% obtained from homogeneous simulated kinetic spectra
were compared with the correspondents obtained from heterogeneous
ones. This analysis was performed to evaluate the impact of the kinetic
variability on SAIF quantification. Since the application of ESA did not
provide reliable results in both term of precision and accuracy, the analy-
sis was limited to SAIF only.
5.2.2 RESULTS
At ROI noise level SAIF demonstrated good precision in the measur-
ing the simulated heterogeneity degree: homogeneous spectra were cor-
rectly detected for 72% of the simulated kinetics, while the heteroge-
neous ones for 89% of simulated cases. To note that, as expected from
the behaviour of SA-based methods (Cunningham et al., 1998), also SAIF
tended to overestimate the number of components present in the data.
In simulated homogeneous conditions, 22% and 6% of the SAIF esti-
mates respectively reported 2 and 3 equilibrating components. In sim-
ulated heterogeneous conditions, instead, 9% of estimates reported the 3
or more equilibrating components. Only 2% of the heterogeneous simu-
lated cases were estimated as homogeneous.
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This tendency of SAIF to overestimate the heterogeneity of the tissues
was confirmed and even amplified at voxel noise level. Only 49% of
the homogeneous simulated spectra was correctly measured, while 49%
and 2% was associated with 2 and 3 equilibrating components. On the
contrary 79% of the heterogeneous simulated spectra was correctly mea-
sured, while the remaining part was associated with 3 or more equili-
brating components. Less than 1% of heterogeneous simulated kinetic
was identified by SAIF as homogeneous. These results suggested that
the SAIF measurement of kinetic heterogeneity has to be very carefully
utilized, especially at low SNR levels.
In term of heterogeneity impact on SAIF estimates, very good results
were found: as indicated by Table 5.2.1, parameter bias between homo-
geneous and heterogeneous results was comparable at both region and
voxel noise level. The highest discrepancy (∼4%)was found for the quan-
tification of K1 at voxel level. The same parameter presented also the
highest bias% for Ki and K1 in homogeneous simulated conditions.
Table 5.2.1: Bias% variability between homogeneous and heterogeneous simulated
spectra
ROI noise error Voxel noise error
Parameters HOM HET HOM HET
Ki -0.70% ± 2.30% 0.20% ± 2.20% -5.10% ± 2.20% -3.10% ± 2.10%
K1 1.60% ± 0.80% 1.40% ± 0.80% 5.80% ± 1.60% 1.60% ± 1.80%
Vb 0.70% ± 0.50% 0.90% ± 0.50% -1.10% ± 1.70% 2.00% ± 1.60%
5.2.3 TOWARD A NEW METHOD FOR MEASURING TISSUE HETEROGENE-
ITY
Results of SAIF in simulations has demonstrated that even though the
quantification of the parameters of interest is not influenced by the homo-
geneity/heterogeneity of the tissues, the method is not reliable for mea-
suring the degree of heterogeneity present in the data. This feature does
not represent a restriction for SAIF applicability, but, since PET quantifi-
cation is based homogeneous kinetic assumptions, it might be of high
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interest to evaluate the distribution of kinetic heterogeneity within the
volume of observation. From this analysis, a more appropriate modelling
approach for the biological system under study might be developed.
In SAIF the major problem of measuring the degree of kinetic hetero-
geneity is related to the noise in the data whose effect is to increase the
measure of heterogeneity. To limit this effect, we might think to repeat
the measure more than one time. Then we could choose the heterogene-
ity degree of the kinetic under study as the most probable heterogeneity
degree measured in all its realizations.
This approach is very simply to be realized in simulation. For each noise-
free TAC, it is sufficient to compute N different noisy realizations and
then to calculate its heterogeneity degree as the most probably hetero-
geneity estimated from all the N noisy realizations.
Respect to the single application of SAIF, the application of this multi-
analysis in simulation showed an increasing of SAIF performance in cor-
rectly measuring the degree of kinetic heterogeneity (Fig. 5.2.1). In par-
ticular, increasing N (number of noise realizations per TAC) the fraction
of successfully characterized cases increased, while the number of under
and over estimated cases lowered. Notably, the figure shows also a large
fraction of simulated cases (almost 80%) that is not associated with a ho-
mogeneous or heterogeneous spectrum. This is possible because, if the
probability to be homogeneous or heterogeneous was not markedly to-
ward a given direction, the correspondent heterogeneity degree measure
was high uncertain. Thus we preferred to not associate these cases with
any heterogeneity level. On the other hand, when the probability to be
heterogeneous was higher than 75%, the correctness of the measure was
almost absolute (>95%).
By considering these results, it appears evident that multi-analysis SAIF
cannot measure the entire heterogeneity of the data. However, when the
heterogeneity is detected we had high probability to take the correct mea-
sure, representing a good starting point for the heterogeneity analysis.
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Figure 5.2.1: Performance of SAIF noise resampling method for the hetero-
geneity measurement. The figure shows the performance of SAIF in measuring
the tissue heterogeneity as function of the number of noise realizations. Solid line
represents the rate of successful classifications; dashed line represents the amount of
not classified cases. Dotted and dashed/dotted lines represent respectively the over
and under estimated cases. As it can be seen from the figure the rate of success
increases with the number of noise realizations, while at the same time, the number
of under and over estimated cases becomes negligible. On the contrary, the number
of not classified voxel remained almost constant to 80%.
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5.3 MEASUREMENT OF KINETIC HETEROGENEITY IN L-[1-
11C]LEUCINE PET DATA
5.3.1 DATASET
The first critic to multi analysis SAIF approach for measuring tissue het-
erogeneity is that in the way it is defined it results inapplicable to mea-
sured data analysis. In fact, since the true kinetics of data TACs are un-
known, the noise resampling cannot be performed. Thus a different strat-
egy for noise simulation must to be applied. As proposed by Turkheimer
and colleagues in 1998 (Turkheimer et al., 1998), a valid alternative might
be represented by bootstrap approach. We will test it in the L-[1-11C]Leu-
cine PET dataset.
A subset of 6 subjects belonging to the dataset presented in Chapter 3
were considered. In addition to these, 2 extra subjects investigated with
low-counts doses (respectively 0.166 mCi/kg and 0.163 mCi/kg, corre-
spondent to ∼30-40% of the normal dose) were added. A comparison
between high and low dose summed dynamic PET over time is reported
in Figure 5.3.1. The inclusion of these 2 new subjects aimed to evaluate
the impact the injected dose on kinetic heterogeneity measurement. To
note that all the subjects were acquired by the same PET scanner, ECAT
HRRT, with FWHM of ∼2.6mm and voxel size of 1.21 x 1.21x 1.23 mm3.
Complete details about acquisition protocol are reported in (Bishu et al.,
2008).
5.3.2 BOOTSTRAP APPROACH
In order to perform the analysis of kinetic heterogeneity through the
multi-analysis SAIF method, we implemented the following bootstrap
approach for the noise resampling:
1. Using the optimal SAIF passband for voxel-wise L-[1-11C]Leuci-
ne quantification (section 3.2.3), data measured in a representative
slice of an individual brain volume, masked to include brain voxels
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A) High counts PET image
B) Low counts PET image
500 30,000
Summed activity (nCi/ml)
Figure 5.3.1: Comparison of High and Low count L-[1-11C]Leucine Pet im-
ages. The figure shows the dynamic PET images summed over time for two subjects
respectively injected with a high-activity and low-activity dose (panel A and B).
Sagittal, coronal and axial views are reported.
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only, were analyzed voxel-by-voxel with SAIF. The set of parame-
ters obtained became the reference, or true, parameter values used
in the simulations. Outliers and algorithm failures produced at this
step were excluded from the simulation.
2. Noise-free TACs were generated by convolving the original mea-
sured arterial input function of the subject with the sum of expo-
nential terms defined by the reference parameters from Step 1. In
addition, for each voxel, normalized residuals Ri(t)were computed
as:
Ri(t) =
C∗T,i(t)− TACi(t)
max[C∗T,i(t)]
(5.1)
for i = 1, 2, · · · , K, where C∗T,i(t) represents total concentration of
11C in the field of view of the PET camera for the i-th voxel, TACi(t)
indicates the noise-free time-activity curve for the i-th voxel, andK
is the number of voxels in the chosen slice.
3. Voxel noise was simulated using a bootstrap approach (Efron, 1979)
based on random resampling of normalized residuals. With this
approach, noise for the i-th voxel (Ni(t)) was simulated as
Ni(t) = Rj(t) ·max[TACi(t)] (5.2)
for i = 1, 2, · · · , K, and j ∈ 1, 2, · · · , K. In eq. 5.2 Rj(t) repre-
sents the resampled normalized residual, originally associated with
the j-th voxel, chosen by random sampling with replacement from
among all brain voxels of the slice.
4. Noisy voxel TACs (TAC∗i (t)) were generated by adding the simu-
lated noise to the noise-free TACs as
TAC∗i (t) = TACi(t) +Ni(t) (5.3)
for i = 1, 2, · · · , K
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The procedure was repeated 50 times, generating 50 different bootstrap-
simulated slices. Note that the bootstrap procedure used here differs
from the usual approach of normalizing each residual vector by its stan-
dard deviation in order to assure that all resampled residuals have equal
variance. In this approach, the required rescaling would be by the stan-
dard deviation in the target voxel residual. In the current study, however,
we do not have good estimates of the variance in each individual voxel
due to the inherent high noise levels of voxel data. Instead, we empir-
ically chose normalization and rescaling to the maxima of the TACs, as
these scale factors have the added advantage of preventing negative val-
ues in the simulated noisy TACs. The sample variances of the original
and bootstrapped residuals were compared to check the effect of the cho-
sen scale factors (Fig. 5.3.2).
Mean TAC of the voxel TACs 
within the region
TAC variability within the 
region
Noisy TAC example
20 40 60 80
0
200
400
600
800
1000
1200
Original ROI TAC
Time [mins]
20 40 60 80
0
200
400
600
800
1000
1200
Representative Simulated  ROI TACMeasured Data Simulated Data
Time [mins] Time [mins]
A
ct
iv
it
y
 [
u
C
i/
m
L]
A
ct
iv
it
y
 [
u
C
i/
m
L]
Figure 5.3.2: Residual consistency in bootstrap approach. The figure shows the
kinetic variability of the voxel TACs in measured data (panel A) and in bootstrap-
simulated data (panel B). The blue area represents the 90%-confidence variability
interval. Black circles represent two examples of single voxel TACs in measured and
simulated data. Data refer to the whole brain region of one representative subjects
(high counts).
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5.3.3 RESULTS
SINGLE ANALYSIS Figure 5.3.3 illustrates the spatial distribution of vox-
els in which two equilibrating components were detected in a representa-
tive transaxial slice at the cortical level. Results refer to single application
of SAIF without any bootstrap approach. From the distribution it ap-
pears evident that the concentration of kinetically inhomogeneous voxels
is randomly distributed across the entire brain slice. From a visual exam-
ination, a higher concentration of these elements seems to be located at
the border between gray and white matter than within the gray or white
matter itself. However, when the heterogeneity fraction was compared
between gray, white and mixed gray-white matter regions no statistical
difference was found in its distribution. A similar pattern was found in
all subjects and brain slices, both low and high-counts subjects. By con-
sidering the results obtained in simulation, we cannot exclude that this
analysis is penalized by the sensitivity of SAIF to the data noise.
BOOTSTRAP ANALYSIS Figure 5.3.4 illustrates the spatial distribution of
inhomogeneous voxels obtained with bootstrap approach, by applying
different threshold levels: the higher the probability threshold, the lower
the amount of heterogeneity measured. This is consistent with the results
obtained in simulation and in particular with the fact that more selective
thresholds increase the number of not classified voxels in advantage of a
superior precision of inhomogeneous voxel detection.
The analysis of heterogeneity distribution obtained with a probability
threshold of 75% showed a concentration of inhomogeneous voxels 3
folds more in mixed gray/white matter areas respect to homogeneous
white or gray matter. The same behaviour was found for both high and
low-counts subjects.
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Figure 5.3.3: Heterogeneity distribution using SAIF single analysis. Panels
A and B show T1-weighted MR image (left) and the same image fused with the
spatial distribution of voxels estimated to be heterogeneous (right). The red area
corresponds to those voxels in which voxel-SAIF detects two or more equilibrating
components. Panel C show the heterogeneity fraction as function of the gray/white
brain segmentation.
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D) Probability Threshold 75%C) Probability Threshold 60%
Two or more equilibrating components
MRI B)A) Probability Threshold 50%
Figure 5.3.4: Heterogeneity distribution using SAIF with bootstrap approach.
Distribution of voxel heterogeneity measured with SAIF by using bootstrap approach
at different threshold levels.
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5.3.4 THE IMPACT OF HETEROGENEITY ON QUANTIFICATION
HIGH AND LOW-COUNTS As shown from the analysis between SAIF
and BFM applied voxel-wise to L-[1-11C]Leucine PET image (Chapter 3),
the presence of heterogeneity in the data did not significantly impact the
quantification results. Even if BFM was based on homogeneous kinetic
assumptions while SAIF on a more flexible model, the parameter esti-
mates, in particular the rate of cerebral protein synthesis (rCPS), were
highly comparable each other, both in term of spatial distribution and
means within ROIs.
Extending the analysis to low-counts subjects, these results were con-
firmed. Figure 5.3.5 shows a comparison of the quantification results
obtained with BFM and SAIF. The same good agreement detected pre-
viously was also found for low-counts data.
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Figure 5.3.5: SAIF vs BFM scatter analysis in low-counts scenario. Scatter
plots of Ki (A), K1 (B) Vb (C) and rCPS (D) are reported. The average (over all
voxels in the ROI) of the parameters estimated using voxel-SAIF are plotted on the
x-axis while the average (over all voxels in the ROI) of the parameters estimated using
voxel-BFM are on the y-axis. All subjects and ROIs are included. In each scatter plot
the slope and intercept of the fitted regression line and Pearsons R2 are reported.
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DIFFERENT RESOLUTION LEVEL The agreement found between SAIF
and BFM for L-[1-11C]Leucine PET datamight be influenced by the image
resolution. The HRRT scanner used image acquisition is a very perform-
ing PET instrument providing images with very small voxel size. Since
the impact of heterogeneity grows with the increase of the volume of ob-
servation, it might be possible that voxel-wise SAIF and BFM differ at
lower spatial resolution.
Thus, to mimic a lower scanner resolution, we applied a Gaussian fil-
ter with FWHM of ∼5mm to HRRT measured dynamic PET images (one
high-counts and one low-counts image). Then, filtered data were ana-
lyzed by both methods and the results compared with those obtained
from not filtered data. The same setting of previous analysis was used
for both SAIF and BFM. Figure 5.3.6 summarizes the results obtained
for high and low-counts cases at HRRT and artificially-lowed resolution.
It appears evident an increase of the mean relative difference between
methods from high to low resolution level. This behaviour was found
for all the parameters in both high and low-counts studies. For rCPS,
in particular, the increase of BFM and SAIF discrepancy was higher than
100% for both high and low-counts studies.
In term of data description and rate of outliers, both BFM and SAIF
maintained a limited number of failures and outliers (<2%). For what
concerns the WRSS and RSS, the methods provided almost the same de-
scription of the data (mean relative difference <3%).
Analysis of heterogeneity for low resolution data showed that for ∼76%
of examined voxels SAIF detected the presence of 2 or more equilibrating
components on the estimated spectra. This result was achieved for both
high and low-counts studies. Even if SAIF tends to overestimate the het-
erogeneity in the tissues, compared to the high resolution data analysis it
represents a statistically significant increase of the heterogeneity fraction.
The same finding was also confirmed by the bootstrap approach.
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Figure 5.3.6: Mean relative difference between BFM and SAIF in high and
low resolution L-[1-11C]Leucine data. Bars refer to the means±SDs across ROIs,
for two representative subjects (one for high-counts case, one for low-counts case).
Black bars refer to HRRT normal resolution data. White bars to lowed-resolution
cases. All the parameter of interest are reported.
5.4 CONSIDERATIONS
A correct quantification of PET data cannot be performed without ac-
counting for the tissue kinetic heterogeneity (Schmidt and Turkheimer,
2002). In common practice, however, this aspect is generally neglected
since the characteristics of the process and the system under study are
such that the use of homogeneous model does not significantly impact
on final result. Unfortunately this condition is not verified for all the
tracers and for all the system of interest. An example is represented by
L-[1-11C]Leucine applied to brain.
Quantification of rCPS with the L-[1-11C]Leucine PET method was ini-
tially carried out at the region-of-interest (ROI) level and was based on
a kinetic model that assumes the tissue ROI is kinetically homogeneous
(Schmidt et al., 2005); effects of tissue heterogeneity were not taken into
account and showed to lead to biased results. The problem was worsen
by the fact that not all the ROIs presented the same level of heterogene-
ity.
To address the problem two different strategies were followed: reduc-
ing the size of tissue regions by using a voxel-by-voxel analysis, while
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retaining the tissue homogeneity assumption (Tomasi et al., 2009b) and,
conversely, by keeping data analysis at the ROI level, but employing a
spectral analytic approach that applies to heterogeneous as well as ho-
mogeneous tissues (Veronese et al., 2010). Use of the voxel-wise analy-
sis reduced, but did not entirely eliminate, effects of tissue heterogene-
ity visible in model fits of measured tissue time-activity curves (TACs)
(Tomasi et al., 2009b). The spectral analytic approach, SAIF, detected het-
erogeneity in all ROIs examined (Veronese et al., 2010). Not all parame-
ters were identifiable in heterogeneous tissue, however, without the use
of parameter constraints. Specifically, determination of rCPS requires
an estimate the fraction of unlabeled leucine in the precursor pool for
protein synthesis that is derived from arterial plasma, λ. In a homoge-
neous tissue, λ can be calculated directly from kinetic model or SAIF
parameters, whereas in a heterogeneous tissue values of λ in different
tissue subregions are not individually identifiable. As a first approxima-
tion we introduced the constraint that values of λ in all tissue subregions
were equal, and on that basis λ and rCPS in heterogeneous tissue were
estimated. Under this constraint, differences between rCPS estimated
with SAIF at the ROI level and rCPS estimated by voxel-wise analy-
sis were small, but rCPS determined with SAIF had a tendency to be
somewhat lower in whole brain and cortical regions, and higher in some
subcortical and white matter regions, than rCPS determined by voxel-
wise analysis (Veronese et al., 2010). The constraint was understood to be
an imperfect approximation, as parametric maps of λ show some spatial
variation (Tomasi et al., 2009b), but sensitivity analysis suggested that the
use of the constraint should have only a small effect on calculated rCPS
(Veronese et al., 2010). Effects may vary from region to region, however,
and even small biases in estimated rCPS may be consequential when at-
tempting to detect changes in rCPS that are small in magnitude.
These results indicated the necessity of a L-[1-11C]Leucine quantification
method to deal with heterogeneity at the voxel level. The improved ro-
bustness of SAIF method to the noise in combination with the capacity
of spectral analysis to take into account tissue heterogeneity have shown
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voxel-wise SAIF a valid solution for this problem. As indicated by the
results presented in Sect. 3.2, SAIF provided a good description of L-
[1-11C]Leucine data but, much more important, its results were found
highly correlated with those provided by BFM. This suggested that the
assumption of homogeneity used by BFM, even if not completely cor-
rected, could be considered reliable for the voxel-wise application of this
method. Moreover it has been shown how this behaviour was indepen-
dent from the injected dose of tracer to the patient.
However, when the resolution of the scanner was lowered, a significant
discrepancy between the two methods was found and much higher het-
erogeneity degree detected. Since the heterogeneity is inversely propor-
tional to the spatial resolution of the image, in the new conditions the ho-
mogeneity assumptions used with BFM might not be completely valid.
The same reasoning can be extend to other PET tracers applied in other
anatomical areas: the presence of heterogeneity is unavoidable in PET
data, but the necessity to manage depends on the characteristics of the
process and system under study as well as on the particular operative
conditions within which the analysis is performed. Image resolution is
one of the most critical elements to be taken into account. In those cases
in which heterogeneity cannot be neglected, SAIFmight represent a valid
solution to address the problem.
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Computers are useless.
They can only give you answers.
Pablo Picasso
6
Spectral Analysis for Kinetic
Estimation: SAKE
6.1 THE NEED FOR A SA-DEDICATED TOOL
DESPITE THE GREAT POTENTIAL offered by standard and filtered Spec-
tral Analysis algorithms, the use of this methodology in the PET com-
munity is limited. At the present moment, only a very selective set of
published works1 report the use of SA for PET data quantification or for
the model development of new PET tracers. The main reason of this poor
diffusion coincides with the lack of a unified and complete software en-
vironment for SA application. Generally SA routines are realized with
in-house code whose implementation is not straightforward, requiring
1Based on pubmed database (http://www.ncbi.nlm.nih.gov/pubmed) and using as
research statement: spectral analysis AND PET
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advanced programming skills. This narrows the application of SA only
to a restrict number of people which represent a very small subset of re-
searchers working with PET that could take advantage from SA use.
SAKE2 (Spectral Analysis Kinetic Estimation) is a software for the elabo-
ration of dynamic PET data developed to overcome this limitation. SAKE
has been designed as a stand-alone license-free application developed to
make dynamic PET quantification via Spectral Analysis friendly usable.
The program allows the analysis of a large variety of PET data at both
high and low SNR and with a minimum number of assumptions. It im-
plements the major spectral analysis algorithms (standard and not fil-
tered (ESA), Rank-shaping (RS) and with iterative filter (SAIF)), provid-
ing an unified pipeline of analysis from pre-processing to results analysis.
SAKE works through a Graphical User Interface (GUI), thus no program-
ming knowledge is required, in order to facilitate its use also by non ex-
pert IT users.
6.2 SAKE: FEATURES AND FUNCTIONALITIES
6.2.1 FUNCTIONAL ORGANISATION
In order to create a unified system to handle the PET data quantifica-
tion as well as other minor aspects of PET data analysis like the data
pre-processing or the visualization of the results, SAKE has been built
on three independent functional blocks. To increase the flexibility of the
program and to maximize its utilization, each block can be used inde-
pendently or in combination with the others. Block functionalities are
described as follows.
The pre-processing block operates an elaboration of the raw outcomes from
a PET exam preliminarily to the quantification. With this block the user
can manage the analysis of arterial input function data as well as per-
form the correction for the measurement delay. The latter is necessary to
account for the time shift between the arterial concentration at the target
2The last released version of SAKE is available at http://bio.dei.unipd.it/sake
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tissue of interest and the one actually measured at the blood sampling lo-
cation (generally the arm of the patient). With the pre-processing block it
is also possible to apply a model-description of the arterial data based on
the sum of 3 exponentials. This operation might be useful to reduce the
noise in the blood measures. In addition to the analysis of arterial data,
the pre-processing block offers the possibility to apply simple operations
to the raw PET measurements for both region- and voxel-wise data. In
particular for the PET images it is possible to compute the summed dy-
namic PET image over the time of experiment weighted for the length
of PET time frames. The pre-processing block allows the radioactive de-
cay correction at each level of analysis (arterial, region-based and voxel-
based data) for the principal types of PET isotopes: 18F, 11C and 15O.
The SAKE quantification block is the part of the software dedicated to the
quantification of PET data. It implements three different types of spec-
tral analysis methods: ESA, RS and SAIF (as defined in Chapter 2). Each
method is available for the quantification of both region and voxel data.
The algorithm settings as, for instance, the grid of beta components (ESA,
RS and SAIF) or the filter definition (RS and SAIF) have to be defined by
the user previously the application of each method.
The analysis of results block allows the user to manage the results obtained
through the previous quantification block. For the region-based analysis
SAKE offers the possibility to visualize the kinetic spectrum, the model
fit of the data as well as the parameter estimates for each of the analyzed
TACs. For the voxel-based analysis, instead, SAKE visualizes the para-
metric maps of the parameters of interest, i.e. VT for ESA and RS, Ki,
K1, Vb and the number of components for ESA and SAIF. For each para-
metric map axial, coronal and sagittal views are available. The results
are corrected for failures (voxels in which the algorithm failed, providing
negative values or infinite precisions for the estimated parameters of in-
terest). On the other hand, the results are not corrected for the presence
of outliers (values too high to be physiological, or unreliable estimates)
and this type of post-processing can be set by the user in a second time.
In addition, for a selected point of the map, it is possible to compare the
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SA model fit with the raw voxel TAC as well as to have the information
of the parameter estimates for the particular selected voxel.
6.2.2 DATA FLOW
Even if the functional blocks have been built to work independently from
each other, the program has been designed to manage the whole process
of PET data analysis (Fig. 6.2.1). This can be realized by a sequential use
of the SAKE functionalities, using the SAKE blocks one after the other. A
typical PET analysis starts with the pre-processing of the raw outcomes
of the study. Once the consistency of the data is verified and all the re-
quired corrections are performed, the quantification can be applied. After
that, the analysis of results can be used for the extraction of the features
of interest. In order to optimize this sequential use of the program, each
block has been designed to provide output with the same format of the
input required by the following block. Moreover, SAKE keeps in mem-
ory all the analyzed data in such way that the user can move block by
block without loading each time the data input. However for those users
who are interested only in spectral analysis quantification it is possible to
deal directly with the quantification block. In fact the user has complete
access to the output, allowing the analysis of results also with external
applications. Input/output data are managed by using principally text
files (.txt) for arterial and region of interest data and NifTi (.nii) or An-
alyze format (.hdr/.img) for the images. This choice was made to maxi-
mize the flexibility of the program. In addition, after each quantification,
SAKE creates a own proprietary file (.sake) which incorporates all the in-
formation of the analysis performed. The aim of this file is to simplify
the re-loading of a specific analysis, avoiding to recall each one of the
analyzed files. A Matlab R© file (The Mathworks Inc., Natick, MA, USA)
for expert users is also stored in the working directory as well as a log
file containing the setting information. The first one keeps track of all the
internal results performed with spectral analysis methodologies. The lat-
ter, instead, gives quick information about the setting used for the anal-
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ysis. Moreover SAKE offers the possibility to create simple .pdf report
of the results obtained. All the details about the standard required by
SAKE for the input data files are reported in the user manual (available
in http://bio.dei.unipd.it/sake/manual.pdf).
.IMG/.NII.TXT
QUANTIFICATION
Implemented methods: 
stdSA, RSSA and SAIF
RESULTS
Analysis at ROI and voxel level
.IMG/.NII.TXT
PET DATA
Report
PRE-PROCESSING ANALYSIS OF RESULT
input output
BLOCK 1 BLOCK 2 BLOCK 3
Figure 6.2.1: SAKE functional blocks. Blocks 1-3 represent respectively the pre-
processing, the quantification and the analysis of results blocks. The management of
input/output data can be performed through the SAKE program (black arrows) or
directly by the user (grey arrows). SAKE works on .txt files while it supports NifTi
and Analyze format for images. Results can be exported in .csv and .pdf files.
6.2.3 SOFTWARE REQUIREMENTS
SAKE is an open-source software released under the Attribution Non-
Commercial ShareAlike 3.0 Unported license (CC BY-NC-SA 3.0). The
software has been developed in C++ code for Window (Windows 7/
Vista/ Microsoft Windows XP Service Pack 2+). Versions for both 32 bit
and 64 bit environment are available.
SAKE works through a graphical user interface (GUI) which allows both
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expert and not expert IT users to exploit spectral analysis potentials in
the easiest and most intuitive possible way. Figure 6.2.2 reports some
representative examples of GUI screen-shots, going through a possible
pipeline of quantification process, showing SAKE’s home (6.2.2A), the
data pre-processing interface (6.2.2B) and the analysis of results at region
(6.2.2C) and voxel level (6.2.2D).
All the pre-processing and the spectral analysis algorithms were origi-
nally developed inMatlab and then incorporated in the program through
the Matlab deployment package. This choice does not impact on the way
in which the user interacts with SAKE and does not obligate the user to
deal with Matlab environment neither. The only requirement is repre-
sented by the installation of Matlab Compiler Runtime, which is license-
free and directly downloadable with the SAKE installer.
For what concerns the system requirements, SAKE needs for ∼ 1 GB of
disk usage and 512 MB of RAM. The resolution of the screen has to be
greater than 1024x768 pixel.
6.3 ALGORITHM IMPLEMENTATION
All the decisions taken to incorporate ESA, RS and SAIF in SAKE aim
to maximize the adaptability of the program to the largest set of PET
data. Following this principle the program leaves to the user the com-
plete possibility to independently define the setting of each algorithm
usable in SAKE. This could be critical, especially because an inappropri-
ate choice of the setting can lead to uncorrected and heavily biased results
(Turkheimer et al., 2003; Veronese et al., 2010).
The unique limitation imposed by the program is represented by the type
of distribution with which the grid of components are defined. In partic-
ular SAKE realizes a logarithmic distribution for βj as defined by DiSte-
fano (1981) (DiStefano, 1981) and Turkheimer (1994) (Turkheimer et al.,
1994).
SA and SAIF methods are based on weighted nonnegative least square
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A) SAKE HOME B) Data pre-processing
C) Analysis at ROI level D) Analysis at voxel level
Figure 6.2.2: SAKE Graphic User Interface. The figure shows some representative
examples of SAKE GUI screen-shots considering a whole pipeline of analysis: A)
SAKE’s home; B) data pre-processing interface; C) analysis of results at region level;
D) analysis of results at voxel level.
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estimator. RS, instead, for its definition requires linear estimator without
the nonnegative constraint. Weights are computed inversely proportion-
ally to the noise standard deviation of the measures. Precision of the
parameters is derived as the inverse of the Fisher information matrix.
6.4 PERFORMANCES IN MEASURED DATA ANALYSIS
In order to provide some examples of SAKE functionalities, the program
was tested on two different measured datasets ([11C]DPN and [18F]FDG
, tracers with reversible and irreversible kinetics respectively). All the
details about image acquisition and scanning procedure are reported in
(Hammers et al., 2007) and (Bertoldo et al., 1998). Being parametric imag-
ing of particular interest in clinics, application of SAKE was performed
only at the voxel-level. In the following subsections SAKE results will be
compared with the ones obtained with Patlak and Logan graphical anal-
ysis, being them the methods applied on these data in previous works.
6.4.1 APPLICATION TO REVERSIBLE TRACER: [11C]DPN
Figure 6.4.1 shows the distribution volume parametric maps obtained
with Logan graphical analysis (panel A), ESA (panel B) and RS (panel
C) for a representative subject in a [11C]DPN. The maps are reported
after correction for failures and for outliers, corresponding to the vox-
els with non-physiological and unreliable VT estimates. This additional
correction was done a posteriori, exporting the results file provided by
SAKE in Matlab. The results are in agreement with the expectation. ESA
showed poor performances when applied at the voxel level, due to its
high sensitiveness to noise in the data. This resulted in very noisy para-
metric maps (Fig. 6.4.1B) and in a 18% of outliers voxels. Both Logan
and RS reported a percentage of failures and outliers <0.01%, being RS
optimized to work with reversible tracers at high noise level. ESA and
RS results were in agreement with the ones obtained in previous works
(Hammers et al., 2007). As expected due to the low SNR of the data, Lo-
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B Standard Spectral Analysis
C Rank Shaping Spectral Analysis
A Logan graphical analysis
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
VT (ml/cm3)
Figure 6.4.1: Parametric imaging in a [11C]DPN brain study. Panels A-C report
respectively the VT parametric maps obtained with Logan graphical analysis, ESA and
RS. All the three views, axial coronal and sagittal are reported. Results refer to a
representative subject.
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gan plot underestimated the VT compared to spectral-based algorithms
(Slifstein and Laruelle, 2001). Moreover Logan analysis is quite depen-
dent on the choice of the time after which the plot shows a linear trend
and this was a problem in particular for [11C]DPN, a regionally hetero-
geneous tracer (Hammers et al., 2007). Thus in general [11C]DPN is not
quantified using Logan analysis, but alternative bias-free solutions to the
Logan plot can be employed (like Likelihood Estimation in Graphical
Analysis, (Ogden, 2003)). In terms of computational time, ESA required
almost 15 minutes for a single subject voxel-wise analysis, while RS took
around 120minutes for the same subject. To note that Logan analysis (im-
plemented with an in-house code) took <5 minutes for the whole quan-
tification. These times were reported with desktop computer with 4 Gb
of RAM and a 3.17 GHz processor.
6.4.2 APPLICATION TO IRREVERSIBLE TRACERS: [18F]FDG
Figure 6.4.2 reports the Ki parametric maps obtained with Patlak graph-
ical analysis (panel A), ESA (panel B) and SAIF (panel C) for a represen-
tative subject in a [18F]FDG study. The maps are reported after correction
for failures and outliers (as defined above). Also in this case, the results
were in agreement with the expectation, with ESA showing the worst
performance both in terms of failures (∼ 10%) and agreement with Pat-
lak plot results (R2 = 0.8, mean relative differences: -15%±15%). On the
other hand, SAIF estimates showed excellent agreement with Patlak re-
sults (R2 = 0.99, mean relative differences: 7%±12%), proving to be robust
also when applied to low SNR data (fraction of failures and outliers ∼
11%). In terms of computational time ESA and SAIF performed compa-
rably with an average time <20 minutes for a whole subject voxel-wise
analysis. To note that, as for Logan analysis, Patlak quantification (im-
plemented with an in-house code) took <5 minutes. These performances
were reported with desktop computer with 4 Gb of RAM and a 3.17 GHz
processor.
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B Standard Spectral Analysis
C Rank Shaping Spectral Analysis
A Patlak graphical analysis
0.000 0.010 0.0200.005 0.015
Ki (ml/cm3/min)
Figure 6.4.2: Parametric imaging in a [18F]FDG brain study. Panels A-C report
respectively the Ki parametric maps obtained with Patlak graphical analysis, ESA
and SAIF. All the three views, axial coronal and sagittal are reported. Results refer
to a representative subject.
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6.5 CONSIDERATIONS
Preliminary studies (Rizzo et al., 2012c; Veronese et al., 2012a) have de-
monstrated the reliability of SAKE as a tool for PET quantification via
Spectral Analysis. SAKE has been specifically designed with the pos-
sibility to manage the whole pipeline of analysis (from raw data pre-
processing to analysis results) without the use of any external applica-
tions. Unlike other programs for PET image processing, only a very basic
set of functionalities is available. But, exactly for this reason, it has been
possible to define a simple and intuitive tool focused to SA applications.
The main core of SAKE program is represented by SA algorithms. In or-
der to maximize the utilization of the program to different tracers and
different biological systems, SAKE leaves to the user the freedom to set
independently the algorithm variables. Thus for a correct use of SAKE
a basic knowledge in kinetic modelling is required. Theoretically this
should not be a limitation because SAKE has been thought for the PET
community as a simple and intuitive tool for spectral analysis utilization.
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If we had had more time for discussion we
should probably have made a great many more
mistakes.
Leon Trotsky
7
Overall discussion
7.1 ADVANTAGES OF SA QUANTIFICATION METHODS
7.1.1 FLEXIBILITY OF THE MODEL
The main strength of SA methods is related to the flexibility of the model
implemented: due to its additive formulation, SA can be applied to re-
versible/irreversible kinetics, single o multi-compartment models and
homogeneous aswell as heterogeneous systems. This characteristic makes
SA adaptable to different tracers and different physiological systemswith-
out any a priori assumptions concerning the number and the types of
compartments necessary to describe the data.
SA, however, is characterized by well-defined applicability limits which
derive from the non negativity constraint used to estimate the coefficients
of its basis function (Sect. 2.1.1). The main drawback of this assumption
is the restriction of SA applicability only to models with a unique input
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function and without cycling connection (Schmidt, 1999). Most of the
models used in PET met these conditions, but unfortunately reference re-
gions models do not belong to this category1.
Respect to standard SA, filtered versions could be characterized by differ-
ent (generally smaller) application domains. SAIF and RS, for example,
respectively require the irreversibility/reversibility of the tracer kinetic.
Thus, this characteristic has to be verified previously to their applications.
RS, however, can be applied to reference region models but only for the
distribution volume estimation. The larger applicability domain of RS is
offered at the cost of a decreased number of outcomes.
Within its applicability domain, SA has demonstrated not only to be adapt-
able to different conditions, but also to be easily modifiable to the specific
characteristics of the system under study. This is the case of what was
done with [11C]SCH442416 tracer (Sect. 3.3) or with the Double Input SA
(DI) (Tomasi et al., 2012). In the first case the structure of SA model was
changed to account for a vascular trapping; in the second case, instead,
SAmodel incorporated the presence of metabolites within the tissues un-
der study. In both situations the structure of SAmodel was enriched with
additional components whose amplitudes were then estimated from the
data as the other ones already present in the its functional basis.
7.1.2 HIGH INFORMATIVE DESCRIPTION
SA represents a complete quantification tool for dynamic PET quantifica-
tion. Where it can be applied, SA allows to describe the entire kinetic
of the tracer in the tissues, providing not only the information about
the macro-parameters of interest, like trapping or tracer transport, but
defining a full-characterization of the kinetic components necessary to
describe the data. As for compartmental modelling, SA returns themodel
description of the entire data time-course, but without requiring a fixed
1It is important to stress the concepet that SA cannot be applied to reference regions,
not because reference region models are inadequate to be described by sum of convo-
lution terms, rather instead because it is not possible to estimate their kinetic spectra
through the non negativity constraints
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model structure. SA can be also used for model development, for the
identification of the number and type of compartments necessary to de-
scribe a given system.
Not all the SA-based methods maintain the SA features, but SAIF has be
designed to do it. SAIF can be applied both region or voxel-wise, provid-
ing parametric maps for Ki, K1 and Vb estimates. In presence of hetero-
geneous systems, SAIF can be used for spatial analysis of heterogeneity
distributions. Since SAIF is a filtered version of SA, its use is not advis-
able for the model development because the filtering procedure might
lead to an incorrect results. SAIF is mainly focused for dynamic PET
quantification, and as shown from Chapters 3 and 4, it represents a valid
methodological alternative to be used for irreversible tracer analysis.
7.2 CRITICALITY OF SA-BASED QUANTIFICATION METHODS
7.2.1 NECESSITY OF ARTERIAL INPUT FUNCTION
For its definition SA requires the assessment of the tracer concentration
over time in arterial plasma. This information is obtained by arterial
blood sampling, which could be performed manually by an operator or
automatically by an appropriate device. Arterial line, however, repre-
sents a risk of the patient (like infections, strokes, ...) and a risk for the
personnel (risk of handling the blood of the patient, exposure to radi-
ation,...), characteristics that limit its use in common practice. The last
statistics offered by a large centre like the National Institutes of Health
explained that among last 3000 PET studies performed with arterial line,
only 2 patients reports problems for blood sampling and all these cases
were easily solved by the personnel (Zanotti-Fregonara et al., 2011b). This
might results in contradiction with the previous statement, but arterial
sampling is not a complete safe practice, and for some particular cate-
gories of patients, like infants or patients with severe cardiovascular dis-
eases for example, the presence of arterial sampling prevents use of PET.
Arterial input function (AIF) is not a requirement only for SA: this fea-
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ture is shared with the most used quantification methods, like graphical
analysis and compartmental modelling. A valid alternative to arterial
sampling could be the use of reference region, but not all the PET studies
can applied these models because reference region is not always present
(like in the case of L-[1-11C]Leucine ) and even if it is, it may be not cor-
rupted.
With the development of non invasive input function techniques, some
alternatives to the arterial sampling are present. Briefly non invasive in-
put function techniques can be organized in 4 categories (Fig. 7.2.1):
1. Image-derived input function (IDIF): the whole blood TAC is ex-
tracted directly from the PET images, by using the measured ra-
dioactivity within largest blood vessels in the field of view (Chen et al.,
1998; Zanotti-Fregonara et al., 2009, 2011a);
2. Simultaneous estimation (SIME): the AIF is simultaneously esti-
matedwith tracer kinetic quantification (Feng et al., 1997; Ogden et al.,
2010);
3. Population-based input function (PBIF): individual AIFs are ob-
tained by the mean of several arterial input functions opportunely
scaled for individual features (Vriens et al., 2009; Zanotti-Fregonara et al.,
2012a);
4. Venous input function (VIF): AIF is derived by the venous blood
measured (Syvanen et al., 2006).
The validity of each methods is strongly dependent to the characteris-
tics of tracer kinetics (fast and slow kinetic in particular) as well as to
the applied quantification methods. Graphical methods, for example,
are not sensitive to the shape of AIF, while depend to its area under
curves (AUCs). Since AIF AUC is much more easier to be reproduced
respect to its time-course, non invasive input function method have been
successfully applied with Logan and Patlak analysis in different tracers
(Zanotti-Fregonara et al., 2011a,b, 2012b).
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Imaged-derived input functions
Population-based input function Venous input function
Simultaneous input-estimation model
Venous Input Arterial input
h(t)
Arterial TAC Tissue TAC
Figure 7.2.1: Alternatives to arterial sampling in PET domain.
On the other hand, compartmental analysis and SA results are strictly de-
pendent to the shape of AIF, and small variations on its time-course can
lead to high biased estimates, both micro and macro parameters. More-
over, the application of non invasive methods results in an increased un-
certainty of the model parameter estimates, which becomes a problem
when groups of subjects have to be statistically compared.
At the moment, it does not exist a valid alternative to arterial sampling
able to correctly reproduce its results. Thus, for all the SA-basedmethods
arterial sampling remains a necessity.
7.2.2 SENSITIVITY OF THE METHODS TO THE ALGORITHM SETTING
One of the main difficulties in using SA-based methods is related to the
choice of the algorithm settings. This step could be particular critical, es-
pecially for non modeller users. The problem is even worsened by the
lack of a theoretically-based criteria generally valid for all conditions and
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all the tracers. The SA-related literature proposes only some rule of thumbs
that we suggest to be used as a starting point for SA applications, because
case by case the correctness of the algorithm setting has to be verified and
eventually adapted to the specific characteristics of the applicative con-
text. Hereafter we proposed some guidelines for SA setting definition.
SA BASIS FUNCTION: DISTRIBUTION All the SA methods, standard and
filtered versions, require the a priori definition of the basis function for
the spectral components. The β grid has to be designed to appropriately
cover the distribution of all the kinetic components detectable from the
PET data, making it more dense where the probability to measure a com-
ponent is higher. Thus, the choice of β grid can be seen as a way of ap-
plying a prior information on the quantification: the more accurate this
information is, the better the quantification results are. It has to be no-
ticed that the relationship between basis function and final results is not
well-formulated as the Bayesian methods, and since the first application
of SA, it has been always preferred to implement a β grid larger than the
actual kinetic of the tracer under study (Cunningham and Jones, 1993;
Turkheimer et al., 1994).
Also the choice of a logarithmic distributions of the spectral components
represents a standard procedure derived principally from the common
practice rather than theoretically formulation. In fact, it has been shown
in (Cunningham et al., 1998) and in (Turkheimer et al., 2003) that other
choices of distribution, like equiangular or orthogonal basis, might im-
prove the performance of SA methods, both standard and filtered ver-
sions.
For the particular characteristics of SAIF, we preferred the use of the loga-
rithmic grid. This choice was driven by the necessity to implement a grid
whose generation could be simply managed: in fact, since SAIF imple-
ments an iterative cycle in which the β grid is involved, the application
of more complex methods would create a too computation demanding
algorithm. In addition, from our experience of SAIF applications, we did
not find any evidence suggesting the necessity to use a different distribu-
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tion of βs for SAIF.
SA BASIS FUNCTION: NUMBER OF COMPONENTS The number of grid
components appears to be less critical than the choice of their distribu-
tions. Different attempts have been done comparing SA results with a
different number of βs (Tomasi et al., 2009b; Veronese et al., 2010): the
advantages of a more populated grid, especially in term of accuracy and
precision of spectral estimates, does not counterbalance the relevant in-
crease of computation time required by the algorithm. On the contrary,
a smaller number of components could be critical if not optimally dis-
tributed around the true kinetic components. As suggested by Rizzo
(2012), 20/30 elements are adequate only when an accurate prior infor-
mation about the data under analysis is available. If this condition is not
verified the final estimates can be strongly biased.
The results obtained in chapter 3 and 4 has confirmed that a grid consist-
ing in 100 βs represents a good trade-off between results precision and
algorithm efficiency. We recommend it for both filtered and standard SA
applications.
FILTER SETTING Respect to the standard SA, filtered SA methods re-
quire also the filtering definition. The filter procedures heavily impact on
the final performance of the methods and thus they have to be carefully
managed, depending on the peculiarities of SA algorithm under utiliza-
tion. The difference of using an adequate or not adequate filtering setting
is determinant to make the methods reliable or not.
For SAIF, for example, the choice of the filter passband coincides with
the assumption of the kinetic interval within which the investigate ki-
netic can be detected. Outside this interval, all the kinetic components
are considered as a mixed of noise, random SA effects and true kinetic
components (like blood volume or trapping) and thus removed from the
estimated spectrum. For its definition, different strategies based on the a
priori information available on the particular dataset and tracer under
analysis, have been evaluated: for L-[1-11C]Leucine PET data we im-
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plemented a simulation approach based on literature kinetic values; for
[18F]FDG , instead, we derived the filter passband bounds directly from
literature kinetic estimates. Finally, for [18F]FLT , we implemented a hi-
erarchical approach, from ROI to voxel analysis. The last approach used
seems to be the most promising, since its definition does not depend on
the particular tracer or system under study.
Independently from the strategy used for filter definition, it is always rec-
ommended to verify a posteriori the assumption correctness. For SAIF, for
example, in the particular case in which the spectral components are con-
centrated at the borders of the filter, the choice of the passband is with
high probability too narrow for the kinetic characteristics of the process
under study (Fig. 7.2.2). In these cases a new quantification with a wider
SAIF passband is highly recommended.
7.3 SAIF: PRONS AND CONS
All the considerations done for SA can be directly extended to SAIF. Since
the method conserves the main proprieties of standard SA, advantages
and drawbacks are also maintained. Figure 7.3.1 proposed a schematic
summary of SAIF features when applied for PET quantification of irre-
versible tracers.
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A) Non optimal passband choice: 0.05-0.3 min-1
B) Adequate passband choice: 0.02-0.4 min-1
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Figure 7.2.2: A posteriori analysis of SAIF kinetic components. Panel A shows
the case of over-fitting passband. Most of the components detected coincide with
the filter passband bounds. Panel B shows the same situation, with an optimal filter
passband. Results refer to SAIF application to the same simulated dataset.
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Disadvantages
All the SA methods require the a
priori definition of the grid of
components
SAIF requires the a priori definition
of the filter setting (critical part of the
procedure that heavily impacts the
quantification process)
? SAIF provides reliable voxel
parametric maps with limited
number of failures and outliers
? Not only Ki: SAIF provides
information of different parameter of
interest like K1, Vb
Advantages
? SAIF exploits the full tracer
kinetics and provides a complete
description of the impulse response
function for the system of interest
Similar to other quantitative
techniques, SAIF requires arterial
input function data
Figure 7.3.1: SAIF prons and cons.
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Writing a book is an adventure. To begin with,
it is a toy and an amusement; then it becomes a
mistress, and then it becomes a master, and then
a tyrant. The last phase is that just as you are
about to be reconciled to your servitude, you kill
the monster, and fling him out to the public.
Winston Churchill
8
Conclusions
Quantification of dynamic PET studies can be performed in several different
ways, which mainly differ on the assumptions about the system of interest and
on the analysis outcomes. In this work we gave particular attention to Spectral
Analysis, a general and flexible quantification method based on minimal model
assumptions. Considering the trade-off between outcomes and requirements,
Spectral Analysis can be located in an intermediate position between graphical
methods and compartmental modelling.
The main limitation of Spectral Analysis is related to its sensitivity to the noise
in the data. For this reason we developed SAIF, a filtered Spectral Analysis
version for the quantification of irreversible tracers. SAIF was first formalized
in the Spectral Analysis context and then validated in different cases of interest,
by comparing its results with those provided by the standard Spectral Analysis
as well as with the methodological state of the art presented in literature. Results
have indicated SAIF as a robust and reliable quantification method, applicable
for both region and voxel-wise analysis, in different tracers, anatomical systems
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and physiological conditions.
We also developed SAKE, a software tool to make Spectral Analysis friendly
usable. SAKE incorporates the main Spectral Analysis methods within a unique
environment designed to manage the entire quantification process, from data pre-
processing to analysis of results.
Despite the great potential offered by the technique, Spectral Analysis is not so
widely applied in PET community, mostly because not completely known and
understood. With this work we tried to support its use by offering an exhaustive
dissertation of the method advantages and drawbacks, with the ambitious wish
to make it more accepted in the PET modelling community.
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A
Voxel-wise quantification of
[11C](R)-Rolipram PET studies
A.1 INTRODUCTION
[11C](R)-Rolipram is a PET radioligand for the quantification in vivo of
phosphodiesterase type IV (PDE4), an enzyme that metabolizes 3’, 5’-
cyclic adenosine monophosphate (cAMP). The cAMP cascade plays an
important role in major depressive disorder (MDD) and is a potential tar-
get for drug development. A recently published study using PET and
[11C](R)-Rolipram showed for the first time that PDE4 is downregulated
in vivo in unmedicated individuals with MDD[1].
A previous study in humans showed that the pharmacokinetics of [11C](R)-
Rolipram is well described by a two-tissue four-rate constant compart-
mental model (2TCM), and that Logan graphical analysis yielded similar
results at the region of interest (ROI) level[2]. While the Logan plot al-
lows the easy computation of parametric images for the total distribution
volume (VT ), it does not account for the vascular component within the
voxel, and generally underestimates the parameter of interest in noisy
data[3], especially when applied voxel-wise. Nevertheless, the resulting
bias is almost constant, and thus these limitations can be neglected when
using Logan plot in statistical comparison between different groups of
subjects.
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It is important to note, however, that voxel-wise analysis of the whole
kinetic of the tracer in tissues may yield the ability to generate quanti-
tatively accurate parametric maps and thus harness the full potential of
[11C](R)-Rolipram for the study of MDD and related diseases. This study
aimed to assess the best methodology for voxel-wise quantification of
[11C](R)-Rolipram in brain PET studies, in order to generate precise and
accurate parametric maps of the parameters of interest.
A.2 MATERIALS AND METHODS
A.2.1 DATASET
The analysis of this study were based on a dataset of 10 healthy sub-
jects. All the subjects underwent a 90-min PET scan following injection of
421±144 MBq of [11C](R)-Rolipram , complete with metabolite-corrected
plasma input functions. T1-weighted MRI was performed as well pro-
viding the anatomical information for the region placement. A detailed
description of experimental protocol and data pre-processing is reported
in [2].
A.2.2 QUANTIFICATION METHODS
Several approacheswere applied for voxel-wise quantification of [11C](R)-
Rolipram PET images. The 2TCMmicroparameters (K1, k2, k3, k4, and Vb)
were quantified for each voxel TAC by using the Weighted Non-Linear
Least Squares (WNLLS). This approach was used based on the assump-
tion that the model that describes tracer kinetics in the ROI can also be
extended at the voxel level. The initial parameters were derived from the
ROI estimates described in the literature[2]. Due to the weakness of the
nonlinear estimator applied at the voxel level (convergence issues, high
computational time, sensitivity to initial estimates), we also identified the
2TCM using H-BFM, as implemented by Rizzo and colleagues[4]. H-BFM
identifies all the system micro- and macroparameters (i.e. K1, k2, k3, k4,
Vb and VT ) following a hierarchical scheme from ROI to voxel analysis.
As alternative to the model-based solutions, standard Spectral Analysis
(ESA) and Rank-shaping Spectral analysis (RS)[5,6] were also applied to
measure the volume of distribution (VT ) at the voxel level. First, ROI anal-
ysis was performed to set and validate the application of these two meth-
ods by comparing their results with those provided by 2TCM applied
ROI level. Then the same setting was extended for SA and RS voxel-wise
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Table A.2.1: Quantification methods
Method Type of method Type of Estimator Parameter of Interest Complete kinetic description
WNLLS Model-based Non Linear K1, k2, k3, k4, Vb and VT Yes
H-BFM Model-based Linear K1, k2, k3, k4, Vb and VT Yes
ESA Data-driven Linear with nonnegative constraints K1, Vb and VT Yes
RS Data-driven Linear VT Yes
Logan Graphical Analysis Linear VT Yes
application. In addition to the methods described above, we also quanti-
fied [11C](R)-Rolipram binding with Logan analysis[7]. A summary of the
methods applied is reported in Table A.2.1.
A.2.3 PERFORMANCE INDEXES
Results obtained at voxel level using 2TCMmodel solved with Weighted
Non-Linear Least Squares (WNLLS) were used as the gold standard.
From the parametric maps obtained with the different methods we dis-
carded those with biologically implausible results; specifically those with
a VT values < 0 and also those with VT values >1.5 (ml/cm
3). For each
subject, we therefore only considered the subset of voxels in which all the
methods reached convergence, and used the statistical analysis in these
groups of voxels.
For each method, we averaged the VT estimates obtained in the voxels
composing each ROI, and considered only the subset of voxels in which
all the methods converged. These average values were compared to the
average of the VT estimates obtained with WNLLS in the same voxels in
terms of mean relative differences.
A.3 RESULTS
At the ROI level all methods provided comparable VT results with 2TCM,
with high correlation (R2 > 0.95). Logan analysis tended to underesti-
mate VT , especially in high binding ROIs, while RS showed a constant
bias (+9%) probably due to a bias introduced by the method filtering pro-
cedure. SA provided the best performance with a computational time x3
lower than 2TCM.
All the parametric maps are presented before correction for outliers in
Figure A.3.1. Here, both WNLLS and SA VT estimates were visually
very noisy, while H-BFM, RS, and Logan had only a limited or negligible
amount of outlying voxels. WNLLS yielded the poorest image quality,
and more than 50% of the voxels had to be eliminated. In particular, 16%
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on average of the voxels had to be discarded for non-physiological es-
timates, 29% for values with a CV > 50%, and 12% for values with an
imaginary CV. Moreover, WNLLS required high computational time (up
to five times greater than the other methods). Although the VT estimates
in the remaining voxels are considered as the gold standard, these results
clearly highlight the necessity of an alternative method for voxel wise
quantification.
2TCM-WNLLS applied voxel-wise required high computational time (up
to x5 compared to the other methods), and image quality was generally
poor. On average, 50% of the voxels were eliminated because their val-
ues were physiologically implausible or inaccurate. Although 6% of the
voxels had a negative VT , 2TCM-HBFM showed one of the highest cor-
relations (R2 > 0.97), the best agreement with 2TCM-WNLLS estimates
(Figure A.3.2) and the lowest percentage relative difference. Logan plot
results presented good correlation but the higher underestimation among
the methods. SA performed better than RS (SA: R2 > 0.98; RS: R2 > 0.96)
but the image quality was poorer, and 5% of the voxels had to be elim-
inated. Similarly to ROI results, RS showed a constant bias (-5%) of VT ,
probably due to the filtering procedure.
A.4 CONSIDERATIONS
2TCM-WNLLS high computation time and poor image quality point to
the necessity of an alternativemethod for quantification at the voxel level.
Compared to the other methods, 2TCM-HBFM showed more accurate VT
quantification with good quality parametric maps and excellent agree-
ment with 2TCM-WNLLS results. Consequently 2TCM-HBFM was se-
lected as the best alternative to the gold standard approach for voxel-wise
quantification of [11C](R)-Rolipram data. Among the data-driven meth-
ods, SA represented the best approach both at the ROI and voxel level.
In conclusion, different techniques exist to generate parametric images,
and each has its own advantages and drawbacks. H-BFM allows the
most complete and reliable quantification of the [11C](R)-Rolipram ki-
netic at the voxel level. If the whole description of the tracer kinetics
is not necessary, or if only the VT estimate is required to compare differ-
ent populations or in longitudinal studies, then Logan plot represents a
valid alternative. Its marginally higher bias is outweighed by the ease of
implementation and robustness of the method.
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Figure A.3.1: Distribution Volume (VT ) parametric maps obtained with (A)
Weighted NonLinear Least Squares (WNLLS) applied to a two-tissue compartmental
model, (B) standard Spectral Analysis (ESA), (C) Rank-shaping Spectral Analysis
(RS), (D) Hierarchical Basis Function Method (H-BFM) and (E) Logan Graphical
Analysis. Results refer to a transaxial slice at the cortical level for a representative
subject. 158
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Figure A.3.2: Comparison between 2TCM-WNLLS and other methodologies at the
voxel level (variability expressed as between subjects SD).
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B
A population-based approach for
plasma metabolite correction in
PET studies
B.1 INTRODUCTION
A notable problem in the quantitative analysis of dynamic PET scans is
the accurate estimate of the parent plasma arterial input function due
to the presence in plasma of radiolabeled metabolites derived from the
metabolism of parent tracer in the liver, kidneys or other parts of the
body. When radiolabeled metabolites are found in the plasma in signif-
icant amounts their presence has to be accounted for, because it is the
concentration of authentic parent tracer that is required for quantifica-
tion of the tissue data. Estimates of the levels of radiolabeled metabolites
in plasma can be assayed directly from samples of blood taken through-
out the PET scans by using high-performance liquid chromatography
(HPLC). However, for practical and technical reasons the number of me-
tabolite samples is limited (typically to 4-7 for a 1-2 hour scan with 11C
or 18F) and they can be noisy particularly later in the scan as counting
statistics deteriorate.
Thus, in order to describe the full parent plasma fraction time course, a
modelling approach based on the assayedmetabolite fractions is applied.
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The parent arterial plasma input function is generated by multiplying
the measured total plasma radioactivity concentration by the continuous
estimate of the parent fraction (PPf). PPf models are usually based on
monotonic functional forms including exponentials[1] and sigmoidal[2,3]
behaviour. There are several advantages to modelling the fraction of
labelled metabolites in plasma: 1) it reduces the effect of measurement
noise, 2) it allows the reconstruction of a time-continuous metabolite frac-
tion curve by interpolating few metabolites measures and 3) it permits
the extrapolation of metabolite measures when the metabolite fraction
can be no longer measured accurately because of low plasma radioactiv-
ity levels.
The particular parent fraction model used to correct the plasma time-
activity curves for labelled metabolites in PET measurements is chosen
to provide the best fit to the data. The choice should be made by integrat-
ing this assessment across all subjects and scans within the study so that
one model is selected for consistent use with all scans.
The common approach to model-fitting of metabolite samples is based on
an individual approach (IND): a parent fraction model for each subject is
fitted solely to the metabolite data obtained from that subject. IND for
metabolite correction can be applied successfully in a data-rich situation,
i.e. in presence of a satisfactorily abundant sampling schedule for each
subject. However, in the case of sparse or noisy data, the estimation of
the parent fraction may be poor, consequently yielding large errors in the
regional tissue parameters of interest following tracer kinetic analysis.
The aforementioned limitations of the IND can be overcome by using
Non Linear Mixed Effects (NLMEM[4]). NLMEM is a population-based
method for quantitative data analysis and given a model for a system of
interest, NLMEM assumes that the set of model parameters, character-
ized by some physiologically meaningful attributes, can be partitioned
into those that do not vary across the population (called fixed effects)
and those that do (called random effects). Thus NLMEM easily accom-
modates both intra-subject as inter-subject variability. Moreover, with
NLMEM it is possible to calculate both the population and individual
parameter estimates, optimizing all the information derived from all the
subject measurements.
In this study, a NLMEM is proposed for modelling the plasmametabolite
fraction and generation of the arterial parent plasma input function in dy-
namic PET scans. Since NLMEM has been developed to provide robust
parameter estimates in the case of sparse sampling schedules and/or
noisy data, it is merits evaluation in comparison to traditional individ-
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ual methods, such as weighted least squares, for the modelling of the
parent data.
B.2 MATERIALS AND METHODS
In order to validate the proposed methodology and to evaluate its im-
pact on arterial input function estimation and on the subsequent tracer
kinetic analysis of tissue data, three different PET datasets were consid-
ered: [11C]-(+)-PHNO (54 scans), [11C]-PIB (22 scans) and [11C]-DASB
(30 scans). For each tracer both simulated and measured data were ana-
lyzed by assuming the literature PPf model [5-7] as reference for the analy-
sis. In simulations, the Residual Sum of Squares (RSS) between simulated
and model estimated PPf and percentage bias were used as performance
indices. Inmeasured data analysis, the mean relative differences between
NLMEM and individual results were performed. The impact of metabo-
lite correction was evaluated both at the level of description of parent
plasma data and at level of influence on tissue kinetic quantifications.
When the INDapproachwas used, PPfmodel parameterswere estimated
by non-linear weighted residual sum of squares. For NLMEM, the esti-
mates were computed with NONMEM R© by assuming log-normal distri-
butions for the PPf parameters and a diagonal covariancematrix tomodel
the inter-subject variability. The same model error description (additive,
Gaussian with zero mean and SD defined by the metabolite measures
uncertainty) was used in both IND and NLMEMmethods.
B.3 RESULTS
Simulations showed that NLMEM provides a more accurate metabolite
description than individual approach (RSSpop/RSSind = 0.24), partic-
ularly in presence of outliers. This NLMEM was shown to be superior
even when the simulated metabolite data are equal to the number of PPf
model parameters, i.e. data poor scenario, (Figure B.3.1) with a percent
difference in the distribution volume (VT ) up to 10%. In measured data
analysis, the differences in PPf modelling between NLMEM and IND do
not significantly affect neither the AIF reconstruction (Area Under Curve
mean relative differences between 0.0% to 3.0%) nor distribution volume
(VT ) estimates (absolute mean relative differences between 1% to 4%).
This behaviour was found to be consistent in all the analyzed tracers
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Figure B.3.1: Comparison of NLMEM and IND methods for plasma metabolite cor-
rection in simulations. The figure compares the data model fit of IND and NLMEM
methods. Panel A refers to [11C]-PIB PPf data in rich scenario conditions. Panel
B refers respectively to [11C]-DASB PPf data in poor scenario conditions. For each
tracer a representative simulated subject is shown. Circles represent noisy PPf sim-
ulated samples; solid lines represent simulated noise-free PPf curves; dashed lines
represent the results for IND; dotted lines represent the results for the NLMEM
method.
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Figure B.3.2: NLMEM vs. IND approaches in Bland-Altman plots. Panels A-C
report respectively [11C]-DASB, [11C]-PHNO and [11C]-PIB volume of distribution
estimates. Solid lines represent the mean of NLMEM and IND relative differences.
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(Figure B.3.2). However, even with real data, there are a few subjects
( 5%) inside the evaluated populations for which high discrepancy be-
tween NLMEM and IND is found.
B.4 CONSIDERATIONS
The application of a NLMEM approach for plasma metabolite correction
is shown to offer improvements in performance over the individual ap-
proach, particularly in the presence of outliers or when the number of
metabolites samples is limited.
For the remaining scenarios, NLMEM performs similarly to the standard
individual approach. However, NLMEM requires a population of at least
10 subjects to be viable.
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Optimal experimental designs in
PET receptor occupancy studies
C.1 INTRODUCTION
The use of PET imaging has greatly contributed to increase the efficiency
of the drug development process of new molecular entities[1]. For neuro-
science in particular, PET technique has been widely applied to investi-
gate the ligand-receptor binding in living brain as well as for the determi-
nation of plasma concentration/receptor occupancy time-course. Since
the knowledge of receptor occupancy and the plasma drug time course
are crucial for a rational drug dose selection, PET occupancy studies has
proved to be a valuable tool for clinical drug development[2,3].
Despite their high informative content, PET receptor occupancy (PET-
RO) studies present some relevant constraints, both ethical and practical.
In particular the overall radiation exposure and the high cost of PET ex-
periments, limit the total number of subjects available in the study as
well as the and number of scans to perform per subject, preventing the
possibility to have dataset with data abundance. Since each scan rep-
resents a precious experimental data for the characterization of a drug
Pharmacokinetic/Pharmacodynamic (PK/PD) behaviour, rational strate-
gies should be adopted to define the best experiential design.
Optimal experimental designs have been successfully used to increase
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the efficiency and minimize cost of the trials by optimizing dose alloca-
tion and sampling schedules[4,5]. These techniques allow to increase pre-
cision and accuracy of population parameter estimates[6-8] by providing
optimized experimental designs which account for the proprieties of the
system of interest as well as the subject response variability. All these
methods rely on maximization of the information content which can be
extract from a particular experiment. They mainly differ on the type of
information to maximize and on the applicative requirements. A simple
classification can be done distinguishing fixed from adaptive algorithms.
Fixed optimal design algorithms use the model description of the investi-
gated system to set the experimental variables by minimizing the estima-
tion error of model parameter estimates. These approaches are simple to
be applied, robust and with a very solid theoretical background behind.
In theory they represents the best way for the experimental design defini-
tion. However some limitations are present. Firstly the application of op-
timal design algorithms requires detailed information about the model of
the investigated system and reliable prior values for its parameters[9-11].
This information is very difficult to be obtained in advance, especially
when new chemical entities are studied for the first time in clinical tri-
als. In fact, although the kinetic and dynamic proprieties of a drug can
be derived from in vitro or preclinical experiments, a conspicuous level
of uncertainty remains when translating this information from animals
to humans. Secondly fixed optimal design algorithms provide only theo-
retic model-based solutions which may not take into account all the prac-
tical constraints that an experiment has when run in practice[12-14]. Thus,
because the optimization could lead to unfeasible practical designs, it fol-
lows that in practice the necessity of comparing different designs perfor-
mance is as important as to optimize the experiment design. In addition,
most of these optimal design techniques planned in advance the entire
experimental project without accounting for the results derived by the
experiments. This strategy may not be ideal since it is in contrast with
the natural way to conduct the PK/PD trials. In dose finding studies, for
example, the experiments are commonlymanaged according to a sequen-
tial adaptive procedure: the population subjects are organized in cohorts;
the first cohort is then treated with an initial dose (selected on the basis
of pre-clinical pharmacokinetic information and early human PK data)
and with a measurement sampling grid chosen to appropriately cover
the time-window of the drug kinetics (with particular attention to the ex-
tremes); afterwards the decision on sample size, dose and measurement
times for the second cohort of subjects is derived from the results of the
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analysis of the initial data. This procedure is repeated for all the groups
of subjects planned in the study. The number of treated subjects, the se-
lection of informative doses and the scan times remain critical issues for
a precise and accurate characterization of the PK/PD relationship.
Adaptive optimal designs (AOD) have been proposed for the sequen-
tially optimization of the design in population studies[15,16]. These are
educated approaches which combine the information derived from the
already performed experiments with that extracted from the model-pre-
diction of the investigated system. This fact requires to organize the pop-
ulation of subjects in cohorts, each one with a different experimental de-
sign. Respect to fixed approaches AOD presents some considerable ad-
vantages: firstly AOD algorithms reflect more the sequential way with
which the experiments are managed in practice, allowing to refine the
choice of experimental variables as the experiments are performed and
their results analyzed; secondly AOD presents a superior robustness to
the prior misspecification which can be corrected step by step with the
running of experiments; thirdly, with an infinite number of cohorts, also
AOD converge to the optimal design solution.
By considering all these features AOD appears to be more adequate for
experimental design definition. In real practice the convenience of using
adaptive respect to fixed procedures depends on the specific characteris-
tics of the experiment to which the methods have to be applied. For ex-
ample, the change of experimental design represents a cost and it cannot
be always performed. It can also happen, like in PET occupancy studies,
that the number of cohorts in which a study is be organized is limited,
counting the advantage of AOD respect to fixed designs. Thus, the type
of experimental design strategy to be used should be evaluated case by
case, considering all the experimental constraints of the system.
In a recently study it has been demonstrated that adaptive optimal design
(AOD) algorithms improve the assessment of drug kinetic time-courses[16],
when applied to PET-RO studies. However the value of applying adap-
tive or non-adaptive optimal design methodologies to PET-RO studies
depends on several factors including drug affinity to the target as well
as feasibility constrains such as sample size, number of scan per subjects
and logistical constrains.
In this work we present a simulation study to explore the potentialities
of optimal design algorithms when applied to PET-RO, by evaluating the
sensitivity of the results to experimental variables like the scanning times
and the patient grouping, as well as misspecified drug kinetic assump-
tions.
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C.2 METHODS
C.2.1 RECEPTOR-TIME COURSE MODEL USING BINDING POTENTIAL
A general representation of PK-occupancy time course model can be de-
scribed as reported in Figure C.2.1. This modelling is however inapplica-
ble in a real PET drug occupancy study, because only few PET scans per
subject (generally <3 scans, one at the baseline and two after the drug
administration) can be acquired. Thus a simplified version is required.
In our study we considered a binding potential kon − koff model defined
as:
dBP (t)
dt
= koff ·BP0 − [Cp(t) · kon + koff ] · BP (t) (C.1)
whereBP (t) indicates the time dependent binding potential after dosing,
BP0 is the baseline binding potential and Cp(t) the plasma concentration
of the drug. kon and kon represent respectively the association and disso-
ciation rates between free brain concentration and receptor. This is equiv-
alent to an assumption that the exchange across the blood brain barrier
and the free to non-specifically bound partitioning of the drug in plasma
and tissue is sufficiently rapid for the association and dissociation of the
specifically bound drug to be considered rate limiting.
From the knowledge of kon and koff it is possible to derive the drug affin-
ity (Kd) to the receptors:
Kd =
kon
koff
(C.2)
Generally in a PET-RO study the experimental design is structured as
follows: with the baseline scan (scan before drug assumption) BP0 is de-
rived; with other two PET scans after drug administration kon and koff
can be estimated. Since the model represented in Eq. C.1 consists in 3
parameters (BP0, kon and koff ) and only 3 PET scans are available, we
are in the case in which the number of experimental measures coincides
with the number of model parameters to be estimated. These are severe
highly-restrictive data-poor conditions which underline how critical the
temporal location of PET scans is.
C.2.2 PRACTICAL ISSUES FOR PET-RO STUDIES
The experimental management of the PET scans in a drug occupancy
study follows some empirical rules of thumb defined according to the
practical issues in which the study is performed. First of all the use of
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Figure C.2.1: Schematic representation of a general PK-receptor binding
model. K1 and k2 represent the plasma to brain tissue and brain tissue to plasma
constant rates respectively. BBB indicates the blood-brain barrier. kon and koff
represent the association and dissociation rates between free brain concentration and
receptor.
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PET for the PD drug characterization does not usually involve more than
10-12 subjects by limiting the precision and accuracy with which the drug
PK/PD behaviour is characterized. Secondly, in a PET scan several unex-
pected events (like patient PET scanner intolerances, failures due to the
synthesis of the tracer,...) can occur with the effect of delaying or even-
tually eliminating its execution. In addition, when more than one PET
scan has to be performed per patient, there is a minimum amount of time
(generally 4 hours) in which no other PET scans can be performed. As
consequence of these two factors, the time location of PET scans practi-
cable in reality cannot cover all the possible combinations definable in
theory.
In common practice the scan times are define targeting themaximal plasma
concentration and lower concentration (usually 24 hours post dose) of
drug PK[17]. For what concerns the drug dose, it is generally selected on
the basis of pre-clinical information and early human data. However,
since this information might be misleading (especially when new drug
compound are evaluated), the experimental design can be corrected dur-
ing the analysis of the patients. Also for this case, however, no particular
criteria about the convenience to change or not the experimental design
is available. The decision is subordinated to the experience of the experi-
ment management committee.
C.2.3 OPTIMAL DESIGNS IN PET OCCUPANCY STUDY
Optimal designs are a class of experimental designs that are defined to
estimate the parameters of interest with the best precision and accuracy
in term of bias and variance. This result is achievable because the op-
timal designs are based on minimizing the estimated parameters’ co-
variance matrix (Ψθ). Ψθ is usually unknown but, from the Cramer-Rao
theorem[18], can be lower bounded by the inverse of the Fisher Informa-
tion Matrix (FIM)[19]. This can be explicitly indicated in
Ψθ ≥ (FIM)
−1 (C.3)
There are different kinds of optimal design algorithms depending on the
system model and the statistical criterion for the information maximiza-
tion. The latter refers to the way in whichΨθ is managed, because, from a
strictly mathematical point of view, the minimization of a matrix has no
meaning. What is usually done is to translate the information contained
in the FIM into a scalar number function of experimental parameters
that becomes the objective function to minimize. There are several ways
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of doing this transformation, thus defining different types of optimal de-
signs. The D-optimality[20,21] is themost common approach and it is based
on the determinant of the inverse of FIM :
xD = argxmax(|FIM |) (C.4)
where xD represents the optimized setting for the experimental variables.
Since the FIM definition is based on the model of the system, any even-
tually error in the definition of the systemmodel aswell as on the identifi-
cation of its parameters can heavily condition the performance of the de-
sign. The last one is a severe limitation for the application of the method-
ology. It is clear that before the execution of the experiments there is
quite a lot of uncertainty on parameter estimates; however we can at least
guess (based on a priori knowledge of the system) its value. The less accu-
rate the assumption on the true values of parameter model is, the worse
the performance of the optimized experiment are. To extend the use of
these methods, different strategies have been successfully proposed[22],
although with time consuming solutions[23]. Alternatively one possible
strategy is to utilize adaptive approaches in which the prior is updated
step by step based on experiment results. This solution represents the
fundamental of AOD.
As for fixed optimal design algorithms, several solutions for AOD im-
plementation are available. The one we considered in this work, refers
to that proposed by Zamuner and colleagues (2010) and already applied
in PET occupancy studies. A schematic representation of this procedure
is reported in Figure C.2.2. The particularity of this AOD solution is re-
lated to the way in which FIM is updated for each step of the study, by
combining the information of performed experiments with that to be pre-
formed. For further information the interesting reader is referred to the
original work[16]. As for all the AOD methods, also for this approach the
larger the number of the experiments is the more accurate the final esti-
mates are. However, from the practical point of view of PET-RO studies, a
trade-off between study duration, number of subjects, and trial costs has
to reach, limiting the total number of performable scans. Thus the con-
venience of applying AOD respect to fixed approaches like D-optimality,
needs to be carefully analyzed by considering all the operative conditions
in which PET-RO studies are performed.
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Figure C.2.2: AOD sequentially estimation and optimization algorithm. Adap-
tive optimization is based on the idea that the estimates derived from the sub popu-
lation composed by groups 1 : (i − 1) becomes the prior for the design optimization
of ith group. This operation is repeated until the last group n. The parameter prior
for the first group is derived from a priori assumptions about the system of interest.
In vitro experiments or literature values might be used to face this step.
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C.2.4 SIMULATION STUDY
In order to compare the performance of AOD with those provided by
D-optimality a simulation study was performed, with particular atten-
tion to the timing of PET scans and the effects of grouping. Simulated
data were generating according the PK-BP model presented in Eq. C.2.
One hundred populations each with 12 subjects were considered. Three
simulated compounds with different brain affinities (low, medium and
high) were tested, with Kd (Eq. C.2) equal to 15, 2.5 and 0.25 respec-
tively. The dose level was held constant for all the simulations in order
to evaluate the impact of different drug affinities without any compensa-
tion with the dose. A complete description of the simulated parameters
is summarized in Table C.2.1. An exponential distribution model was
assumed for the inter-subject variability (CV=30%) of BP0, kon and koff
and a proportional error model was assumed for the residual variability
(CV=10%). A two-compartmental model with first order absorption was
applied for the plasma concentration kinetics and individual PK parame-
ters were assumed known in the PK-BPmodel. The population PKmodel
was parametrized as clearance (CL=34.9 L/h), volume of distribution at
steady state (Vss=1200 L), inter-compartmental clearance (Q=21.7 L/h),
fractional central volume (FVC=0.671) and rate of absorption (ka=0.605
hrs-1). Exponential distribution for inter-subject variability was also used
for the PK parameters (CVs assumed in the 30 to 45% range). A repre-
sentation of simulated parameter distribution (for the medium affinity
compound) and simulated BP time course is reported in Figure C.2.3.
Simulated experimental designswere chosen according to adaptive (AOD),
non-adaptive (D-optimal) optimal designs and non optimized (Empir-
ical) designs by using different levels of parameter misspecifications re-
spect to the true simulated values (range: [-300%;+300%]). Only two time
points were assumed per subject, chosen in a time window of 0-36 hours
(minimum distance 4 hours). Data simulation and parameter estimation
were performed by using AODware, an in-house Matlab-based software
package. In AODware data quantification uses NONMEM[24] while ex-
perimental optimization was performed by using POPED[25].
Result comparison was done by computing the bias (Bias%) as well as the
mean square error (RMSE%) of the estimated parameter values with re-
spect to the true parameter values. With these two performance indexes
result precision and accuracy was evaluated.
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Table C.2.1: Simulated parameter values
Drug Affinity kon koff Kd Affinity (1/KD) BP0
[hours-1] [hours-1] [unitless] [unitless] [unitless]
Low 0.044 0.66 15.1 0.07 3
Medium 0.088 0.22 2.5 0.4 3
High 0.440 0.11 0.25 4.0 3
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Figure C.2.3: Simulated parameter distributions and BP time-course. Panel
A, B and C represent respectively the inter-subject variability for kon, koff and Kd
parameters, simulated for the medium affinity drug. For each parameter dashed line
represents the population mean. In Panel D the population means of binding potential
time courses are reported for all the three tested scenarios: dotted line represents low
affinity drug; dashed line represents the medium affinity drug; solid line represents
the high affinity drug.
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C.3 RESULTS
C.3.1 THE EFFECTS OF GROUPING
Figure C.3.1 shows the performance in the estimation ofKd parameter of
D-optimality compared to a fixed empirical design approach. Different
number of cohorts within the population were considered. No misspec-
ification was applied for the computation of D-optimal designs. From
the analysis of the performance indexes two results are particularly ev-
ident: 1) D-optimality provides better performances than the empirical
approaches using both unique or multi-groups designs; 2) with the in-
creasing of affinity, there is an evident increasing of precision and accu-
racy with which the parameters are estimated. This last condition was
verified for all the tested designs.
Similar results were obtained for BP0, while a much higher sensitivity
was found for kon and koff parameters. For these parameters the appli-
cation of D-optimality produced a mean reduction of 500% for the bias%
and 300% for RMSE% respected to the empirical designs. This result was
achieved for considering both unique and multi-group studies. As for
Kd, the results of BP-model parameters (BP0, kon and koff ) for the high
affinity compound were superior to those for the low one.
The effects of grouping with D-optimality was almost negligible, with a
mean bias% difference lower than -1% for all the parameters. This re-
sult is in agreement with the features of D-optimality and with the fact
that when it is applied without any misspecification on the prior param-
eters D-optimality returns the best possible design, independently from
the population group organization. The empirical-based design, instead,
demonstrated to perform generally better in presence of multi-groups de-
sign. The mean differences between bias% reported using unique and
multi-groups designs were -2% for Kd, -61% for kon and -52% for koff .
Similar results were reported for RMSE%. Considering all the tested
designs, all the affinity levelsand all the parameters, the application of
multi-groups populations led to more precise and accurate results respect
to unique-group design. Thus, we decided to consider only populations
with multi cohorts, organized in 3 groups with 4 subjects each.
C.3.2 THE EFFECTS OF MISSPECIFICATION
Figure C.3.2A reports the performance of D-optimality in presence of
prior parameter misspecification. The sensitivity of the parameters to
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Figure C.3.1: The effects of grouping. Panel A and B represent respectively the
Kd bias% and RMSE % obtained for all the simulated levels affinity. Four different
scenarios are reported: 1) Empirical design (no optimization applied) for a unique-
group population; 2) D-optimal design (no misspecification applied) for a unique-
group population; 3) Empirical design (no optimization applied) for a multi-groups
population; 4) D-optimal design (no misspecification applied) for a multi-groups
population. Empirical design scan timing were fixed to [0,6,24] hours for the unique
group population and to [0,6,24], [0,3,12] and [0,8,36] hours for the multi-groups
population. In this last case 3 cohorts each one with 4 subjects were considered. *
indicates out of scale values.
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the experimental design as well as the impact of design on compound
with different levels of affinity was found to be consistent with previous
results: 1) kon and koff estimates were much more sensitive to the change
of time schedule thanKd and BP0; 2) the higher the affinity the better the
performance of the design.
In term of misspecification D-optimality applied to PET occupancy stud-
ies is reasonable only when drug affinity misspecification is limited <
100%(absolute values). In other cases, there could be an important bias
(>50%) in micro (kon and koff ) as well as macro (Kd) parameters. In addi-
tion it can be see that the presence of positive misspecification on kon and
koff parameters does not affect the performance of the estimates as the
underestimation of the true parameter values. This fact is consequence
of a different location time samples. Figure C.3.2B shows the D-optimal
time window define without misspecification and with ±300% of mis-
specification. When a fast PK/PD drug kinetic is assumed the presence
of PET-RO practical constraints (especially the need to wait for at least
4 hours between a PET scan and the next) compensate the effect of mis-
specification. On the contrary when the behaviour of the compound is
assumed lower than the true behaviour (i.e. the case of -300% of mis-
specification) the timing of PET scans is completely shift from the correct
time window.
C.3.3 THE EFFECTS OF AOD
In order to test the capability of AOD to recover from uncorrected pa-
rameter assumptions, we tested the methodology to the misspecified sce-
narios in which D-optimality reported the worst performances (i.e. with
±300% of misspecification on kon and koff parameters), considering the
medium affinity simulated compound. The starting point applied to
AOD algorithm, i.e. the experimental design for the first cohort of sub-
jects, was exactly the same to the misspecified design indicated by D-
optimality. Figure C.3.3A shows the results of AOD on Kd, kon and koff
bias%. It is clearly evident how step by step, AOD allows to recover from
the presence of misspecification by reducing both bias% and RMSE%
compared to the misspecified design used as starting point. Notably, the
quality of the final estimates is comparable to those provided by design
without misspecification. Compared to the misspecified D-optimal sce-
nario the decreasing of bias% provided by AOD at the third step ranged
from 3% (Kd in case of +300% kon/koff misspecification) up to 47% (for
kon, in case of -300% kon/koff misspecification). With AOD all the param-
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Figure C.3.2: The effects of misspecification on D-optimality. Panel A rep-
resents the Kd bias% obtained for all the simulated levels affinity. Results for the
empirical design, for the D-optimal design without misspecification and for D-optimal
designs applied with different levels of parameter misspecification are reported. All
the simulations were performed by using multi-groups populations (3 groups and 4
subjects each). * indicates out of scale value. Panel B reports the scanning time
windows obtained by using D-optimality without misspecification (red lines) and with
±300% of parameter misspecification (light blue lines). BP (t) is also shown (solid
line).
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eters of interest reported bias% < 10% and RMSE < 30% in all the tested
conditions, while D-optimality produced significantly larger variability
(bias% range: 0% - 47%; RMSE% range: 10%-309%). As for the other
analysis, the effects of chosen designs are much more evident for kon and
koff estimates than for the other parameters of interest (Kd and BP0).
Figure C.3.3B shows the distribution of AOD scanning times. Results
refer to -300% misspecified scenario, but for the correspondent -300%
performed very similar. In particular the distributions of AOD scanning
times were found to be consistent each other and not influenced by the
starting misspecification level. From the figure it emerges that the distri-
butions of PET scan times optimized with AOD are likely aligned with
the PET scan times defined with D-optimality without misspecification.
This is an important evidence of howwell AOD algorithm can correct the
initial wrong assumptions about the values of system parameters.
C.4 CONSIDERATIONS
In this work we have presented a simulation study with the final aim
to define a some guidelines for a rational management of experimental
design variables in PET receptor occupancy studies. In particular, the ap-
plication of optimal designmethods have shown to significantly improve
experimental performance, increasing both precision and accuracy with
which the PK/PB parameters were estimated. However, results were
highly dependent on the choice of optimal design algorithm applied as
well as on the level of uncertainty on the true model parameter values.
Among all the tested experimental designs, the best performances were
achieved using non-adaptive D-optimal method applied without param-
eter misspecification. Even though, the absence of misspecification is
impossible in real practice, the performance obtained in this case repre-
sented the best results we should aspired to. At the same time, the worst
performances were reported by the same algorithm in presence param-
eter misspecification. This indicates that the use of D-optimality is ade-
quate onlywhen a complete and sure a priori knowledge about the system
of interest is available. In light of our results we suggest D-optimality ap-
plication only when kon and koff misspecification is lower than < 100%.
In agreement with previous studies[16], AOD has shown to valid alterna-
tive for PET-RO design definition. In particular, when AOD was applied
to high misspecified cases, precision and accuracy of parameters were
promptly recovered respect non adaptive methods.
183
Optimal Experimental design in PET-RO studies
Parameters
Experimental Designs
B
ia
s 
(%
)
Kd
Kon
Koff0%
10%
20%
Empirical   
(3groups)
D-optimal 
(3groups)
Kon/Koff 
miss 
+300%
AOD step 
1
AOD step 
2
AOD step 
3
Kon/Koff 
miss -
300%
AOD step 
1
AOD step 
2
AOD step 
3
*
* *
*
A
B
0%
10%
20%
30%
40%
50%
0
1
2
3
4
0 5 10 15 20 25 30
F
ra
ct
io
n
 o
f 
S
im
u
la
te
d
 p
o
p
u
la
ti
o
n
s
B
P
(t
)
Time (hrs)
D-optimal
scanning window Miss -300%
Figure C.3.3: The effects of misspecification on AOD. Panel A represents the
Kd, kon and koff bias% obtained for all the simulated drug with medium receptor
affinity. Results for the empirical design, for the D-optimal design with and without
misspecification and for AOD are reported. All the simulations were performed by us-
ing multi-groups populations (3 groups and 4 subjects each). * indicates out of scale
value. Panel B reports the scanning time windows obtained by using D-optimality
without misspecification (red lines) and -300% of parameter misspecification (light
blue lines). Dashed and dotted lines represent the distributions of PET scans ob-
tained by AOD (second and third PET scan respectively). BP (t) is also shown (solid
line).
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The analysis of simulation results has also offered some interesting con-
siderations about PET-RO experimental criticalities. These can be sum-
marize as follows. Firstly the overestimation of the drug PK/PD be-
haviour is preferable to an underestimation. In fact, if for the first case
the practical constraints of PET-RO experiment allow to compensate for
the error, the underestimation of the drug kinetic and dynamic could lead
to an unrealistic location of the PET scans respect to the true behaviour
of the compound.
Secondly, the organization of the studied population in cohorts as well as
the level of drug affinity were found to be two important characteristics
to taken into account for the experiment design definition. Combined
with the PET scan timing, these aspects were shown to directly affect the
precision and the accuracy of parameter estimates. In particular, high-
affinity compounds andmulti-cohort populations were found to bemuch
more robust to experimental setting changes respect to low affinity drugs
and unique-group populations.
Moreover, the sensitivity PK/BP parameters to the experimental design
was found to be significantly different: Kd was themost robust parameter
(bias% range [1%; 30%]), while kon and koff were much more sensitive to
experimental choices (maximum bias% 64% and 50% respectively). This
indicates that a correct characterization of the drug affinity is much more
easier respect to the identification of binding potential rate constants.
In conclusion, a rational location of the PET scan time, defined accord-
ing to the characteristics of the tested compounds (kinetics, dynamic and
inter-subjects variability) can greatly ameliorate the quality of the esti-
mates in PET receptor occupancy studies. This result can be achieved by
organizing the studied population in cohorts with different experimental
designs and by applying the available methods for experimental design
optimization. In particular adaptive optimization, compared to the fixed
approaches, is shown to be robust to the misspecified prior parameter
assumptions and therefore it might represent a valid tool to support the
user for experimental design definition in PET-RO studies.
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